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Heart failure is one of the leading causes of death in industrialized countries and is 
expected to become a global epidemic within the 21st century. Myocardial infarction (MI), a 
main cause of heart failure, leads to a loss of cardiac tissue impairment of left ventricular 
function. Cardiac tissue engineering promises to revolutionize the treatment of patients with 
end-stage heart failure and provide new solutions to the serious problems of heart donor 
shortage. Repair of diseased myocardium with in vitro engineered cardiac muscle combined 
with biopolymers and cells may become a viable option for heart failure patients. In this 
project, it is hypothesized that electrospun poly(caprolactone) (PCL)/gelatin nanofibers 
mimicking myocardial extracelluar matrix (ECM) can induce the cardiogenic differentiation 
of MSCs and promote myocardial regeneration after MI. 
PCL/gelatin nanofibrous scaffolds with weight ratios of 50:50 (PG1:1) and 25:75 (PG1:3) 
were fabricated by electrospinning process. PG1:1 nanofibers showed small fiber diameter of 
239 ± 37 nm, required tensile strength of 0.17 ± 0.05 MPa and Young’s modulus of 1.45 ± 
0.20 MPa in wet condition, with suitable biodegradation properties to match the requirements 
of a cardiac tissue. Cell assay exhibited that PG1:1 scaffold improved cardiomyocyte (CM) 
attachment, proliferation, interaction and expression of cardiac-specific proteins, promising 
for application as a suitable graft for cardiac reconstruction. 
The differentiation potential of human mesenchymal stem cells (hMSCs) to 
cardiomyogenic differentiation was investigated on PG nanofibrous scaffolds. Vascular 
endothelial growth factor (VEGF) was incorporated into the nanofibers by blending or 
coaxial electrospinning to improve the cardiac differentiation. The cell culture results 
indicated that the incorporation of VEGF into nanofibers improved the proliferation of MSCs, 
and immunoﬂuorescence staining analysis showed that after 15 days of in vitro culture the 
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hMSCs differentiated on PG/VEGF nanofibers and expressed significantly higher level of 
cardiac specific proteins, such as α-actinin, troponin-T and myosin heavy chain, compared to 
tissue culture plates (TCP) and PG nanofibers, demonstrating that electrospun PG nanofibers 
encapsulated with VEGF enable to promote cardiac differentiation of hMSCs. 
The PG nanofibers seeded with MSCs isolated from rat bone marrow was implanted on 
the epicardium of the infarcted region of the rat MI heart. After four weeks of transplantation, 
the PG-cell patch was found to restrict the expansion of the LV wall, reduced the scar size, 
improved cardiac function and increased the density of the microvessel formation. Stem cells 
within the patch were able to migrate into the scar tissue and differentiate to cardiomyocytes 
and endothelial cells, resulting in cardiomyogenesis and angiogenesis. MSC-seeded PG 
nanofibrous patches are demonstrated to provide mechanical support, promote 
cardiomyogenesis and angiogenesis of the infracted heart.  
Inspired by low-resistance pathways for electrical signal propagation in the native 
myocardium, electrically conductive nanofibrous scaffolds were electrospun by incorporating 
different concentrations of polypyrrole (PPy) to PG solution, to provide electrophysiological 
cues to CM. Our data showed that by increasing the concentration of PPy (0 to 30%) in the 
composite, the average fiber diameters reduced from 239 ± 37 nm to 191 ± 45 nm, and the 
tensile modulus increased from 7.9 ± 1.6 MPa to 50.3 ± 3.3 MPa. Conductive nanofibrous 
scaffolds containing 15% PPy (PPG15), possessing the most balanced properties of 
conductivity, mechanical properties and biodegradability, were cultured with CM to assess 
the biocompatibility. The cell proliferation assay, SEM and immunostaining analysis showed 
that the PPG15 scaffold promote cell attachment, proliferation, interaction and expression of 
cardiac-specific proteins, signifying the potential of using PPy containing nanofibers for the 
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of MHC in CMs on nanofibers as positive control. Scale bar =40 µm. (N) The signal intensity 
of MHC expressed in differentiated MSCs on TCP and PG, PGV/B and PGV/CS nanofibers. 
Fig. 4.9 Normalized gene expression of Tnni3 in differentiated hMSCs on TCP and PG, 
PGV/B and PGV/CS nanofibers with 5-aza treatment. 
Fig. 5.1 A. Proliferation of rat MSCs on TCP, PCL and PG, as determined by MTS assay. * p 
≤ 0.05 indicates statistically significant difference. B. Live/dead cell assay showing MSCs on 
TCP, PCL and PG after 9 days of culture. Live cells produced green fluorescence and dead 
cells showed red fluorescence. 
Fig. 5.2 SEM micrographs showing the morphology of rat MSCs on (A) TCP, (B) PCL, (C) 
PG and cytoskeleton staining (F-actin) of the MSCs on (D) TCP, (E) PCL, (F) PG after 9 
days of culture. 
Fig. 5.3 A. Cardiac function of rats with MI examined by echocardiography at 4 weeks after 
transplantation. B. and C. the change of EF and FS, D. and E. the change of LVEDD and 
LVESD, F. and G. the change of LVEDV and LVESV. *p < 0.01 compared with control 
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groups; #p < 0.01 compared with PCL groups; &p < 0.01 compared with PG groups; $p < 
0.01 compared with baseline. N = 6. 
Fig. 5.4 Morphological changes of the left ventricular wall at four week after transplantation 
(HE staining). A. Microphotographs of the transverse sections of whole hearts at the widest 
parts of the infarcted regions (×20). B. The peri-infarcted region of the free wall of the left 
ventricule. C. The infarcted region of the free wall of the left ventricle. Asterisks indicate 
nanofibers. Bar = 200 m. 
Fig. 5.5 A. Masson’s staining of scar size of the infracted hearts after transplantation for four 
weeks. Fibrous tissue (blue), myocardium (M, red), peri-infarcted (PIR) and infarcted regions 
(IR), vessel (V). Arrows indicate microvessels. Asterisks indicate nanofibers. Bar = 100 m. 
B. Statistical analysis of scar size of the infracted heart. * p  0.05, ** p  0.01, compared 
with control group respectively; # p  0.01 compared with PCL group; and & p  0.01 
compared with PG group. N = 12. 
Fig. 5.6 A. Immunostaining of TP-T and CX43 of the myocardium at the infarcted region 
after transplantation for four weeks. B. Differentiation of transplanted cell retraced by Y 
chromosome fluorescence in situ hybridization towards CMs. Asterisks indicate nanofibers. 
Bar = 100 m. 
Fig. 5.7 A. Immunostaining of CD31 at the peri-infarcted (PIR) and infarcted regions (IR) 
after transplantation for four weeks. Bar = 100 m. B. The distribution of the transplanted 
cells (arrows) traced with Y chromosome fluorescence in situ hybridization. Bar = 50 m. 
Asterisks indicate nanofibers. Epi: epicardium. C. Statistical analysis of microvessel density 
in the peri-infarcted and infarcted regions. * p < 0.01, compared with control group; # p < 
0.01, compared with PCL group; & p < 0.01, compared with PG group. N = 12. 
Fig. 5.8. immunostaining of LYVE-1 indicating the lymphatic capillaries at the peri-infarcted 
regions after transplantation for four weeks. Asterisks indicate nanofibers. Bar = 100 m. 
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Fig. 6.1 SEM micrographs of electrospun (A) PG, (B) PPG15, (C) PPG30. 
Fig. 6.2 FTIR spectra of PG, PPG15 and PPG30 nanofibers. The characteristic PPy peaks are 
marked with ↑, gelatin peaks are marked with ★, and PCL peaks are marked with ●. 
Fig. 6.3 The typical Current verses Voltage (I-V) curve for PPG15 and PPG30 scaffolds. 
Fig. 6.4 (A) Degradation profile of PG, PPG15 and PPG30 nanofibers with incubation time, 
and (B) the morphology of PG, PPG15 and PPG30 after 7 days of degradation. 
Fig.6.5 Proliferation of CMs on TCP, PG, PPG15 and PPG30 nanofibers, as determined by 
MTS assay. *Significant against cell proliferation on PG scaffolds at p ≤ 0.05. 
Fig. 6.6 Morphology of CMs on electrospun nanofibers. (A) CMs on PG after 4 days of 
culture, (B) CMs on PPG15 after 4 days of culture, (C) CMs on PG after 8 days of culture, (D) 
CMs on PPG15 after 8 days of culture 
Fig. 6.7 Immunofluorescent staining of CMs on (A-C) PG and (D-F) PPG15 nanofibers for 
(A, D) α-actinin, (B, E) troponin-T and (C, F) connexin-43. Scale bars = 50 µm. 
Fig. 6.8 (A) Proliferation of CMs on PPG15 with or without ES after 3, 6 and 9 days of 
culture, and immunofluorescent staining of CM for CX43 on PPG15 (B) without ES and (C) 
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The heart is one of the important organs in the circulatory system that pumps blood 
through the blood vessels for delivery of essential materials, such as nutrients and oxygen to 
the tissue to maintain homeostasis. The heart wall consists of three distinct layers: epicardium, 
myocardium, and endothelium. Myocardium is the middle thick layer that consists of 
interlacing bundles of cardiac muscle fibers (interconnected cardiomyocytes (CMs)), 
responsible for the contraction and relaxation of the ventricles and atria 
1, 2
. myocardial 
extracelluar matrix (ECM) is composed primarily of fibrillar types I collagen (80%) and III 
collagen (11%), and small amount of type IV and V collagens and glycosaminoglycans 
(GAGs) are also presented in cardiac ECM and the basement membrane of myocytes 
3, 4
. 
Collagen forms a complex array of nanofibers, which is not only responsible for the support 




Cardiovascular disease has been recognized as one of the most widespread causes of death 
in the both developing and developed countries and it will become the most important global 
threat of the twenty-first century. Myocardial infarction (MI), a main cause of heart failure, 
results to the injury of cardiac tissue and failure of left ventricular function 
6
. The damage of 
the heart wall muscle is permanent as, after a huge number of CMs loss caused by MI, the 
heart muscle is short of the important intrinsic regenerative capability to restore the lost cells 
7
.  
Pharmacological therapy, such as utilising diuretics, nitrates, is the current standard 
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conservative treatment for heart failure, and it is not suitable for patients with serious 
symptoms of heart failture 
8, 9
. Reperfusion therapy, including fibrinolytic therapy, 
percutaneous coronary intervention (PCI) and bypass surgery has become so central to the 
modern treatment of the patients with acute myocardial infarction 
10, 11
. Yet, both 
pharmacological and interventional therapies are not adequate to stop disease progression to 
the end stage of heart failure, and heart transplantation becomes the only choice for the 
patients for survival 
12
. Due to the lack of organ donors and concerns with immune rejections, 
researchers are still looking for new approaches to treat the damaged heart. 
Cardiac tissue engineering (TE) is composed of both biomaterial scaffolds and healthy 
cells and is recognized as a hopeful therapy for heart failure. Current technologies in stem 
cell isolation, the synthesis of bioactive materials, and design of bioreactors enable scientists 
to develop engineered heart tissue in vitro. Several cell sources, such as neonatal CMs, 
skeletal myoblasts, smooth muscle cells, mesenchymal stem cells (MSCs) and embryonic 
stem cells (ESCs), have been proposed for improving myocardial function as they are easily 





. Stem cells are currently gaining great attention for cardiac muscle regeneration 




The biomaterial scaffold plays a crucial role in TE. An ideal cardiac graft should possess a 
similar hierarchical structure and comparable mechanical properties to the myocardial ECM. 
Both natural and synthetic polymeric materials have been utilized as biomaterials for cardiac 
TE. Natural polymers used in cardiac TE include collagen, fibrin, gelatin, alginate etc, and 
they are able to perform specific biochemical, structural and functional roles in the body. But 
their poor mechanical properties, potential of immune response and difficulty to process limit 
their application. Synthetic polymers applied in cardiac TE include poly (glycerol-sebacate) 
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(PGS), polylactic acid (PLA), poly(caprolactone) (PCL), polyurethane (PU), poly 
(esterurethane) (PEU), poly (ethyleneterepthalate) (PET), polypropylene (PP), poly 
(tetraﬂuoroethylene) (PTFE), and poly (N-isopropylacrylamide) (PNIPAAm). The main 
advantages of synthetic polymers are good mechanical properties and the potential defined 
chemical properties with stable degradability 
6
. However owning to the lack of bioactive 
signals, synthetic biomaterials alone are less biofriendly than native biomaterials. 
In all, cardiac TE offers a promising alternative to reestablish the structure and function of 
injured myocardium, but it is still a challenge to develop a tissue-engineered cardiac graft 
incorporating an effective and safe cell source in combination with an ECM-mimicking 
scaffold with appropriate mechanical properties. 
 
1.2 Motivation 
To create an ideal tissue-engineered cardiac graft, scaffolds should be enriched with 
suitable cell source. CMs seems to be the ideal donor cell type in theory, but the difficulty to 
obtain and expand as well as the allogenic response in the host tissue limits their application 
and make them only to be a model cell to evaluate the biocompatibility of scaffolds 
18, 19
 Stem 
cells, with the ability of self renewal, proliferation, and multipotency, show great potential for 
myocardial regeneration. Among several types of stem cells, MSCs, due to their easy 
availability and established culture and differentiation procedures, are selected as a potential 
cell source for cardiac TE. MSCs have been reported to be able to differentiate into CMs in 
vitro by treatment of 5-azacytidine (5-aza), Bone morphogenetic proteins (BMP-2) or 
fibroblast growth factor-4 (FGF-4), as well as by co-culturing with CMs 
20
. Animal studies 
have also suggested that transplanted MSCs were able to grow and differentiate into CMs 
and/or vascular cells to regenerate injured heart muscle and improve cardiac function after 





. In addition, engrafted MSCs have also reported to increased the vasculature in the 
ischemic myocardium by secreting amounts of growth factors and bioingredients under 
beneficial paracrine effects to contribute to myocardial regeneration 
20, 22
. In clinical trials, 
MSC therapy also showed positive results in cardiac function, ventricular remodeling 
inhibition, and scar size decreasing. Therefore, the application of MSCs in cardiac TE holds 
great potential in promoting cardiac repair and myocardial regeneration after MI. 
Another major challenge of cardiac TE is to produce a biodegradable substrate with 
suitable mechanical properties by mimicking the myocardial ECM structurally and 
functionally. In the native tissue, the ECM is composed of a network of collagen-based 
fibrillar structures, which provides structural support to resident cells and, more importantly, 
modulates cellular activities. Recent advances in TE techniques have invoked interests in 
making scaffolds with biocompatible and/or biodegradable polymer nanofibers because of 
their nanoscaled morphology mimicing the hierarchy of native ECM, and their high porosity 
accelerates blood vessel formation, and high surface area benefits for cell growth and and 
tissue regeneration 
23-25
. For cardiac TE, the fibrous structure of nanofibers could provide 
more binding sites to enhance cellular attachment and functions, while the elasticity of 
nanofibers are able to provide mechanical support for the graft cells and withstand the 
circularly contraction of heart beating. 
Currently there are three manufacturing technologies commonly applied to generate 
nanofibrous scaffolds: electrospinning, molecular self-assembly and thermally induced phase 
separation (TIPS). Electrospinning has been recognized as the most simple and efficient 
technique for the fabrication of polymer nanofibers because it can produce long and 
continuous nanofibers with uniform diameters. Moreover, adjustment of electrospinning 
parameters and solution properties enables manufacturers to control the properties of the 
resultant nanofibrous scaffolds, such as fiber diameter, porosity, area to volume ratio, surface 
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topography and mechanical properties 
26-29
. In this project, electrospinning technique was 
utilized to fabricate nanofibrous scaffolds for cardiac TE by blending the synthetic polymer 
PCL with natural polymer gelatin and evaluated the PCL/gelatin nanofiber/MSC composites 
as cardiac patch for myocardial regeneration in rat MI model. In addition, a novel electrically 
conductive nanofibrous scaffolds were developed as potential substrates for cardiac 
regeneration. 
 
1.3 Hypothesis and objectives 
1.3.1 Hypothesis 
Electrospun PCL/gelatin nanofibers mimicking natural ECM can induce the 
cardiogenic differentiation of MSCs and promote myocardial regeneration after MI. 
 
a) Synthetic polymer PCL and natural protein gelatin can be blended for co-
electrospinning to fabricate cardiac scaffolds with appropriate mechanical 
properties, biodegradability and bioactivity to favor cardiac cell growth. 
b) MSCs will differentiate into cardiogenic lineage on PCL/gelatin nanofibrous 
scaffolds in vitro. 
c) The incorporation of vascular endothelial growth factor (VEGF) into the 
nanofibers can improved the cardiogenic differentiation of MSCs. 
d) PCL/gelatin nanofibers seeded with MSCs as cardiac patch can improve cardiac 
function and promote myocardial angiogenesis in rat MI model. 
e) Electrically conductive nanofibers could promote the cell-cell interaction and 
establish gap junction between cardiac cells. 
 




a) To electrospin PCL/gelatin nanofibers to develop ECM-mimicking scaffolds with 
suitable mechanical, biodegradable and bioactive properties for CM growth. 
b) To induce the cardiogenic differentiation of MSCs on PCL/gelatin nanofibrous 
scaffolds incorporated with VEGF in vitro. 
c) To demonstrate PCL/gelatin nanofibers seeded with MSCs as cardiac patch to 
improve cardiac function and promote myocardial angiogenesis in rat MI model. 
d) To fabricate electrically conductive nanofibers as potential substrates for the 
electrical stimulation and improvement of cell-cell interaction. 
 
1.4 Work scope 
In this dissertation, a detailed literature review is presented in Chapter 2 that includes 
native heart structure and function, heart disease, current treatments for MI, cardiac TE and 
potentials of MSCs and nanofibers for cardiac repair and myocardial regeneration. Table 1.1 
summarizes the project scopes from chapter 3 to chapter 6. Conclusions for this thesis and 
recommendations for future work are described in Chapter 7. 
 
Table 1.1 Overview of project scope. 
Hypothesis Objective Descriptions Thesis 
Synthetic polymer PCL and 
natural protein gelatin can be 
blended for co-electrospinning 
to fabricate cardiac scaffolds 
with appropriate mechanical 
properties, biodegradability 










for CM growth. 
Nanofibrous scaffolds were 
electrospun by blending 
different ratio of gelatin into 
PCL and further characterized 
for its morphology, diameter, 
chemical composition, 
mechanical and degradable 
properties etc. 
The viability and cellular 
behaviour of CMs on the 
PCL/gelatin nanofibers were 
evaluated. 
Chapter 3 
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(1) MSCs will differentiate 
into cardiogenic lineage on 
PCL/gelatin nanofibrous 
scaffolds in vitro. 
 
(2) The incorporation of VEGF 
into the nanofibers can 
improved the cardiogenic 
differentiation of MSCs. 
 







VEGF in vitro. 
 
(1) VEGF was incorporated 
into PCL/gelatin nanofibers by 
two different methods: (i) 
blend spinning (ii) core/shell 
spinning. 
 
(2) The material properties 
(morphology, fiber diameter 
and mechanical properties) 
ofPCL/gelatin/VEGF 
nanofibers was analyzed, and 
the release profile of VEGF in 
vitro was carried out. 
 
(3) MSCs were induced 
towards a cardiogenic lineage 
on the nanofibers by the 
treatment of 5-aza. 
Chapter 4 
PCL/gelatin nanofibers seeded 
with MSCs as cardiac patch 
can improve cardiac function 
and promote myocardial 




with MSCs as cardiac 
patch to improve 
cardiac function and 
promote myocardial 
angiogenesis in rat 
MI model  
 
Animal studies on rat has been 
done to show the capacity of 
PCL/gelatin/MSCs composites 
as cardiac patch to improve 
cardiac function and induce 




nanofibers could promote the 
cell-cell interaction and 











(1) Polypyrrole (PPy) was 
blend into PCL/gelatin to 
electrospin novel conductive 
nanofibers and the material 
properties were evaluated. 
 
(2) The cell behavior and cell-
scaffold, cell-cell interactions 
was studied by culturing CMs 
on the conductive nanofibers 
Chapter 6 
 






2.1 Introduction to the heart 
The heart is the hollow, muscular organ in the circulatory system that contracts 
rhythmically to establish the blood pressure gradients to push blood to flow 
throughout in our body. All body tissues constantly depend on the life-supporting 
blood flow provided by the heart. To maintain homeostasis, the heart ejects blood 
into the blood vessels for delivery of essential materials, such as oxygen and 
nutrients to the tissue in sufficient amounts. Throughout a human life span from just 
few days following conception until death, the beat goes on and the heart contracts 
about three billion times averagely.  
 
2.1.1 Pumping action of the heart 
As a single organ anatomically, the heart is a dual pump with four chambers 
(Fig.2.1) 
30
. An atrium refers to the upper chamber on each side of the heart, and it 
collects the blood coming to the heart and transfers it to the lower chamber, the 
ventricle, which pushes blood into the blood vessels and to all body tissues 
eventually. The heart is divided into right and left halves by the septum, a 
continuous muscular partition that prevents blood mixing from the two sides of heart. 
The right side receives oxygen-poor blood from the systemic circulation and delivers 
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it into the pulmonary circulation, while the left side of the heart collects oxygen-rich 
blood from the pulmonary circulation and pushes it back into the systemic 
circulation. Under the regulation of the rhythmic changes in cardiac electrical 
activity, the heart contracts (systole) and relaxes (diastole) cyclically and constantly. 
Despite the same amount of blood delivered from both sides of the heart, the left 
side works harder as it ejects an equal volume of blood into the systemic circulation 
which needs a higher pressure to overcome the higher-resistance. Accordingly, the 

















2.1.2 Heart wall anatomy 
The heart is covered by the double-walled, membranous pericardium, a sac with 
 
Fig. 2.1 The basic structure of a normal heart. A normal heart contains four chambers (right 
atrium, left atrium, right ventricle, left ventricle), and the heart wall consists of three tissue layers: 
endocardium, myocardium and epicardium 
30
. 
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two layers: a tough, fibrous covering and a secretory lining. The outer fibrous layer 
attaches to the surrounding structures, anchoring the heart to remain properly 
positioned within the chest. The inner serous layer is composed of a parietal layer 
and a visceral layer, between which a thick layer of pericardial fluid locates to 
provide a slippery surface to lubricate for the every heart beat 
1
. 
The heart wall consists of three distinct layers: epicardium, myocardium, and 
endothelium (Fig.2.1) 
30
. Epicardium is the outer layer of heart tissue, which also 
forms the visceral layer of the pericardium. The largest constituent of epicardium is 
connective tissue with the function as a protective layer. Endothelium is the 
innermost layer of the heart wall, which is primarily made up of endothelial cells 
that lines not only the chambers of the heart, but the entire circulatory system. The 
cardiac endothelium is responsible for the regulation of the contractility and 
electrophysiological environment of the CMs, and it may also act as a kind of blood-
heart barrier to control the ionic composition of the extracellular fluid in which the 
CMs bathe. Myocardium is the middle thick layer that is composed almost 
completely of CMs and constitutes the bulk of the heart wall. The cardiac muscle 
fibers interlaced in myocardium arrange spirally and are responsible for the 
contraction and relaxation of the ventricles and atria 
1, 2
.  
Cardiac muscle fibers are formed by the oriented CMs which connect end to end 
at intercalated discs. There are two main kinds of cell-cell connections presented 
within an intercalated disc: desmosomes and gap junctions. A desmonsome is a kind 
of adhering connection that binds cells together though mechanical forces, allowing 
tissues to be subject to considerable mechanical stress 
31, 32
. A gap junction is 
another specialized intercellular connection, which form electrically conductive 
areas that enable action potentials to propagate from on CMs to adjacent cells by 
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allowing the exchange of ions between cells, leading to contraction of the heart 
muscle 
33
. Once one CM generates an action potential spontaneously, the electrical 
signal transmits to all the other CMs that are connected by gap junctions so that they 
depolarize and excite. The synchronous contraction of muscle cells in the heart walls 
produces the force needed to eject the enclosed blood.  
 
2.1.3 Electrical activity of the heart 
Contraction of heart muscles is induced by action potentials spreading through 
the myocardium. The nervous system does not regulate the beating of the heart. 
Even if all the nerves in the heart are removed, the heart will still contract 
rhythmically. The reason is that the heart autorhythmically generates its own 
rhythmic action potentials. 99% of the cardiac muscle cells are only contractile cells, 
which normally do not generate their own action potentials. On the other hand, a few 
of cells, called autorhythmic cells, do not mechanically pumping but are response 
for producing and transmitting the action potentials to control the rhythmic beating 
of the heart. Unlike nerve or skeletal muscle cells, these cardiac autorhythmic cells 
do not have a resting membrane potential and their membrane potential drifts 
towards threshold (called the pacemaker potential) to fire action potential all the 
time. The sequence of drift and excitement repeats continuous in a rhythmic manner.  
The autorhythmicity cells lie in the following specific sites: the sinoatrial node 
(SA node), the atrioventricular node (AV node), the bundle of His (atrioventricular 
bundle) and Purkinje fibers. Normally, the action potential of the heart is initiated in 
the SA node due to its fastest rate of action potential initiation. From the SA node, 
the action potential spreads rapidly to the right and left atria through the atrial 
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intermodal tracts. Simultaneously, the action potential is conducted to the AV node 
and spreads relatively slowly through it to allow time for complete ventricular filling. 
After the AV nodal delay, the action potential propagates rapidly down the septum 




2.1.4 The coronary circulation 
Although all the blood flows through the heart, the heart muscle is not able to 
obtain oxygen or nutrients from the blood in its chambers. One reason is that the 
impermeable endothelial lining does not allow blood to penetrate from the chamber 
into the myocardium. The other reason is that the heart walls are too thick for 
effective diffusion of oxygen and other supplies from the blood in the chamber into 
the individual cardiac cells. As a result, similar to other tissues, heart muscle 
requires blood supply through blood vessels. The coronary circulation is the blood 
vessel system that supplies oxygen and nutrients to the heart muscle and cells. The 
coronary arteries start from the aorta, and the coronary veins end into the right 
atrium.  
 
2.2 Cardiovascular diseases and treatments for myocardial infarction 
Cardiovascular diseases (CVD) are the leading cause of death all over the world, 
especially in developed countries. In 2008, the overall rate of death from CVD was 
244.8 per 100000, accounting for 32.8% of all death in 2008 
34, 35
. Although 
significant progress has been made to prevent and treat CVD in the past decades, the 
incidence and prevalence of heart failure is still increasing steadily recently, 
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especially in the elderly. Coronary artery disease caused about 1 of every 6 deaths in 
the United States, more than from all cancers combined, and it can cause myocardial 

















2.2.1 Cardiac failure and remodeling 
When one or more coronary vessels are completely plugged, the cardiac tissue 
served by the vessel dies soon from oxygen deprivation and MI occurs. MI typically 
results in an initial inflammatory response and myocyte slippage (Fig.2.3) 
37
. 
Furthermore, matrix malleoproteases set off initiating the degradation and 
remodeling of the collagen ECM, which leads to heart wall thinning as well as 
ventricular dilation 
38, 39
. The damage of the cardiac muscle is permanent as the 
 
Fig. 2.2 Myocardial infarction. The shaded area beneath the left coronary artery represents an 
area of infarct 
36
. 
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myocardial tissue has limited intrinsic regenerative capability to restore the lost CMs 
40
. Due to the formation of scar tissue which lacks the contractile, mechanical and 
electrical capabilities as native myocardium, compensatory ventricular remodeling, 
the ventricular dilation combined with progressive structural and functional changes 
in heart muscle wall, is induced to response to the reduced cardiac output, 
potentially leading towards the end stage of heart failure, whereby the heart cannot 
pump adequate blood for all the metabolic requirements of the body (Fig.2.4) 
14, 41
. 
Table 2.1 describes the four possible outcomes of acute MI: immediate death, 




















Fig. 2.3 Scar formation in the heart. Heart Scarring post-MI (Arrow 1) Infarcted coronary artery 
results in death of localmyocytes and recruitment of neutrophils and macrophages to the site of 
injury where they release pro-inflammatory cytokines. (Arrow 2) Fibroblasts and myofibroblasts 
are recruited from the surrounding myocardium and begin to lay down collagen. Note that 
connexin 43 (CX43) is down regulated in the infarct border zone and no longer localized at the 
end-to-end abutments of themyocytes. (Arrow 3) Myofibroblasts expressing CX43 and forming 
intercellular junctions with adjacent myofibroblasts persist in the dense collagen scar 
37
.  






















2.2.2 Current therapies for myocardial infarction and heart failure 
2.2.2.1 Pharmacological therapy 
Existing pharmacological therapies for MI or heart failure have three main 
therapeutic goals: (1) to relieve congestion, (2) to reduce abnormal loading 
conditions, and (3) to improve myocardial contractility and relaxation 
8
. The 
Table 2.1 Possible outcomes of acute myocardial infarction 
2
 




Recovery with impaired 
function 
Acute cardiac failure 
occurring because the 
heart is too weakened to 
pump effectively to 
support the body tissues 
 
Fatal ventricular 
fibrillation brought about 
by damage to the 
specialized conducting 
tissue or induced by 
oxygen deprivation 
Fatal rupture of dead, 




congestive heart failure 
occurring because the 
weakened heart is unable 
to pump out all the blood 
returned to it 
Replacement of the 
damaged area with a 
strong scar, accompanied 
by enlargement of the 
remaining normal 
contractile tissue to 
compensate for the lost 
cardiac musculature 
Persistence of permanent 
functional defects, such 
as bradycardia or 
conduction blocks, 






Fig. 2.4 Post-MI adaptations: Acute compensation of the LV after an MI involves cardiac 
expansion, thinning of the infarcted wall, and hypertrophy of the viable myocardium. These 
compensatory responses can lead to adaptation or cardiac remodeling and overt heart failure. This 
latter phase is characterized by gross dilation of the organ, accompanied by a very low LV 
ejection fraction, which cannot sustain homeostatic tissue demands 
41
. 
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treatment algorithm is shown in Fig.2.5 42. Among all the pharmacologic therapies, 
diuretic therapy remains the mainstay in congestive states of acute heart failure, with 
over 85% of admitted patients receiving this kind of therapy as their primary 
therapeutic intervention. The aim of diuretic therapy is to remove excess volume 
accumulated in the setting of heart failure, contributed by a combination of 
neurohormonal overactivation, excess sodium intake from dietary noncompliance, 
drug noncompliance, and changes in underlying medical conditions (eg, arrhythmia, 
renal insufficiency, myocardial ischemia) 
43, 44
. It includes loop diuretic therapy 
(furosemide, torsemide, bumetanide) and vasopressin receptor antagonists (Arginine 
vasopressin, Tolvaptan, lixivaptan) 
45-47
. However, the application of diuretic 
therapy is limited by the difficulty to define and assess the appropriate “targets” of 
therapy. Recently, no general agreement is firmed up regarding guidance from 
biomarkers or other noninvasive physiologic measures that can provide a reliable 
objective assessment of intravascular volume status.  
Since heart failure is confirmed as a problem of vascular insufficiency (with 
associated abnormal relaxation) rather than just an incremental impairment of 
myocardial contractility, the interest in the appropriate use of vasodilator therapy to 
target abnormal loading has been resurged for the treatment of MI. Sodium 
nitroprusside and nitroglycerin have been used in clinic presenting with heart failure 
by exerting their actions via conversion to nitric oxide 
48
. Natriuretic peptides 
(nesiritide) have emerged as potentially useful vasodilator agents in the treatment of 
heart failure by providing a dose-dependent reduction in intracardiac pressures and 
improvement in hemodynamics and heart failure symptoms 
49, 50
. Several 
neurohormonal systems demonstrating vasoconstrictive properties have also been 
identified as potential therapeutic agents for heart failure. Angiotensin-converting 
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enzymes (ACE inhibitors) have been proved to be the only treatment that is 
unequivocally beneficial in improving symptoms and prolonging life in patients with 
left ventricle dysfunction 
51
. Several trials have demonstrated that ACE inhibitors 
could functionalize to reduce residual left ventricular function and further decrease 

















Inotropic therapy (inodilator), targeting impaired myocardial contractility or 
relaxation, shows the benefit of rapidly improving adverse hemodynamic profiles, 
particularly in the setting of low cardiac output. Aiming to augment myocardial 
contractility via direct stimulation of β1-adrenergic receptors, catecholamines 
 
Fig. 2.5 Treating heart failure. (ACE, angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter defibrillator; MI, 
myocardial infarction; NICE, National Institute for Health and Clinical Excellence) 
42
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(dobutamine, dopamine) are currently used to treat patients with advanced refractory 
heart failure to relieve symptoms and to improve end-organ function in low-output 
states 
52
. Levosimendan is found to have a unique dual mechanism of treatment. 
First, as a “calcium sensitizer”, levosimendan enable to increase inotropy via 
increasing the sensitivity of cardiac troponin C to intracellular ionized calcium 
without increasing myocardial oxygen consumption. Second ability of levosimendan 
is to facilitate potassium-ATP channel opening, providing additional beneficial 
vasodilatory effects. However, on inotropic therapy right now is able to avoid the 
increase in oxygen demand and the promotion of intracellular calcium accumulation 
resulting in potential arrhythmic complications. 
 
2.2.2.2 Reperfusion therapy 
Currently, reperfusion therapy has become one of the most effective approaches 
to treat the patients with acute MI. Immediate reperfusion, either with fibrinolytic 
therapy, PCI always is the first choice for the candidate patients, and bypass surgery 
will be performed only if these therapies are failed. 
 
2.2.2.2.1 Thrombolytic (Fibrinolytic) therapy 
As a crucial method of applying reperfusion for years, thrombolytic therapy is a 
treatment utilized to dissolve blood clots that block coronary arteries after heart 
attack. The major aim of thrombolytic therapy is to unblock the occluded coronary 
artery with high quality reperfusion at both the epicardial and microcirculatory level 
in the shortest period and preventing re-occlusion after firstly successful 
thrombolysis 
53
. The effectiveness of thrombolytic therapy reaches the top in the first 
2 hours after the beginning of symptoms. All the evidence has indicated that the 
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fibrinolytic treatment for patients within 12 h of the beginning of MI symptoms is 
overwhelmingly beneficial, while the danger of thrombolytic therapy increased 

















To carry out fibrinolytic treatment, doctors inject fibrinolytic agents into a blood 
vessel for clot-dissolving. As shown in Table 2.2, there are several types of 
fibrinolytic agents approved by FDA and used for MI treatment 
55
. Streptokinase is a 
first-generation agent that is not used much anymore, as this drug had a high risk for 
bleeding. Third-generation fibrinolytic agents, such as reteplase and tenecteplase, 
are used more frequently recently 
53
. These drugs are safer, easier to use and more 
effective against fibrin compared to the older generation drugs 
10
. The tissue 
plasminogen activator congeners tenecteplase and reteplase with short initial plasma 






IV Dosing Comments 
Alteplase AIS 0.1 mg/kg bolus, then; 
0.8 mg/kg infusion over 60 min 
ICH: 0.4%-0.9% 




Acute PE 100 mg infusion over 2 h 
STEMI >67 KG: 100 mg IV (total) 
15 mg bolus over 1-2 min 
50 mg over 30 min 
35 mg over 60 min 
< 67 Kg: 100 mg IV (max) 
15 mg bolus over 1-2 min 
0.75 mg/kg over 30 min (max 50 mg) 
0.5 mg/kg over 60 min (max 35 mg) 
Reteplase STEMI 10 units IV push over 2 min 
Repeat in 30 min 
Anaphylaxis 
ICH: 0.8% 
Streptokinase STEMI 1.5 million units over 60 min Anaphylaxis 
ICH not reported Acute PE/DVT 250000 IU IV over 30 min, then: 
100000 IU/h for 24 h(PE) or 72h (DVT) 
Tenecteplase STEMI <60 kg: 30 mg IV bolus 
60-69 kg: 35 mg IV bolus 
70-79 kg: 40 mg IV bolus 
80-89 kg: 45 mg IV bolus 
>90 kg: 50 mg IV bolus 
IV push over 5 sec 
Most fibrin specific 
Fibrinogen sparing 
ICH: 0.9% 
Urokinase Acute PE 4,400 IU/kg over 10 min bolus, then: 
4,400 IU/kg/h IV for 12 h 
Anaphylaxis 
ICH: <1% 
AIS: acute ischemic stroke; DVI: deep venous thrombosis; ICH Intracerebral hemorrhage; IU: 
international units; PE: pulmonary embolism; STEMI: ST-segment elevation myocardial infarction 
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half-lives (15 to 30 minutes) become the most up-to-date, easily administered bolus 
fibrinolytics, as they not only limit the risk of medication errors but also greatly 
simplify the prospects of prehospital fibrinolysis 
56, 57
.  
However, some serious side effects and drawbacks including perceived or 
definite contraindications, intracranial bleeding, inability to establish Thrombosis In 
Myocardial Infarction flow, and high risks of recurrent ischemia and reocclusion 
limits the application of thrombolytic therapy 
58
. Accordingly, primary PCI has 
emerged to be the favorite reperfusion treatment. 
 
2.2.2.2.2 Percutaneous coronary intervention 
PCI, also named as coronary angioplasty, is a therapeutic strategy to 
mechanically widening the stenosed coronary arteries after heart attack or MI. A 
balloon catheter is inserted into the stenotic locations, and then the balloon inflated 
to a proper size to smash the blood clots, opening up the blood vessel for enhanced 
flow, and the balloon is then deflated and withdrawn. A metal stent or drug eluting 
stent may be placed at the time of ballooning to ensure the vessel would not be 









Introduced in 1977, the use of PCI has raised considerably and it has become one 
of the most commonly medical performed interventions. Emergency catheterization 
 
Fig. 2.6 Aspriation thrombectomy of a thrombotic occlusion in the coronary artery of a patient 
with a myocardial infarction. Awire is passed across the coronary occlusion (left), the aspiration 
catheter is passed to the lesion and thrombus is aspirated through the lumen of the catheter 
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is suitable for almost all acute MI patients, and primary PCI establishes Thrombosis 
In Myocardial Infarction flow in more than 90% of patients, coupled with reduced 
rates of recurrent ischemia and reocclusion compared to thrombolytic therapy. The 
addition of stenting can reduce reocclusion to 5% at routine 6-month angiography 
60
. 
Moreover, with the help of pharmacological adjuncts to PCI such as abciximab, 
myocardial perfusion might be improved and the size of infarction can be limited 
exclusive of the possibility of bleeding found within thrombolytic therapy 
61-63
. In 
addition, novel technologies including coronary thrombectomy, distal projection, 
and systemic cooling have been developed and utilized in the catheterization 















However, PCI needs a skilled team, including both sophisticated interventional 
 
Fig. 2.7 Examples of CABGs. A right saphenous vein graft (SVG) (a) is attached to the anterior 
aorta proximally and to the posterior descending artery distally. A left SVG (b) has an altered 
appearance because it is attached to the aorta with an aortic connector device (arrow); the origin 
of this SVG is moved laterally to prevent kinking. A typical left internal mammary artery graft (c) 
is left intact at its origin and grafted to the LAD artery distally 
64
. 
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cardiologists and experienced technical staff. It indicates that hospitals without a 
mature interventional cardiology program are not able to use primary PCI as a 
routine therapeutic procedure for patients with acute MI. Another challenge is that 
there is no reliable non-invasive techniques available for evaluating patency of the 
occluded coronary artery, which therefore requires “rescue PCI”, defined as PCI 





2.2.2.2.3 Coronary artery bypass surgery 
Introduced in 1968, coronary artery bypass surgery (CABS) is a surgical 
procedure performed to create new channels around stenotic and occluded arteries 
with a healthy artery or vein taken from the patient’s other parts, letting adequate 
blood flow to transport oxygen and nutrients to the heart muscle (Fig. 2.7) 
64, 65
. 
With the addition of advanced technologies such as off-pump surgery, minimally 
invasive surgery, improved myocardial preservation, application of arterial conduits, 
and enhanced post-operative care, CABS has successfully decreased morbidity, 
mortality, and rates of graft occlusion 
66-70
. 
The number of patients with acute MI who need a CABS is small, but CABS 
might be preformed after PCI is unsuccessful, coronary occlusion cannot be opened 
up by PCI, refractory symptoms, cardiogenic shock, or mechanical complications 
are developed after PCI 
10, 11
. However, lots of factors need to take in account when 
choosing suitable patients for CABS, such as the presence of angina post MI, the 
severity of heart failure symptoms, cardiac function, and comorbidities. Moreover, 
the grade of stenosis, the quality of the vessel grafts, and the degree of reversible 
ischemia should also be under consideration 
71
. 




2.2.2.3 Heart transplantation 
Recently, pharmacological and interventional therapies are receiving widespread 
application in clinic and shows positive results, but these therapies are not adequate 
to stop disease progression towards the end stage of heart failure. At this stage, the 
damaged myocardium does not have capacity to pump adequate blood to satisfy the 
metabolic needs of the body, and heart transplantation is the ultimate treatment 
option for the patients for survival 
12
. However, the application of heart 
transplantation is limited because of the issue of donor shortage and complications 
related with immunosuppressive therapies 
72, 73
. With advances in medicine, there 
are some devices such as ventricular assist devices now available, which can be 
surgically implanted for short time to decrease the load on the heart and bridge the 
time gap while patients wait for a donor heart 
74-76
. However, owing to the high cost 
and blood compatibility issues, new strategies to repair the injured heart are still 
under requirement. 
 
2.3 Cardiac tissue engineering 
Cardiac TE has emerged as an exciting new therapeutic idea for heart repair. 
Based on cell therapies, scientists and doctors have applied the idea of “growing” 
heart muscle to develop novel approaches to treat heart failure 
13
. In cardiac TE, 
basic therapeutic strategies include: (1) Direct injection of grafted cells into injured 
myocardium; (2) Tissue engineering approaches to regenerate new cardiac tissue ex 
vivo.  
The cell implantation method focuses on restore of the damaged heart muscle by 
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injection of functional cells, which is called cell therapy. Several cell types that 
might regenerate new cardiac muscle and decrease scar area have been under 
consideration. Progenitor or stem cells have also been utilized to the injected tissue 
or induction into a regenerative program within the area. Although cell 
transplantation has shown some positive results for improvement of cardiac 
performance; poor cell retention and transplantation survival still is a major 
challenge in this technique 
7, 77
. Evidence shows that greater than 90% of the 
injected cells were missing during circulation or they leaked out of the injection site 
78
. Even in the cases involving the success of -injected cells, approximately 90% 
cells died in the first week of transplantation 
79, 80
, which limits the efficiency of cell 
therapy. Therefore, highly death rate of “naked” cells in the infarct myocardium is 













To date, cardiac TE has become a novel and ambitious strategy that combines 
 
Fig. 2.8 Current approaches of using cells, scaffolds or injectables for cardiac tissue 
engineering. 
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knowledge from material science, chemistry with biology and medicine. Cardiac TE 
using biomaterial scaffolds offers a promising alternative to enhance the efficiency 
of cell transplantation, and the use of biomaterial to deliver cells into the injured 
tissue (infarct wall) might increase cell survival 
14
. TE, defined by Langer and 
Vacanti, is “an interdisciplinary field that applies the principles of engineering and 
life sciences towards the development of biological substitutes that restore, maintain, 
or improve tissue function.” 81 Three elements build up the base of TE: healthy cells, 
bio-scaffolds, bioactive molecules (e.g. growth factor, gene, etc.), in which 
biomaterials, as a mechanical carrier for cell attachment and proliferation, play an 
crucial function in tissue regeneration 
25. The “golden criteria” to design a TE 
scaffold is to emulate the native ECM of the target tissue in order to regulate cellular 
behavior. Fig. 2.8 shows the current approaches of using cells, scaffolds and 
injectables for cardiac TE. 
 
2.3.1 Stem cells for cardiac tissue engineering 
An ideal donor cell type for cardiac TE should be easily available, proliferative, 
and capable to differentiate into mature, functional CMs. Theoretically, CMs, 
especially foetal CMs, with the natural electrophysiological, and contractile 
properties is the optimal cell source 
18
. Nevertheless, the difficulty to harvest and 
proliferate, the sensitivity to ischemic insults and the allogenic response in the host 
tissue limits the application of CMs 
19
. Skeletal muscle-derived progenitors, or 
myoblasts, and crude bone marrow mononuclear cells are most popular cell sources 
for cardiac cell treatment in clinic recently, and both cell types share advantages that 
they are easy to obtain, autologous, proliferative and reproducible in vitro 
15
. 
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Nevertheless, These cells are not able to transdifferentiate into cardiomyogenic or 
endothelial linage, which limits their efficacy 
13
. Stem cells are clonogenic and are 
able to symmetrically divide unlimitedly, and maintain a constant diploid karyotype 
all the time. They are also able to divide asymmetrically, meaning one daughter 
resembling its mother, and one daughter giving rise to multiple types of 
differentiated cells. Stem cells can be categorized anatomically or functionally, or by 
cell surface markers, transcription factors, and protein expression studies. Therefore, 
stem cell-based therapy recently has showed a great potential for the treatment of 















2.3.1.1 Bone marrow-derived mesenchymal stem cells 
MSCs, mainly isolated from bone marrow (BM), are a heterogeneous population 
 
Fig. 2.9 Mechanisms of MSC action in cardiac regeneration and repair. Cardiomyocyte and 
vascular regeneration represent the two mechanisms of action originally proposed to explain 
the reparative effects observed after MSC therapy in ischemic heart disease models. More 
recently, it has been demonstrated that soluble factors produced and released by MSC 
determine beneficial paracrine effects, resulting in myocardial repair. CMC: cardiomyocyte, 
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of cells that reproduce in vitro, have fibroblast-like morphology adhering to plastic 
surfaces, form colonies in vitro and can differentiate into mesenchymal lineages, 
including bone, cartilage, cardiac, adipose, and endothelial cells 
82
. Some specific 
advantages make MSCs as the most preferred stem cell model for myocardial 
therapeutic development: 1) genetic stability, reproducibility, multipotency 2) well 
established isolation/culture technology 3) ability to differentiate into many vital 
tissues, such as bone, cartilage, skin, nerve etc 
83
. There are three explanations for 
BM-MSC in cardiac regeneration: 1. CMs regeneration, 2. angiogenesis, and 3. 
paracrine effects (Fig. 2.9) 
20
. 
The capability of functional multipotency enables MSCs to regenerate heart 
muscle and numbers of studies showed that BM-MSCs are able to differentiate into 
CMs both in vitro and in vivo. To treat MSCs with 5-aza, an analogue of cytidine, 
has become the most widely used method to induce cardiac differentiation in vitro. 
The potential of MSCs to differentiate into myogenic cells in vitro was first reported 
in 1995 
84
. After exposing rat BM-MSCs to 5-aza for 24h, it was observed that long, 
multinucleated myotube was formed in 7-11 days period, showing evidence that 
MSCs in the BM might become a donor cell type for myoprogenitor cells, which 
could promote cardiomyogeneic regeneration in clinic. Later in 1999, similar results 
were found by using immortalized murine BM stromal cells, which were also 
cultured in 5-aza-containing medium and a cardiomyogenic cell type was isolated 
after repeated screening of spontaneous beating cells 
85
. nearly 30% of the stem cells 
was found to have CM markers like typical sarcomeres with centrally positioned 
nucleuses, atrial granules, action potentials and CM-associated gene expression. 
Five years later, human MSCs at passage 2, treated with 5-aza, were found with the 
capability of cardiac differentiation 
86
. The differentiated myogenic cells expressed 
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high level of proteins, including beta-myosin heavy chain, desmin and alpha-cardiac 
actin. It was suggested that fibroblast growth factor might have functioned 
synergistically with 5-aza in the process of differentiation resulting in an increased 
expression of myogenic phenotype and formation of myotubes 
86
. But some 
adipocyte-like cells were also observed at the same time, and a similar phenomenon 
was also reporte by Wakitani et al. 
84
. Some extra-cellular molecules or 
polysaccharide, such as chitosan and hyaluronic acid, have been also reported to 
assist the process of cardiac differentiation. The reason might be the presence of 
plenty CD44 surface markers on the surface of MSCs which connect to extra-
cellular molecules, and promote cellular functions significantly including as cell 
attachment, matrix assembly, endocytosis, and cell signaling, to stimulate cell 
paracrine signaling or even secrete bioingredients accelerating cell differentiation 
87
.  
Other reports for the cardiogenic differentiation of MSCs utilized bone BMP-2 
and FGF-4 
88
. MSCs cultured in a cardiac differentiation medium with insulin, 
dexamethasone, and ascorbic acid were also found to express CM-specific proteins, 
like cardiac troponin Ⅰ, sarcomeric tropomyosin and cardiac connectin after 4-5 
passages 
89
. Differentiation might have occurred with the presence of 
dexamethasone, and ascorbic acid, which promoted the expression of the cardiac 
specific protein. By co-culturing human MSCs and human CMs at 1:1 ratio, 
Rangappa et al. observed differentiated human MSCs expressing myosin heavy 
chain (MHC), β-actin, and troponin-T (TP-T) 90. The elements of the 
microenvironment, cell density and the ratio of the two cells might also have 
affected the stem cell differentiation. 
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2.3.1.2 Haematopoietic stem cells 
Haematopoietic stem cells (HSCs) are vital stem cells resident in the adult BM, 
and their responsibility is to generate and regenerate the blood-forming and immune 
(haematolymphoid) systems. They are able to generate a very large number of 
progeny HSCs and potential to differentiate into non-haematopietic tissues, such as 
liver and nerve, suggesting that HSCs might also be applied in myocardial repair.  
 It is suggested that HSCs can generate de novo myocardium in vivo. Lin- c-kit+ 
BM cells were injected in the left ventricle of mice, and fetal resembled neonatal 
myocardium was observed after 9 days of injection, and the tissues were tested to 
express numbers of cardiac specific and transcription makers such as GATA-4, 
MEF2, and Csx/Nkx2.5. Connexin 43 (CX43) and a gap junction/intercalated disc 
structure was also observed 
91-93
. However, this protocol was limited by high death 
rate and a highly grafting failure rate (nearly 60%). Thus, the primitive BM cells 
were modified by cytokines, stem cell factors and granulocyte-colony-stimulating 
factors to enhance the viability of stem cells after injection 
94, 95
. Results showed that 
cytokine-modified stem cells significantly decreased the cell death rate by 68%, 
cardiac infarct size by 40%, cavitary dilation by 26% and diastolic stress by 70%.  
Autologous AC133+ bone-marrow cells were implanted into the infarct border 
zone in six MI patients, and their global cardiac function was improved and infarct 
tissue perfusion was increased in 3-9 months after surgery 
91
. Recently, the results of 
three clinical trials proved that the infusion of BM stem cells (including MSCs and 
HSCs) was safe and feasible in patients and improved left ventricular contractile 
function was found 
92, 93, 96
. By comparing the ability to improve the cardiac function 
by three methods - without cell infusion, circulating blood cell infusion and bone 
marrow stem cell infusion, a considerable increase was found in left ventricular 
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2.3.1.3 Adipose-derived stem cells 
Adipose-derived stem cells (ADSCs) can be easily isolated and possess many 
similar properties of BM-MSCs, like rapid proliferation and multipotent capabilities 
97, 98
. ADSCs show the capability of differentiating not only along typical 
mesenchymal lineages: adipogenesis, chondrogenesis, osteogenesis, and myogenesis, 
but also into some non-mesenchymal lineages: skeletal myogenesis, cardiac, 
neurogenesis etc 
99
. Compared with BM-MSCs, the main advantages of ADSCs for 
regenerative medicinal applications includes its ability of harvest by a minimally 
invasive procedure and it also contains a higher number of MSCs (2-10% in total 
adipocytes number) than present in BM (about 0.002% in nucleated cells) 
100
. 
Therefore, ADSCs provide a promising alternative option to cardiac repair. 
Similar to BM-MSCs, the treatment of 5-azacytidine could drive ADSCs into 
CMs. The differentiation of ADSCs from rabbits to CM lineage by using 5-aza was 
first reported in 2003 
101
. Three weeks after 5-azacytidine treatment, cells began to 
spontaneously beat and showed positive to cardiac protein markers, including 
myosin heavy chain, α-actinin, and troponin-I. Furthermore, these differentiated 
cells maintained the characters of cardiac cells more than two months after the 
treatment. Later in 2004, ADSCs of C57Bl/6N mice were found to be able to 
differentiate spontaneously into CMs by culturing in a semisolid methylcellulose 
medium with insulin, transferrin, IL-3, and IL-6, without the addition of 5-aza 
treatment 
102
. After culturing for 2 weeks, some cells started to contract 
independently and revealed a pacemaker activity and specific cardiac markers, such 
as MLC-2v and connexin43. A similar phenomenon was observed using a standard 
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culture condition (αMEM, 20% serum) for ADSCs 103, but the rate of differentiation 
ranged from 0.005% to 0.07%, which was very low. It is also found that ADSCs 
secreted high level of VEGF, and when anti-VEGF receptor antibodies were added, 
the cardiac differentiation was blocked. These results also indicate that VEGF is a 
vital factor for spontaneous differentiation of ADSCs into CMs. It is reported that 
CD133+ brown ADSCs have the capability of induction of BM-MSCs into CMs 
when mixed together and co-cultured 
104
. It is also reported that transient exposure to 
a rat CM extract could drive human ADSCs to differentiate into CMs 
105
. Three 
weeks culture after 1h exposure to a nuclear and cytoplasmic extract of rat CMs, 
ADSCs formed binucleated and striated cells and expressed spontaneous beating and 
several CM markers, such as sarcomericα-actinin, desmin, and cardiac troponin I. It 
is proposed that the induction of differentiation might be relative to the stage of stem 
cell cycle, and remodeling of DNA and chromatin might also be involved 
105
. It is 
interesting to note that rat CM extracts can drive the differentiation of human cells, 
but requires further investigation. 
It is found that cardiac function after MI was improved and left ventricular 
remodeling was reduced after intramyocardial injection of ADSCs into Lewis rats’ 
hearts 
106
. The effect of intracoronary application of ADSCs compared with BM-
MSCs to improve cardiac function was assessed in a porcine acute MI model 
100
. 
The result indicated that after injection for 30 days, ADSCs and BMSCs 
significantly decreased the perfusion defect, increased cardiac ejection faction, and 
improved the thickness of the heart wall and blood vessel density in the infarct area 
than the carrier administered control samples.  
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Table 2.3 Effect of various growth factors and chemical reagents on cardiogenic differentiation of 
embryonic stem cells 
Extrinsic factors & 
(ESC source) 
Main results Reference 
①Growth factors:   
Activin and BMP-4 
(human) 
Engrafted human myocardium attenuated the ventricular 
dilation and preserved regional and global contractile function; 









BMP-2 or BMP-4, in combination with FGF-4, induced 
cardiac myocyte formation in posterior mesoderm 115 
TGF-β and BMP-2 
(mouse) 
TGF-b1 and BMP-2 enhanced CM differentiation, resulting in 
increased contractile regions with in embryoid bodies together 
with increased myofibrillogenesis. 
119 
BMP-2 or BMP-4 
(chick) 
Expressions of CNkx2-5 and GATA-4 were elicited and the 





Up-regulation of cardiac-specific proteins and mature CMs 





CM differentiation was enhanced in the early phase but 
inhibited in the later phase 
128 
FGF-2 and BMP-2 
(mouse) 
FGF-2 and BMP-2 could only enhance the cardiac 
differentiation at the optimized concentration (1.0ng/ml in 




The number of beating embryoid bodies was increased and the 
expression of the cardiac-specific transcription factors and 








Proliferation of premyocardial cells were increased and 




The number of beating embryoid bodies and cardiac-specific 
myosin heavy chain αand β were increased. 
122 
②Chemical reagents:   
5-azacytidine 
(human) 
The beating cells expressed markers characteristic of CMs and 




DMSO induced the expression of cardiac specific transcription 
factors GATA-4 and Nkx2.5, and increased the intracellular 
Ca2+ levels 
35, 110, 117 
Dynorphin B 
(mouse) 
Cardiac differentiation of mouse ESCs was found associated 
with dynorphin B and complex subcellular redistribution of 




Accelerated expression of cardiac-specific genes was induced 




The number of beating embryoid body-like spheres increased 




Spontaneous and rhythmic contractile activity was displayed 




H2O2 or menadione are of benefit to cardiomyogenesis 116 
HGF: hepatocyte growth factor; IGF: insulin-like growth factor; PGF-BB: platelet-derived growth factor-
























2.3.1.4 Embryonic stem cells 
ESCs are derived from the inner cell mass of the pre-implantation embryos, 
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possessing the capability of self-renewal and pluripotency to differentiate towards 
any cell type. They contain a variety of transcription factors and signaling molecules 
and potentially generate derivatives of all three germ layers (ectoderm, mesoderm, 
endoderm), including muscle, hematopoietic, endothelial, pancreatic, hepatic, lipid, 
cartilage, or neuronal and glial cells
107
. Lots of studies have been carried out to 
establish various protocols to differentiate ESCs into CMs, and a lot of culture 
protocols have also been established. It is reported that human ESCs cultivated in 
suspension are able to spontaneously differentiate into CMs 
108
. After culturing for 
more than 30 days, cells from the spontaneously contracting areas in embryoid 
bodies expressed several cardiac-specific genes and proteins, as well as action 
potential. The strategy of co-culturing hESCs with visceral-endoderm-like cells from 
the mouse was also utilized for differentiation to CMs 
109
. Sarcomeric marker 
proteins, chronotropic responses, and ion channel expression were observed after 1 
week. Table 2.3 shows the different growth factors and chemical reagents used 
commonly to drive ESC differentiation to CMs 
35, 110-132
.  
In general, the cardiac differentiation from ESCs is mediated by several growth 
factors and signaling biomolecules associated with some cardiac specific 
transcription factors. Studies showed that GATA-4 and Nkx-2.5 are two most 
critical factors for cardiacmyogenic differentiate. In addition, BMP-2 was found to 
functionalize importantly in stimulating cardiac formation in vertebrate embryos
133
, 
and GATA-4 and Nkx-2.5 could regulate the expression of BMP-2. The other 
soluble molecules and functional bioingredients, such as FGF, insulin-like growth 
factor and dimethyl sulfoxide (DMSO), have also been demonstrated to participate 
in cardiac formation of vertebrates
133
. It was reported that the exposure of ESCs to 
electrical fields was found to promote cardiomyogenic differentiation. The 
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mechanism of electrical stimulation driving ESCs into CMs might be that the 
electrical field generates reactive oxygen species (ROS) in cells, which might further 
affect ESCs to differentiate into cardiac cells 
134
. ROS plays an important role as 
intracellular second messengers and stimulate signaling cascades for growth and 
differentiation of numbers of stem cells. The key challenges for ESCs are prevention 
of immunological rejection of grafted cells, avoiding the introduction of 
undifferentiated cells and control of specific cardiac differentiation.  
 
2.3.1.5 Induced pluripotent stem cells 
A novel induced pluripotent stem (IPS) cells has been established to open a new 
gate for basic research and regenerative medical applications, even in cardiac repair, 
as these cells do not have the ethical issue of ESCs anymore. IPS cells are a type of 
“artificial” stem cells that induced originally from mouse and human adult somatic 
cells through reprogramming by transduction of defined transcription factors 
135
. IPS 
cells are pluripotent and have the ability to differentiate towards all three germ layer-
derived cells
136-139
. The same growth factors and protocols which can drive ESCs to 
differentiate into CMs are applied for IPS cell differentiations 
138-140
.  
Comparative differentiative ability of ESCs and IPS cells indicated that the 
analyzed IPS cells form beating embryoid bodies much slower and with lower 
efficiency, but showed nearly identical features on molecular, structural, and 
functional aspects to ESC-derived CMs. Later, mouse IPS cells were treated using 
VEGF, and their differentiations were found not only into CMs, but also to 
endothelial and mural cells, as well as to arterial, venous, and lymphatic endothelial 
cells 
135
. In 2009, the differentiation of human IPS cells into CMs was induced by 
OCT4, SOX2, NANOG, and LIN28 transgenes, and results showed that although 
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there were less numbers of contracting embryoid bodies from IPS cells, the cardiac 
gene expression patterns, sarcomeric organizations and electrophysiology 
characteristics of IPS cells derived CMs were indistinguishable to ESC derived CMs, 
which means IPS cells are an alternate choice as an autologous donor cell type for 
cardiac regeneration and cardiovascular research 
140
. Later, IPS cells, induced from 
murine fibroblasts reprogrammed with human stemness factors OCT3/4, SOX2, 
KLF4, and c-MYC, was injected into infarcted hearts of male athymic nude mice, 
and the post-ischemic contractile performance, ventricular wall thickness, and 
electric stability were restored while in situ regeneration of myocardium, and blood 
vessels were also achieved 
141
.  
Although IPS cells are promising, concerns exist on the risks in applying IPS 
cells directly in clinic practices. The pluripotency of IPS cells and the risk of 
tumorigenicity might increase due to the retroviral insertion of c-Myc 
142, 143
. 
Moreover, in cardiogenenic differentiation, mixed population of CMs including 
nodal, atrial and ventricular cells are generated, which would raise concerns of 




2.3.2 Materials for cardiac tissue engineering 
Biomaterials have critical functions in TE. They serve as matrices to provide 
physical and chemical environment to mimic the native tissue, to release bio-
molecules to stimulate cell migration and attachment, to provide mechanical support 
and to induce tissue regeneration. The basic idea of current biomaterial fabrication is 
to mimic the ECM of specific tissue to provide physical, chemical or biological cues 
to determine cell behavior. Therefore, specific requirements are targeted on specific 
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tissue engineering scaffolds. Scaffolds for cardiac TE should possess the features 
such as 1) the ability to deliver and foster cells 2) biodegradability 3) suitable 
mechanical property that suits the contraction of native myocardium and 4) porous 
structure for vascularization. 
Biomaterials used for myocardial TE include both natural and synthetic 
polymeric materials. Natural polymers used in cardiac TE include collagen, fibrin, 
peptide nanoﬁber, gelatin, alginate etc, and they are capable of performing specific 
biochemical, structural functions in site. To mimic natural microenvironment, the 
preference of using native polymers is inevitable because of the presence of 
multifunctional and highly bioactive groups. But their poor mechanical properties, 
potential of immune response and difficulty to process limit their application. On the 
other hand, Synthetic polymers applied in cardiac TE include PGS, PLA, PCL, PU, 
PEU, PET, PP, PTFE and PNIPAAm. The main advantages of synthetic polymers 
are precise design of mechanical properties and geometric form, and the potential 
defined chemical properties with stable degradability 
6
. However owning to the lack 
of bioactive signals, synthetic biomaterials alone are less biofriendly than native 
biomaterials, and hence they need to be modified with adhesion peptides or 
biological molecules. 
Conductive polymeric scaffolds, such as PPy, polyaniline (PANI) and poly (3,4-
ethylenedioxythiophene) (PEDOT), have recently been applied for myocardial repair, 
though they are successfully applied in muscular and neural TE 
144-152
. The 
investigation of the adhesion and proliferation of H9c2 rat cardiac myoblast cells on 
conductive and non-conductive PANI films showed that the cells grown on 
conductive films exhibited a slightly prolonged period of delayed attachment and 
growth 
153
. Injectable alginate-PPy scaffolds were fabricated and injected into rat 
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infarcted myocardium, and the scaffolds were found to increase the inﬁltration of 
myoﬁbroblasts into the infarct area and enhanced the myocardial repair 154. It has 
also been reported that conductive polymer-contained scaffolds could enhance the 
proliferation of cells, such as the nerve cells and cardiac cells. NSCs on PLLA/PANi 
scaffolds showed higher proliferation than those on PLLA nanofibers after 8 days of 
cell culture [43]. Compared to poly(ε-caprolactone-co-lactide) (PLCL) nanofibers, 
the myoblasts proliferation was higher on PLCL/PANi nanofibers even after using 
30% of PANi within these scaffolds [44]. Conductive polymers are therefore very 
useful scaffolds for myocardial TE that could potentially assist in the electrical 
stimulation of CMs. 
Hydrogels in cardiac TE have potential of injectables and convenience to integrate 
with the active force generated by the cardiac tissue. Zimmermann et al. had an 
important contribution towards hydrogel-based cardiac TE 
155, 156
. CMs in collagen 
gels incorporated with growth factors were cultured and loaded with cyclic 
mechanical stretch, and the engineered tissue was found to display specific 
characteristics of myocardium, and even displayed contractile properties. The 
injection of in situ-forming alginate hydrogel into the infarcts of rats was showed as 
an effective approach towards adverse cardiac remodeling and dysfunction 
157
. A 
novel photopolymerizable PEGylated ﬁbrinogen hydrogel was fabricated and 
cultured with rat neonatal CMs or human ESCs 
158, 159
. Results showed that CMs 
demonstrated fast maturation and spontaneous contraction, and the ESCs expressed 
cardiogenic differentiation. A biodegradable, thermoresponsive poly(NIPAAm-co-
AAc-co-HEMAPTMC) hydrogel was fabricated and injected into the infarcted heart 
and a thicker left ventricular wall and higher blood vessel density was observed in 
the injected area 
160
. A family of injectable hydrogel composites based on collagen, 
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chondroitin sulfate and PNIPAAm copolymer was developed and the hydrogel 
exhibited good oxygen permeability and mechanical properties, which is potentially 
used for cardiac TE 
161
.  
Porous scaffolds are suitable options in tissue engineering, providing macroscopic 
pores for the migration of cells and affect vascularization in cardiac TE. ESC 
derived CMs (ESC-CMs) were cultured in macroporous gelatin microspheres and 
the CMs entrapped in microspheres were found to express cardiac specific proteins 
and retain identical action potentials comparable to the control group 
162
. Recently, 
the growth of rat MSCs (rMSCs) cultured on silk fibroin–polysaccharide cardiac 
patches was examined for cardiomyogenic differentiation using 5-aza 
87
. The 
cellular effects of silk fibroin/chitosan (SF/CS) and SF/CS/hyaluronic acid hybrid 
patches on cardiomyogenic differentiation of induced rMSCs showed remarkable 
upgrade in the expression of cardiac muscle genes (Tnnt2 and Acta1) and of cardiac 
proteins (cardiotin and CX43). Porous acellular bovine pericardium with MSCs and 
poly glycolic-acid with ESCs have been applied as cardiac patches to repair 
infracted myocardium in animal model and the results were promising 
163, 164
. In 
addition, specific design of unique porous microstructures might mimic the 
anisotropic mechanical properties of ventricular myocardium to a higher extent. An 
accordion-like honeycomb microstructure in PGS was created, which could match 
the anisotropic mechanical property of ventricular myocardium and promoted the 
formation of rat CMs’ alignment 165.  
 
2.3.3 Nanofibrous scaffolds for cardiac tissue engineering 
The “golden criteria” of designing a TE scaffold is to emulate the native ECM of 
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the target tissue in order to regulate specific cellular behavior. In the native tissue, 
the ECM is composed of a network of nanometer-sized proteins and GAGs, and gels 
of these molecular components fill the interstitial space and act as a compression 
buffer against the stress placed on the ECM, dynamically influencing on phenotypic 
and other cellular behavior by providing chemical and biological informational 
signaling cues 
166, 167
. The architecture of the native tissue highlights the challenges 
that we encounter, so as to achieve the nano-structured scaffolds with the 
biomimetic features and excellent physiochemical properties closely mimicking the 
native ECM. Nanofibrous scaffolds are of much interest recently because of their 
nanoscaled morphology mimicing the hierarchy of native ECM, and their high 
porosity accelerates blood vessel formation, and high surface area benefits for cell 

















Fig. 2.10 Schematic depiction of the electrospinning process. (A) The random fibers collect 
on a grounded plate. (B) A rotating mandrel technique to create aligned fibers. 
Corresponding random and aligned fibers produced from shown setup 
170
. 
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2.3.3.1 Fabrication of nanofibrous scaffolds 
Numbers methods have been developed to fabricate nanofibers, but the 
techniques to control the architecture of the scaffold mimicking the fibrous 
architecture of ECM are still rare. There are currently only three manufacturing 




Developed in the early 1900s for application in the field of textiles and filters, 
electrospinning was the most common and cost-efficient method to prepare ultrafine 
polymeric fibers in the size of micro/nano-scale 
168
. Its principle is to use 
electrostatic forces to draw polymer solutions or melts into whipped jets, producing 
continuous fibers on a conductive collector after solvent evaporation 
169
. A typical 
electrospinning set up (Fig. 2.10A) consists of a (1) syringe pump to control the flow 
rate of the polymer solution to be electrospun; (2) conductive capillary tube to guide 
the solution to a high electric field; (3) high voltage source to stretch the polymer 
solution into ultrathin fibers; and (4) grounded collector to collect electrospun fibers 
in a static or dynamic way 
170-172
. During the electrospinning process, the polymer 
solution held at the needle tip (the Taylor cone) is subjected to the surface tension as 
well as the opposed electrostatic force by the high voltage source. Once the electric 
potential surpasses a threshold, the electric force overcomes the surface tension and 
viscoelastic force of the polymer droplet, resulting in the initiation of a charged jet 
from the tip of the Taylor cone. While the solvent evaporates during the jet spraying, 
the continuously flowing polymeric fibers are captured on an appropriate collector 
173, 174
. According to this theory, it is obvious that the electrospinning process can be 
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tuneable by a number of variables and parameters, including solution properties 
(polymer molecular weight, solution concentration, viscosity, conductivity and 
surface tension), system set-up (flow rate, electrical field strength or voltage, needle 
tip design, collecting distance and collector geometry), and environmental factors 
(temperature and humidity) 
26, 175-179
. Adjustment of these processing parameters and 
solution properties enables manufacturers to control the properties of the resultant 
nanofibrous scaffolds, such as fiber diameter, porosity, area to volume ratio, surface 
topography and mechanical properties 
26-29
. Moreover, fiber alignment can be 
controlled by rotating the grounded collector and higher velocity of the grounded 
surface leads to better fiber alignment (Fig. 2.10B) 
180, 181
. Due to its production 
simplicity, flexibility and cost efficiency, electrospinning has attracted considerable 
attention for a broad range of applications, such as filtration, textiles, energy, 
acoustics, as well as in regenerative medicine 
171, 182
. 
There are a wide range of polymers capable of being electrospun, which are 
appealing to biomedical application and give flexibility to scientists and engineers in 
designing the nanofibrous scaffolds. Generally, two groups of polymers, synthetic 
polymers and natural polymers, are mainly used in electrospun nanofiber fabrication. 
Synthetic polymers, such as PLA, poly(lactic-co-glycolic acid) (PLGA), PCL, PET, 
poly(ethylene oxide) (PEO) and poly(vinyl alcohol) (PVA), provide great flexibility 
in synthesis, processing, and modification and possess good mechanical properties 
183-188
. On the other hand, natural polymers, including collagen, gelatin, chitosan, 
silk protein and fibrinogen, are extracted from the natural ECM of human or animals. 
As both synthetic and natural polymers have advantages and disadvantages, research 
has progressed to fabricate composite nanofibers by blending two kinds of polymers 
together in an effort to maximize the benefits of both. These novel composite 
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nanofibers, taking advantage of the physical properties of the synthetic polymer and 
the bioactivity of the natural polymer while minimizing the disadvantages of both, 
have become the active trend of electrospun nanofibrous scaffold designing 
189
. 
Additionally, drugs or grow factors can be incorporated into the polymers to create a 
controlled delivery system required for tissue regeneration 
25
. Various drugs, grow 
factors and biomolecules can be successfully introduced into nanofibers with the co-
axial electrospinning technique, which uses one (or more) coaxial needles or 
capillaries that form one or more inner and outer channels 
190-192
. The fabrication of 
core-shell nanofibers, using drugs or bioactive components as the core and a 
synthetic polymer as the shell  offer mechanical and structural support to the cells, 
and enable controlled release of the active components through these scaffolds 
193
.  
Recently, electrospun scaffolds have been considered high-attentive fibrous 
scaffolds because they can easily control the diameters, mechanical properties, and 
even orientation of fibers, which all are significant for cardiac TE. Rat CMs were 
seed on electrospun PCL nanofibers, and the cells were found to attach on the 
scaffolds, start beating after 3 days, and cardiac-specific proteins such as α-myosin 
heavy chain, connexin43 and cardiac troponin I were expressed after 14 days 
194
. 
Thick cardiac grafts were created by overlapping up to 5 layers of the cell-nanofiber 
membranes 
195
. After 1 week of culture in vitro, morphologic and electrical 
communication between the intimately adhered layers was established, and 
synchronized contraction was also observed. Stable and homogeneous PLGA-
gelatin-elastin nanofibers were electrospun for cardiac TE, and it was found the 
scaffolds promoting H9c2 rat cardiac myoblasts proliferation and assisting BMSCs 
to penetrate into the center of scaffolds 
196
.  
Although the benefits of electrospinning make it an attractive choice for fiber 
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fabrication in the biomedical field, some obstacles still need to be overcome. This is 
because three dimensional (3D) scaffolds could be required in TE application, while 
the electrospinning technique can mainly fabricate two-dimensional (2D) 
nanofibrous sheets, and it is a challenge to create suitable 3D constructs for clinical 
applications. Another drawback of electrospun nanofibers is that the scaffolds do not 
have pores large enough for not only cell penetration, but vascular ingrowth, which 
is imperative for vascularised tissues.  
 
2.3.3.1.2 Self-assembly 
Molecular self-assembly provide a novel and attractive appoarch to develop 
nanoscale materials base on its simplicity, practicality and diversity of application. 
To fabricate supramolecular architectures, this technique is a spontaneous process 
that causes biomolecules to undergo self-association and form structurally ordered 
and stable arrangements without any external manipulation 
197
. These biomolecules, 
including bi- or tri-block copolymers, complex DNA structures, lipids, proteins and 
peptides, interact and aggregate in aqueous solutions through a number of non-
covalent bonds such as hydrogen bonding, hydrophobic, electrostatic, metal-ligand, 
π-π, and van der Waals interactions 198-203. The greatest advantage of molecular self-
assembly for the fabrication of nanoscale scaffolds is that the structures of the final 
assemblies can be easily and finely manipulated by molecular chemistry, assembling 




To recognize the interactions and mechanisms of self-assembly of biomolecules 
is crucial for the design of nanoscale materials. Among a variety of self-assembling 
molecules present in the nature, peptides and proteins were considered more 
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important and motivation in understanding the mechanisms of pathological 
aggregation and, more importantly in regenerative medicine, knowing the functions 
and mechanisms of higher order assembly of proteins such as collagen, because 
natural collagen is the basic component in ECM and has been proved useful 
biological functions in improving cell growth, tissue regeneration and drug delivery 
203. The assembly of collagen molecules into collagen fibrils is a “bottom-up” 
process, which is motivated by the loss of solvent molecules from the surface of 
protein molecules, resulting in assemblies with a circular cross-section to minimize 
the surface area to volume ratio of the ultimate architecture  
205, 206
. The collagen 
fibrils are further stabilized and crosslinked side-by-side as parallel bundles by lysyl 
oxidase to assemble collagen fibers with diameter ranging from 50 to 500 nm 
206, 207
. 
However, it is complex and difficult for these biomolecules to be assembled by 
laboratory procedures, and most of the biomolecules require specific configurations 
or need modification.  
Peptide-amphiphiles (PAs), because of their inherent biocompatibility and 
biodegradability, have been known as one of the most common building blocks for 
fabricating self-assembled nanofibers for clinic applications. PAs consist of a 
hydrophilic peptide head and a hydrophobic tail, where the head integrates a 
bioactive sequence and the tail is responsible for aligning the head, promoting self-
assembly and inducing suitable secondary, super-secondary and tertiary 
conformations 
203, 208
. There are three major driving forces to regulate self-assembly 
of PAs: (1) hydrophobic interactions of the alkyl tails, (2) hydrogen bonding among 
the middle peptide segments, and (3) electrostatic repulsions between the charged 
amino acids. The hydrophobic interactions and hydrogen bonding are both attractive 
forces that potentially improve the aggregation of PA molecules, while the 
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electrostatic repulsions cause disassociation of the molecules. The subtle balance of 
these energy forces results in final assemblies, including size, shape and interfacial 
curvature of the scaffold 
204
. Therefore, the nano-arrangements and subsequent 
physicochemical behaviors of PAs can be controlled by the adjustment of the 
molecules and electrostatic forces that are relative to the self-assembly process. The 
manipulation can be tuned by molecular design, parameters of the assembly setting 
and introduction of co-assembling moluecules 
204
. Assembled PA nanofibers, 
consisting of a hydrophobic core and a hydrophilic shell in aqueous condition, have 
been widely applied in encapsulating small biomolecules such as hydrophobic drugs 
or semiconducting organic molecule, guidance of the assembly of inorganic 
nanoparticles and template inorganic mineralization, as well as tissue regeneration 
204, 209-217
.  
By using self-assembly, it is possible to fabricate nanostructured fibers with 
diameters of approximately 10 nm, which is much smaller than those produced by 
electrospinning, and the nanofibers with the ability of self-assembling in vivo can be 
potentially used as an injectable scaffold for tissue regeneration. However, similar to 
electrospun nanofibers, incapability of controlling the pore size and pore structure of 
self-assembled nanofibers is the main drawback. Moreover, small pore sizes ranging 
from 5 to 200 nm are insufficient for cell accommodation, migration and 
proliferation 
218
. Another concern is the biocompatibility of self-assembled 
nanofibers, because they are fragmented and may be susceptible to endocytosis 
218, 
219
. Finally, the weak mechanical properties and fast biodegradation ratio of these 
nanofibrous hydrogels need improvement to enable support of cell growth, matching 
the requirements of tissue regeneration. 
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2.3.3.1.3 Thermally induced phase separation 
TIPS has been utilized for long time to produce porous polymer membranes and 
scaffolds for TE under the mechanism of the thermodynamic instability of polymer 
solutions at certain temperatures 
220-223
. The process of TIPS usually includes five 
steps: polymer dissolution, phase separation and gelation, solvent extraction, 
freezing, and freeze drying 
168, 197
. The solution of some polymer, for example 
aliphatic polyesters, is thermodynamically unstable at certain low temperatures, 
which leads to phase separation. After the solvent is extracted, evaporated or 
sublimed, the polymer-rich phase solidifies and results in a polymer foam. Scaffolds 
with different pore sizes and structures can be created by tuning the types of 











PLLA is one of the biodegradable polymers which was firstly fabricated into 
nano-fibrous matrices to mimic natural ECM architecture by using TIPS technique 
224, 225
. PLLA is dissolved in tetrahydrofuran (THF) with a polymer concentration of 
5% or lower, and further reduce the temperature to stimulate phase separation. After 
the solvent is removed, the construct is freeze-dried to yield the nanofibrous PLLA 
scaffolds with fiber diameters ranging from 50 to 500 nm with high porosity of 98% 
 
Fig. 2.11 SEM micrographs of a PLLA fibrous matrix prepared from TIPS: (a) ×500; (b) ×20000 224. 





. Besides PLLA and other aliphatic polyesters, some biopolymers, 
such as polyhydroxyalkanoate (PHA), chitosan and gelatin, are also fabricated into 
nanofibers by TIPS procedures 
226-229
. It is reported that an appropriate gelling 
temperature is critical for the formation of nanofibrous structures, where higher 
gelling temperatures result in microfiber formation and lower gelling temperatures 
lead to fiber diameters reducing to nanoscale 
226
. However, fiber diameters of the 
scaffolds cannot be managed by changing either the gelling temperature or the 
solution concentration, as both of them show little influence on fiber diameter 
224
. 
On the other hand, increasing the solution concentration was able to improve the 
mechanical properties of the scaffolds 
224
.  
Macroscopic pore structures (> 100 µm) with good interconnectivity in a scaffold 
play an significant role in cell penetration, neo-vascularization and tissue 
regeneration 
230, 231
. Unfortunately, electrospinning and self-assembly are only able 
to fabricate nanofibrous scaffolds with micropores structures (less than 10 µm). A 
big benefit of TIPS is that it can fabricate nanofibrous scaffolds coupled with other 
processing techniques, such as particulate leaching or 3D printing, to develop 
complex 3D structures with macroscopic pore network 
200
. Zhang et al. combined 
particulate leaching with TIPS to generate macroporous and nanofibrous polymer 
scaffolds 
225
. They dripped PLLA-THF polymer solution onto a sugar particle or 
fiber assembly in a mold and reduce the temperature to the gelling point for phase 
separation to occur. Afterwards, the gel-sugar composite was soaked in distilled 
water to remove the solvent and sugar was leach out. Further freeze-drying was 
carried out to obtain, 3D nanofibrous scaffolds with interconnected macropores. In 
this way, various complex porous architectures are designed and developed by 
incorporating sugar porogens with different geometrical shapes and size scales 
225, 




. However, only a limited number of polymers could be processed with TIPS 
technique, and the difficulty of building up a commercial setting also limits its 
application. 
 
2.3.4 Challenges in cardiac tissue engineering 
Current research in cardiac TE is approaching a breakthrough, but the 
requirement to reestablish the functional complexity of heart muscle is still a key 
challenge for cardiac TE. The organization of cardiac cells and ECM together with 
its electrical & mechanical properties is all factors that challenge the bioengineering 
field of heart regeneration. 
 
2.3.4.1 Cell alignment 
Cell alignment is found in myocardial tissues in the body and aligned ECM plays 
an important role in CM behavior and function in vivo. However, it is still a crucial 
challenge in cardiac TE to develop an anisotropic tissue graft substitute with ECM-
like molecular composition and structure for guiding cell alignment 
234
. Aligned 
nanofibers have been widely reported to be able to direct the cell morphology and 
guide cell orientation 
235, 236
. Aligned biodegradable non-woven PLGA nanofibers 
were fabricated to provide topographical cues for isotropic or anisotropic growth of 
neonatal rat CMs, and cell orientation and elongation were enhanced on aligned 
nanofibers 
237
. Random and aligned PU microfibers were electrospun seeded with 
primary cardiac ventricular cells to investigate the influence of substrate-enforced 
cell alignment 
238
. The electrically-coupled CMs were found to be organized along 
fiber orientation on both scaffolds with CX43 localized to cell-cell connection. 
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Furthermore, aligned scaffolds yielded highly oriented CMs with extensively lower 
steady state degrees of atrial natriuretic peptide, indicating that substrate-enforced 
cell organization lead to the maturity of cell phenotype. Electrospun 
polymethylglutarimide nanoﬁbrous meshes was fabricated to guide the orientation of 
CMs and aligned cell growth was guaranteed when the distance between fibers is 
below 30 μm 239. To mimic the cell alignment of myocardium and enhance cardiac 
differentiation, a tissue engineered cardiac graft were generated by simultaneously 
electrospinning elastic PU nanofibers and electrospraying MSCs 
240
. By controlling 
the processing parameters, the obtained tissue constructs possessed the fibrous and 
anisotropic structure, and mechanical response similar to native myocardium. 
Enhanced cardiac differentiation was detected in the cardiac graft by the higher 
expression of cardiac markers, such as GATA4, Nkx2.5 and MEF2C.  
 
2.3.4.2 Vascularization for cardiac regeneration 
The basic reason for heart infarction is due to inadequate blood supply, and even 
new CMs or stem cells can be induced or generated, they will also need an 
integrated vascular supply network to maintain their survival and functional 
expression 
17
. The similar factor limits the thickness of an engineering tissue 
construct, because cells without oxygen and nutrition supply in the centre area die. 
Current tissue culture systems can only maintain the viability of CMs on 2D 
scaffolds. Some researchers tried to apply rotating or perfusion bioreactors to 
convect and diffuse oxygen and improve the viability and differentiation of cultured 
cells 
241-244
. However, only perfusion or rotation cannot serve as a substitute for 
complete vascularisation, and vascular infiltration is critical for 3D engineering 
tissue scaffold.  
 Chapter 2 Literature review 
50 
 
Several growth factors have been demonstrated to stimulate formation of new 
blood vessels. VEGF and basic fibroblast growth factor (bFGF) are major regulating 
molecules of neovascularization, and both of them have been applied for the 
vascularization of myocardial tissue engineering. VEGF was incorporated into 3D 
porous poly (lactide-co-glycolide) matrix to promote scaffold vascularization 
245
. A 
porous alginate scaffold was fabricated incorporating poly (lactic-co-glycolic acid) 
microspheres which were capable of controlled bFGF release 
246
. After implantation 
into rat perioneum, the released bFGF encouraged the formation of vasculization. 
The efficacy of slow-releasing bFGF by gelatin hydrogel microspheres was 
evaluated. After implanting bFGF microspheres into ischemic myocardium of rat 












2.3.4.3 Advanced bioreactors for cardiac tissue engineering 
As in vitro studies sometimes give different outcomes from animal models, 
bioreactors mimicking in vivo physiochemical (e.g. temperature, pH, pO2, and 
pCO2), electrical, mechanical and biological conditions are designed to encourage 
 
Fig. 2.12 Cardiac tissue engineering within bioreactor systems. 





. Bioreactors provide various mechanical, electrical and 
chemical signals to stimulate the biological behavior of cells. If these stimulations 
are insufficient, cells would lose their functions, become disorganized, and even die. 
Therefore, bioreactors are considered important for tissue regeneration, especially 
for cardiac regeneration.  
Bioreactors suitable to drive cardiac differentiation are designed to simulate 
several aspects of the real in vivo environment, as shown in Fig. 2.12, including the 
convection of oxygen, the presence of hemoglobin via oxygen carriers, mechanical 
loading and electrical stimulations 
248
. Oxygen perfusion was found to improve the 
spatial uniformity of cell distribution and enhance cardiac gene expression 
242, 244, 249, 
250
. Perfluorocarbon emulsion was added into the culture medium to imitate oxygen 
supply by hemoglobin and the engineered cardiac tissue was found to produce 
higher amounts of DNA, express cardiac markers and have better contractile 
properties 
244
. Table 2.4 summarizes the details of bioreactors and stimulation 
conditions used by various researchers for cardiac TE










Several reports shows the importance of mechanical force for the reorientation of 
tissue-engineering structures and the phenotypic modulation of cells, which might 
Table 2.4 Types of Bioreactors and stimulations utilized for cardic tissue engineering 
Stimulation Biomaterials Cells Reference 
Convection of oxygen fibrous PGA NRCMs 250 
Convection of oxygen collagen sponge NRCMs 242 
Presence of hemoglobin PGS NRCMs 244 
Mechanical loading collagen I + MPM NRCMs 252 
Electrical stimulation - ARCMs 254 
Electrical stimulation - ARCMs 255 
Electrical stimulation - NRCMs 256 
Electrical stimulation collagen gel ARCMs 258 
Electrical stimulation collagen sponge NRCMs 259 
Electrical stimulation PVC NRCMs 260 
Electrical stimulation collagen scaffold NRCMs 261 
Electrical stimulation carbon nanotube PLA nanofiber MSCs 262 
NRCM: neonatal rat cardiomyocyte; ARCM: adult rat cardiomyoctye; PGA: polyglycolic acid; 
PGS: poly(glycerol-sebacate); MPM: membrane protein mixture; PVC: Polyvinyl carbonate 
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enhance the function of adult cells and stimulate the differentiation of stem cells 
258
. 
engineered heart tissues (EHTs) were casted with neonatal rat cardiac myocytes, 
collagen Ⅰand matrix factors. Under phasic mechanical stretch, EHTs displayed 
important hallmarks of differentiated myocardium, including highly organized 
sarcomeres, gap junctions, desmosomes, and contractile characteristics 
252, 253
. An 
electro-tensile bioreactor was designed to load mechanical force on cardiac 
engineering tissue structures and detected the contractile force response to 
investigate the effect of mechanical forces on CMs structure 
258
. 
The function of CMs is not only to contract and generate pressure to pump the 
blood, but also to rhythmically spread the wave of electrical activation over the 
entire myocardium. During a heartbeat, billions of CMs are synchronized to transmit 
contractile forces from one cell to the next through the electrical spread of action 
potential. Due to the lack of the sinoatrial cells and atrioventricular cells to 
spontaneously generate and spread action potentials, CMs cannot passively generate 
action potential and contraction, and hence loss their function and gap junction with 
other cells easily, so they normally cannot survive long in vitro. Proper electrical 
stimulation may cause the cellular membrane potential to increase up to the 
threshold in order to generate action potential and contraction, which might help the 
functional recovery and orientation of CMs. Electrical field might alter receptor 
conformations, move the receptors or channels on the cellular membrane, and affect 
DNA transfection via electrophoresis, or activation of calcium channels. Therefore, 
electrical stimulation is an important approach in cardiac TE 
263
. 
Researchers have investigated the properties and mechanisms of CMs under 
electrical stimulation in vitro 
254-256
. Tandon et al. spent most of their time and 
energy to design electrical stimulating bioreactors for myocardial TE and to 
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optimize the parameters 
248, 264, 265
. The electrical stimulation chamber and the 
protocol they designed are able to be applied not only for cell cultivation on 2D 
substrates, but also for engineering 3D cardiac construction. In addition, as to 
initiation of electrical stimulation, they recommended 24h after cell seeding for 2D 
substrates and 3 days for 3D scaffolds, like matrigel. The electrical signal 
parameters, especially the pulse frequencies and amplitudes depend on the types of 
cells and species, which range from 0.05-20 Hz and 0.1-10 V/cm, and 1-2 ms of 
pulse duration is long enough to excite heart tissue and cells. As to electrodes, 
among carbon, stainless steel, titanium and titanium nitride, carbon electrodes were 
determined because of their superior current injection characteristics and high 
resistance to chemical reactions and corrosion. By electric field stimulation 
(rectangular pulse, 2 ms, 5V/cm, 1Hz) for 5 days, CM alignment and coupling were 
induced, and the amplitude of synchronous contraction was increased 
259
. Neonatal 
rat CMs were cultured on the microstructured polyvinyl carbonate under electric 
field to study the impact of microstructure and electrical signals on cells, and it was 
observed that the influence of mircostructure of scaffolds to cell alignment is larger 
than the effect of electrical stimulation 
260
. Electrical stimulation might assist in the 
alignment of CMs and functional enhancement, providing a potential method of 
application in myocardial TE.  
To date, some conductive nanofibers have been used in cardiac TE. The co-
electrospinning of PANI with gelatin was carried out to obtain conductive 
nanofibers with diameters of 60-800 nm and H9c2 rat cardiac myoblast cells were 
further seeded to investigate their potential for cardiac TE 
266
. Results showed that 
the concentration of PANI, influenced the conductivity of the nanofibers and further 
influenced the morphologies of cells seeded on them. The cells were found to reach 
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conﬂuency and retained cell morphology after 1 week in culture media. Carbon 
nanotube based PLA nanofibers were electrospun as a conductive platform to direct 
MSCs differentiation towards a CM lineage under electrical stimulation 
262
. 
Electrical stimulation guided the orientation and elongation of the cells 
perpendicular to the direction of the electric field. Moreover, an upregulation of 
cardiac markers, such as cardiac MHC, Nkx2.5, GATA-4, cardiac TP-T and CX43 
was detected after 10 days. Above studies indicated that conductive nanofibers, 
providing nanoscale biomimetic and electroactive cues, would be promising 
electrical stimulation platform for cardiac regeneration. 
 
2.4 Summary 
Heart failure is one of the most common health issues with increasing prevalence 
and it has become the leading cause of death in most developed countries. The lack 
of regenerative ability of adult human myocardium is limited and grossly 
insufficient to compensate for the loss of CMs and supporting vasculature after MI. 
Cardiac TE, aiming to create engineered functional cardiac tissue constructs, holds 
great potential to restore injured myocardium. A large number of studies have been 
carried out on cardiac TE, but several limitations exist in its application and greater 
improvements are required in the field of myocardial regeneration. Choosing the 
right cell sources are the first step that drives regeneration of any tissue including the 
cardiac tissue. Stem cells have been proven to be able to contribute to 
vascularization and to differentiate into CMs in certain stimulations, and hence stem 
cells are the most promoting cell sources for myocardial regeneration and require 
extensive investigations. Biomaterials or scaffolds are another important factor that 
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might revolutionize the aspect of myocardial regenerations. Nanofibers are 
promising materials for regenerative medicine, as they structurally mimic the 
architecture of the native ECM. Electrospinning is the most common method to 
produce nanofibers in TE application due to its low-cost, simplicity and versatility, 
and cell behaviour can be regulated by tuning the properties of nanofibers, including 
chemical component, fiber diameter and fiber alignment. Therefore, a combination 
of stem cells with novel nanofibrous scaffolds might be able to enhance cell growth 
and proliferate, to promote vascularisation and to support the damaged heart, bring 
new treatments for patients with heart failure. 
 
(Note: Some of the text and figures in this chapter have been published and 
reprinted from Kai D, Jin G, Prabhakaran MP, Ramakrishna S. Electrospun synthetic 
and natural nanofibers for regenerative medicine and stem cell. Biotechnol J.8:59-72. 
2013 Copyright with permission from John Wiley and Sons) 
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Chapter 3  
Fabrication of electrospun 
polycaprolactone/gelatin nanofibers 
 
3.1 Introduction  
MI is one of the most common heart diseases which results in cardiac remodeling 
and inability of the heart to pump sufficient amount of blood to meet metabolic 
requirements 
40
. Furthermore, the loss of CMs is irreversible and leads to 
progressive heart failure, because CMs from adult hearts have limited intrinsic 
regenerative capability to replace the lost cells 
40
. Cardiac TE is one of the most 
promising strategies to reconstruct infarcted myocardium and one major challenge is 
to produce a bioactive substrate with suitable chemical and mechanical properties by 
mimicking the ECM structurally and functionally.  
Electrospun nanofibers are considered attractive as scaffolds for cardiac 
reconstruction applications, because they can be conveniently processed to meet the 
criteria of promoting cell attachment and proliferation due to their high surface area-
to-volume ratio and high porosity of electrospun membranes 
149, 267-270
. Helping cell 
function maintenance or differentiation due to the nanoﬁbrous ECM-mimicking 
features with modifying the biodegradation rates by incorporation and adjusting of 
multiple polymers are also possible by this method 
14, 237
. Electrospun nanofibers 
though demonstrated effective for cardiac TE, there are several challenges facing 
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cardiac TE and the most important criteria for engineering scaffolds is appropriate 
mechanical properties. It is known that the scaffolds for bone repair should have 
proper compressive strength for load bearing and avoiding stress shielding, and the 
materials for nerve regeneration should have suitable mechanical properties for 
bearing of stresses during the surgical procedures etc 
267, 271
. However for 
myocardial reconstruction, a scaffold should have suitable mechanical properties, 
which are able to not only support and protect the donor cells until sufficient new 
ECM is synthesized, but also have optimal compliance for heart beating (diastole 
and systole) 
14. Typically, at the beginning of diastole, the Young’s modulus of the 
heart muscle is 10-20 kPa, and the passive strains almost reach up to 15–22% at the 
end of diastole, and the Young’s module is around 0.2-0.5 MPa (at the end of 
diastole), and tensile strength is about 10-20 kPa 
14, 272
. But most of the commonly 
utilized biodegradable synthetic polymers, such as PLA, PLGA, have high stiffness 
of 1-10GPa, which might inhibit the heart normal contractions. On the other hand, 
the stiffness of native polymers such as collagen, gelatin etc are too less to provide a 
supportive function to the heart. Therefore a composite polymeric scaffold 
fabricated by blending of a synthetic polymer and native polymer could create a 
support scaffold with optimized mechanical property suitable for cardiac TE.  
PCL is a semi-crystalline biodegradable polyester with a low melting point of 
around 60°C and a glass transition temperature (Tg) of about −60°C, which means 
PCL expresses good ductile and elastic properties at 37ºC 
273, 274
. Despite these 
advantages, its poor hydrophilicity inhibits cell adhesion, migration, proliferation, 
and differentiation 
235, 275
. On the other hand, as a native polymer, gelatin is a 
derivative of collagen and its merits, such as good biodegradability and 
biocompatibility, assist gelatin to be popularly applied in regenerative medicine field 




. In our experiment, PG nanofibrous scaffolds were electrospun for myocardial 
TE. We aimed to mimic the structure and mechanical properties of native heart 
muscles by compositioning the synthetic polymer PCL with natural polymer gelatin 
and thus fabricate scaffolds with proper chemical, mechanical, biodegradable and 
cell adhesion properties for cardiac TE. 
 
3.2 Materials and methods 
3.2.1 Materials 
PCL (Mw = 80,000), gelatin type A, 1,1,1,3,3,3-hexafluoro-2-propanol (HFP), 
Dulbecco Modified Eagle’s Medium (DMEM), monoclonal anti-α-actinin antibody 
produced in mouse, anti-troponin-T antibody,  anti-connexin-43 antibody, were 
purchased from Sigma–Aldrich (St. Louis, MO). Hexamethyldisilazane (HMDS) 
and polyvinyl alcohol mounting medium were obtained from Fluka. Fetal bovine 
serum (FBS), phosphate buffered saline (PBS), trypsin–EDTA were obtained from 
Gibco, Singapore. CellTiter 96 AQueous One solution reagent was obtained from 
Promega (Singapore). Methanol was from Sinopharm chemical reagent Co. , 
Singapore. 
 
3.2.2 Fabrication of nanofibrous scaffold 
PCL was dissolved in chloroform/methanol (25:75) to make an 18 wt% solution 
by stirring for 12 h. PCL/gelatin solutions were obtained by dissolving 7 wt% of 
PCL and gelatin at a weight ratio of 50:50 (PG1:1) and 25:75 (PG1:3) into HFP, by 
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overnight stirring. The solution was filled into a 5 ml syringe with a 27G blunted 
stainless steel needle for electrospinning. The flow rate was 1 ml/h and high voltage 
of 12 kV (Gamma High Voltage Research, USA) was applied one the tip of the 
needle. The polymer solution was drawn into fibers by electrical force and collected 
on an aluminum foil covered collector. The distance between collector and needle 
tip was 10 cm. After collection, nanofibers were restored into vacuum oven at room 
temperature before characterization and cell culture experiments.  
 
3.2.3 Characterization of scaffolds 
The morphology of electrospun nanofibrous scaffolds were studied by scanning 
electron microscopy (JSM5600, JEOL, Japan) at an accelerating voltage of 15 kV. 
Before observation, the scaffolds were coated with gold using a sputter coater (JEOL 
JFC-1200 fine coater, Japan). The diameter of the fiber was measured from the SEM 
micrographs using image analysis software (Image J, National Institutes of Health, 
USA). 
Attenuated total reflectance Fourier Transform Infrared (ATR-FTIR) 
spectroscopic analysis of electrospun nanofibrous scaffolds was performed on 
Avatar 380 (Thermo Nicolet, Waltham, MA, USA) over a range of 800–3500 cm-1 
at a resolution of 4 cm
-1
. 
Tensile properties of electrospun nanofibrous scaffolds were determined using a 
tabletop tensile tester (Instron 3345, Canton, MA, USA) at a load cell capacity of 10 
N. Test specimens of dimensions 10 mm breadth × 30 mm length were tested at a 
crosshead speed of 5 mm/min at a gauge length of 20 mm with or without soaking in 
PBS (24h). A minimum of six specimens of individual scaffolds were tested and the 
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results obtained were plotted for the stress–strain curve of the scaffolds. 
To test the degradation of nanofibers, the scaffolds were placed in excess PBS 
(pH 7.4) and shaken at 37 ºC. At each time point, samples were removed from PBS, 
washed with DI water and dried in vacuum. The dry sample weight was measured 
and compared with the initial dry weight to determine the fractional mass remaining. 
In addition, electrospun nanofibrous scaffolds were soaked in PBS in vitro at 37ºC 
for 1 week. After the degradation period, samples were washed with DI water and 
dried in vacuum oven at room temperature for 48 h. Later, SEM was applied to 
evaluate the morphology of the scaffolds.  
 
3.2.4 Cardiomyocytes isolation and seeding 
Primary CMs was isolated from New Zealand white rabbits (2.0-2.5 kg) by 
collagenase digestion as previously reported by Takasaki et al. 
279
. Then, after 
successful isolation, the harvested CMs continued to culture in DMEM 
supplemented with 10% FBS, and 1% penicillin/streptomycin.  
The electrospun nanofibers with 15 mm diameter were placed in 24-well tissue 
culture plate and stainless steel rings were used to press the nanofibers to prevent 
them from floating up and ensure fully contact between nanofibers and wells. After 
sterilized under UV light for 2 h, the specimens were washed three times with PBS 
and seeded with CMs on the scaffolds at a cell density of 1.0×10
4
 cells/well.  
 
3.2.5 Cell proliferation assay 
The colorimetric MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was utilized to evaluate 
cell proliferation on electrospun PCL, PG1:1, PG1:3 scaffolds and tissue culture 
plates (TCP). After culturing for 2, 4 and 6 days in 24-well tissue culture plate, 
medium was removed and CMs were washed with PBS for three times. After PBS 
was siphoned off, 20% of MTS reagent containing serum free medium was added 
into the well to incubate. After incubation with the reagent for 4 h at 37ºC in 5% 
CO2 incubator, aliquots were added into a 96-well plate. The absorbance of each 
well was detected by a spectrophotometric plate reader (Fluostar Optima, BMG Lab 
Technologies, Germany).  
 
3.2.6 Cell morphology 
SEM was utilized to analysis the morphology of rabbit CMs cultured on 
electrospun PG nanofibers after 6 days of cell culture. After washed three times with 
PBS, the samples was fixed with 3% glutaraldehyde solution for 4 h. The cell-
nanofiber constructs were further washed in DI water, and further dehydrated with 
different concentrations of ethanol (50%, 70% 90%, 95% 100%) for 15 min each. 
Finally HMDS was added onto the wells and the samlpls was dried in fume hood at 
room temperature for 24 h. 
 
3.2.7 Immunocytochemistry 
After 6 days of culture, medium was removed and 300 μl of ice cold methanol 
was added to fix the CMs and further 0.1% Triton X-100 was used for pretreatment. 
CMs were then blocked with 3% bovine serum albumin and incubated individually 
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with primary antibodies α-actinin (α-ACT) and TP-T, respectively for 2 hour period 
at dilutions of 1:100 each. After washing with PBS, cells were incubated with 
secondary antibody, Alexa flour 488 at a dilution of 1:400 at room temperature. 
4’,6’-diamidino-2-phenylindole hydrochloride (DAPI) was also added for 
counterstaining. Samples were then mounted on glass slides using mounting 
medium and observed with a confocal laser scanning microscopy (CLSM). 
 
3.2.8 Statistical analysis 
All the data presented are expressed as mean ± standard deviation of the mean. 
Single-factor analysis of variance was carried out to compare the means of different 
data sets, and a value of p ≤ 0.05 was considered statistically significant. 
 
3.3 Results 
3.3.1 Morphology, chemical and mechanical properties of electrospun nanofibers 
Fig. 3.1 shows the morphology of electrospun PCL, PG1:1, and PG1:3 nanofibers. 
The average fiber diameters were obtained as 430 ± 108 nm , 239 ± 37 nm, 273 ± 20 







Fig. 3.1 SEM micrographs of electrospun (A) PCL, (B) PG1:1, (C) PG1:3. 
 Chapter 3 Fabrication of electrospun PCL/gelatin nanofibers 
63 
 
Surface characterization of PCL and PG nanofibers was carried out by FTIR. Fig. 
3.2 shows the FTIR spectra of PCL, PG1:1 and PG1:3 nanofibers. PCL showed the 
characteristic carbonyl peak at 1720 cm
-1





(symmetric), C–O stretching at 1050 cm-1, C–O–C stretching at 1240 
cm
-1
 (asymmetric). These PCL related stretching modes were observed in all three 
electrospun scaffolds, but the strengths of these peaks decreased with the decreasing 
PCL concentration in composite scaffolds. PG1:1 and PG1:3 showed the 
characteristic amide I and amide II peaks of gelatin at 1650 cm
-1
 and 1550 cm
-1
, and 















Fig. 3.3 shows the typical stress-strain curves of PCL, PG1:1 and PG1:3 
electrospun nanofibrous scaffolds with or without soaking in PBS. In dry condition, 
Table. 3.1 Young’s modulus and tensile strength for nanofibers under dry and wet conditions. 
  PCL PG1:1 PG1:3 
Dry 
Young’s modulus (MPa) 8.84 ± 1.41 21.96 ± 1.09 25.31 ± 1.96 
Tensile strength (MPa) 1.82 ± 0.16 1.14 ± 0.10 1.71 ± 0.27 
Wet 
Young’s modulus (MPa) 4.72 ± 0.53 1.45 ± 0.20 0.17 ± 0.04 




Fig. 3.2 FTIR spectra of PCL, PG1:1 and PG1:3 nanofibers. 
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the average Young’s modulus of PCL scaffold was 8.84 ± 1.41 MPa, with the tensile 
strength of 1.82 ± 0.16 MPa. PG1:1 showed Young’s modulus of 21.70 ± 0.99 MPa 
and tensile strength was 1.14 ± 0.10 MPa, while the Young’s modulus for PG1:3 
was 25.32 ± 2.0 MPa and tensile strength of 1.71 ± 0.27 MPa. After soaking in PBS, 
the Young’s modulus, tensile strength and the strain at break of the three nanofibers 
decreased significantly (Table. 3.1). In wet condition, PCL showed Young’s 
modulus of 4.72 ± 0.53 MPa and the tensile strength decreased to 0.73 ± 0.12 MPa. 
Young’s modulus for PG1:1 reduced to 1.45 ± 0.20 MPa and tensile strength 
reduced to 0.17 ± 0.05 MPa, while the Young’s modulus for PG1:3 dropped to 0.17 
± 0.04 MPa and tensile strength of 0.02 ± 0.01MPa. The low mechanical properties 
of gelatin containing nanofibers are due to the weak physical properties of gelatin. 
As shown in Fig. 3.3, the strain at break of PG1:3 in wet condition is below 25% 









3.3.2 In vitro degradation of PCL/gelatin nanofibers 
The degradation properties of the nanofibers were revealed by calculating the 
mass loss of the samples with regard to the incubation time. The results (Fig. 3.4A) 
 
Fig. 3.3 Typical stress-strain curves of PCL, PG1:1 and PG1:3 nanofibers in dry and wet 
condition. 
 Chapter 3 Fabrication of electrospun PCL/gelatin nanofibers 
65 
 
showed that the PCL degraded very slowly and it only lost <2% of its original mass 
in 10 weeks. On the other hand, the incorporation of gelatin increased the 
degradation rates of the nanofibers dramatically and the main degradation occurred 
in the first week, in which PG1:1 lost 23.9% of its original mass and PG1:3 lost 76.4% 
of its mass. In this period, No significant morphological changes in PCL scaffoldwas 
observed (data not shown). PG1:1 scaffold was found to show a certain degree of 
swelling and degradation (Fig. 3.4B), while PG1:3 scaffold showed significant 
morphological changes (Fig. 3.4C). After inculbation for 10 weeks, PG1:1 remained 
59% of its original mass and PG1:3 only remained 27.3% of its mass. PCL is a 
synthetic polymer with low degradation properties, while gelatin can easily dissolve 
in aqueous phase and hence by blending PCL with gelatin the degradability of the 
nanofibers are tunable by adjusting the concentrations of gelatin within the blend. 
Results of this study showed that the biodegradability of PCL/gelatin nanofibrous 











Fig. 3.4 (A) Degradation profile of PCL, PG1:1 and PG1:3 nanofibers with incubation time, 
and the morphology of (B) PG1:1 and (C)PG1:3 after 1 week of degradation. 
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3.3.3 Cell proliferation 
The proliferation of CMs on different electrospun nanofibrous scaffolds were 
evaluated after 2, 4 and 6 days by MTS assay. As shown in Fig. 3.5, cell 
proliferations on both PG1:1 and PG1:3 scaffolds were significantly higher than 
PCL scaffolds (p ≤ 0.05). The results indicated that the gelatin containing scaffolds 
benefitted in proliferation of CMs, due to the presence of natural protein gelatin in it. 
Conversely, the cell proliferation on PG1:3 was not significantly higher than the cell 












3.3.4 Cell morphology and cell-scaffold interaction 
Fig. 3.6 shows the SEM micrographs of CMs grown on different nanofibrous 
scaffolds. Compared to PCL nanofibers, more cell attachment and proliferation was 
observed on both PG1:1 and PG1:3 nanofibrous scaffolds. The SEM images at 
 
Fig. 3.5 Proliferation of CMs on TCP, PCL, PG1:1 and PG1:3 nanofibers, as determined 
by MTS assay. *Significant against cell proliferation on PCL scaffolds at p ≤ 0.05. 
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higher magnification (Fig. 3.6F, H) also showed that the cells spread on PG1:1 and 
PG1:3 and interacted with each other throughout the surface of the nanofibers. 
Furthermore, the gelatin-containing nanofibers were found to retain CM morphology 
and orientation similar to those observed on TCP controls, but this was not observed 


















3.3.5 Cardiac protein expressions 
To validate the cardiac cell phenotypic protein expressions, immunofluorescent 
 
Fig. 3.6 Morphology of CMs on TCP (A, B), PCL (C, D), PG1:1 (E, F) and PG1:3 (G, H) 
after 6 days of cell culture. The magnification is 500 in (A), (C), (E), (G), and 1000 in (B), 
(D), (F), (H). 
 
Fig. 3.7 Immunofluorescent staining of CM on TCP, PCL, PG1:1 and PG1:3 nanofibers for α-
actinin (green) and troponin-T (red). Scale bars = 50 µm. 
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staining for α-ACT and TP-T was carried out for cells cultured on the nanofibrous 
scaffolds after six days of culture time. Fig. 3.7 shows that the rabbit CMs expressed 
three major cardiac specific proteins on different nanofibrous scaffolds. Less number 
cells were found to attach on PCL nanofibers, and they showed round morphologies 
with lesser cell spreading and also expressed low levels of the cardiac markers. 
Conversely, CMs on PG1:1 and PG1:3 expressed high level of α-ACT and TP-T and 
showed multi-angular shapes, attaching on nanofibers interactively and elongating 
along the nanofibers, orientating with cross-striations, the sarcomeric structures of 
mature cardiac myocytes. 
 
3.4 Discussion 
By integrating cells, suitable materials, and biological cues in carefully designed 
biomaterial scaffolds, TE could be one of most effective and valuable approaches for 
the reconstruction and regeneration of injured heart by MI or other heart diseases 
13, 
14, 280, 281
. However, there are many challenges facing cardiac TE and the crucial 
challenge is the development of a suitable cardiac graft substitute with cardiac-like 
molecular composition, structure, and mechanical properties 
280
. Therefore while 
considering materials suitable for myocardial regeneration, a good elastic and ductile 
mechanical property for the material should be given priority. Polymers such as PCL 
with a low melting point and a glass transition temperature has a soft and flexible 
characteristic, and can be electrospun to obtain continuous and uniform nanofibers 
with defined patterns, and it has also been successfully applied in many tissue 
reconstructions, including cardiac TE 
149, 235, 270, 282, 283
. Shin et al. electrospun PCL 
nanofibers on wire rings as a mechanical-loading scaffold for cardiac TE, and 
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showed PCL nanofibers could withstand contractive force 
194, 195
. However, the low 
hydrophilicity and lack of surface cell-recognition sites of PCL limits its cell affinity 
267
. On the other hand, gelatin is a derivate from collagen, present in several animal 
tissues and has excellent biocompatibility 
284
. However, the weak mechanical 
property and high degradability of gelatin makes it highly unsuitable for TE research 
276, 285
. Therefore, in our study, electrospun nanofibers were fabricated from a blend 
of PCL and gelatin to mimic the fibrillar structure and mechanical characteristics of 
native cardiac muscle ECM, and the in vitro cell proliferations and cardiac protein 
expression were evaluated. Our study demonstrated the efficacy of electrospinning 
composite PCL/gelatin nanofibrous scaffolds and utilizing them as a potential 
scaffold for cardiac TE. 
SEM images of the electrospun nanofibrous scaffolds showed that simple 
blending of gelatin with PCL significantly decreased the fiber diameters of PG 
nanofibers compared to PCL nanofibers. Small fiber diameters of electrospun 
scaffold provide higher surface area that is beneficial for sufficient oxygen and 
nutrient perfusion for cell growth on PG nanofibers compared to those on PCL 
nanofibers. The FTIR analysis of PG1:1 and PG1:3 scaffolds showed amide peaks at 
1650 cm
-1
 and 1550 cm
-1
, indicating the functional amino groups present on the 
surface of the composite scaffolds and this was not present on PCL scaffolds. The 
appearance of amide functional groups might increase the hydrophilicity of 
PCL/gelatin scaffolds, and further favors cell adhesion, proliferation and elongation 
286
. 
A suitable mechanical property is important for a scaffold and different 
mechanical properties are required for different tissue regeneration applications 
287, 
288
. For cardiac TE, the scaffold should not only be able to provide a temporary 
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support for cell growth and assist surgical procedures, but also, more importantly it 
must be soft and elastic enough to assist heart beating 
165, 272, 280
. Previous 
nanofibrous scaffolds used in cardiac TE usually have very strong mechanical 
properties. The Young’s modulus of PLGA/gelatin/elastin nanofibers fabricated by 
Li et al. ranged from 100-500 MPa 
196, and the Young’s modulus and tensile 
strength of  PANI/gelatin nanofibers electrospun by Li et al. even reached up to 
1300 MPa and 10 MPa, respectively 
266
. The extremely high stiffness might 
influence the cardiac contractile function to inhibit the relaxation of heart. In our 
study, the Young’s modulus (21.70 ± 0.99 MPa) and least tensile stress (0.87 ± 0.11 
MPa) of dry PG1:1 were significantly less than the PLGA/gelatin/elastin and 
PANI/gelatin nanofibers reported, and these values further reduced in wet condition 
to match the mechanical properties of native heart muscle, indicating that PG1:1 
nanofibers provide lower resistance to cardiac contraction. It is a great challenge to 
use synthetic materials to repeat the unique non-linear elasticity of naturally cardiac 
muscle, but electrospun PCL/gelatin nanofibers provide a promising candidate 
towards mechanical compatibility of the heart. In addition, biodegradability test 
indicated that higher concentration of gelatin resulted in weak structure and fast 
degradation rates, which limited PG1:3 as a favorable substitute for cardiac 
reconstruction. We therefore confirmed PG1:1 as a more suitable scaffold for 
cardiac TE compared to PCL and PG1:3, due to its comparatively low mechanical 
property and slow degradation properties, with encouraging cell proliferations on 
PG1:1 scaffolds compared to PG1:3 scaffolds. 
MTS assay showed PG nanofibers significantly improved CM proliferation, 
showing that the presence of gelatin accelerated cell attachment and proliferation. In 
a similar study by Li et al. reported that blending PLGA nanofibers with gelatin and 
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elastin promoted H9c2 rat cardiac myoblasts proliferation and migration 
196
. Cell 
proliferations on PG1:3 were found 67% and 85% higher than PG1:1 scaffolds on 
day 2 and day 4, respectively. However a mere 7% increase in cell proliferation was 
found on PG1:3 scaffolds than PG1:1 on day 6, indicating that a higher amounts 
(75%) of incorporation of gelatin improved CM proliferation for the first few days 
(until day 4), and further cell proliferation was comparable to cell proliferation on 
scaffold containing 50% gelatin (PG1:1). Results of cell proliferation shows that the 
stability of PG1:1 and optimal concentrations of gelatin requirement is optimal for 
PG1:1 nanofibers and a higher concentration of gelatin in PG1:3 did not necessarily 
improve the cell proliferations, most probably due to the higher degradations of 
gelatin within this scaffold loosing the integrity of the nanofibers. Due to the fast 
degradation rate and loss of stability of nanostructure of the scaffolds over 6 day 
period, it’s possible that PG1:3 might not be as good a scaffold in comparison to 
PG1:1 for promoting CM proliferations on a long run. 
The SEM micrographs of CM grown on different scaffolds showed PG surface 
was almost fully covered with cells while there were only a few cells on PCL, 
confirming gelatin improves CM attachment and proliferation. The SEM images at 
higher magnification showed that unlike cells on PCL, CMs on PG1:1 
communicated more frequently with each other along the nanofibrous structures and 
created more cell-cell connections, potentially increasing the functional gap 
junctions, cytoskeletal organization, and excitation-contraction coupling that is 
necessary for cell contraction. In Fig. 3.6H, PG1:3 nanofibers were broken by the 
stresses of cell grabbing, meaning the scaffold is too weak to support and integrate 
with cells. Moreover, if the scaffold completely degrades before sufficient number 
of cardiac cells proliferate, migrate and ECM secretion to form an integrative tissue, 
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the graft cells will die and reconstruction will fail. Results of our study confirmed 
that weak and unstable structure of PG1:3 nanofibers limits its application as a 
suitable scaffold for cardiac TE. 
Immunostaining test showed that the cultured CMs expressed cardiac-specific 
proteins such as α-ACT and TP-T. The protein expressions showed that the CMs 
preserved their characters and were not overgrown by cardiac fibroblasts. α-ACT is 
a functional protein, which attaches to thin filaments in adjacent sarcomeres in 
muscle cells and coordinates contractions between sarcomeres 
289, 290. Also α-ACT 
expresses the cohesiveness and mechanics of the cytoskeleton. Results of SEM 
images in Fig. 3.7 shows that cells on PCL did not spread out, indicating the high 
hydrophobic nature of PCL. Conversely, on PG1:1and PG1:3 scaffolds, cells 
attached, proliferated and spread along the orientation of nanofibers, and cross-
striations were also visible. TP-T protein is a component of thin filament, and it 
regulates cardiac muscle cell contractions by binding with calcium ion 
87
. TP-T was 
observed to be dispersed more diffusely and expressed higher in CMs on PG1:1, 
indicating that PG1:1 scaffold performs better to retain the contractile ability of CMs. 
Results of cell proliferations together with CM protein expression studies indicated 
that PG1:1 is a favorable scaffold for cell growth and interaction, to potentially 
assist cell contraction and orientation. Overall, PG1:1 nanofibrous scaffolds showed 
desirable physicochemical characteristics and superior biocompatibility, for 
application as a suitable graft for cardiac reconstruction. 
 
3.5 Conclusion 
An ideal matrix for promoting cardiac tissue regeneration requires an ECM 
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mimicking structure for cell attachment and proliferation with appropriate 
mechanical strength for developing contractile force and withstanding expansion 
loads. In this study, we prepared PCL/gelatin nanofibrous scaffolds with weight 
ratios of 50:50 (PG1:1) and 25:75 (PG1:3) by electrospinning process. PG1:1 
nanofibers were found to provide suitable mechanical and degradation properties 
compatible for cardiac regenerations than PCL and PG1:3 scaffolds. CMs seeded on 
PG1:1 nanofibrous scaffolds showed significantly higher cell adhesion, proliferation, 
and enhanced expression of cardiac specific proteins. Hence PG1:1 holds great 
potential as a suitable cardiac substrate, promising its convenient application for 
reconstruction of infarcted myocardium. 
 
(Note: Some of the text and results in this chapter have been published and 
reprinted from Kai D, Prabhakaran MP, Jin GR, Ramakrishna S. Guided orientation 
of cardiomyocytes on electrospun aligned nanofibers for cardiac tissue engineering. 
Journal of Biomedical Materials Research, Part B-Applied Biomaterials.98B:379-86. 
2011 Copyright with permission from John Wiley and Sons) 
 




Cardiomyogenic differentiation of human 
mesenchymal stem cells on nanofibers 
 
4.1 Introduction 
To date, attention has turned to the potential of stem cells to repair the damaged 
myocardium, and multiple stem cell types have been considered for MI therapies, 
including MSCs, HSCs, ESCs and IPS cells 
280
. Attempting to amplify and/or 
recreate the natural processes of tissue formation, the therapeutic stem cells are 
expected to augment the creation of myocardium in vivo, and even replace damaged 
or dead cells. Among all the stem cells, MSCs isolated from bone marrow, possess 
some specific advantages as the most preferred stem cell model for MI therapeutic 
development due to 1) self-renew and multipotency, 2) well established 
isolation/culture technology, 3) wide used in tissue engineering application, such as 
bone, skin and cartilage regeneration 
83
. These advantages makes MSCs most 
preferable stem cell model for MI regeneration.  
Recently, a number of studies suggested that MSCs could differentiate into CMs 
by treatment of 5-aza, BMP-2 or FGF-4, as well as by co-culturing with CMs 
20
. A 
possible hypothesis for the in vivo differentiation of migrated MSCs into 
functionally specialized cells is that the tissue-specific microenvironment or the so-
called ‘stem cell niche’ can trigger the commitment of MSCs into a specific cell type 
291, 292
. Nanofibrous scaffolds are able to recapitulate both the structural features of 
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this “stem cell niche” and material features via modifications of the fiber surfaces 
inducing biochemical cues. This type of artificial scaffold with enhanced 
biofunctionality would comprise a more biomimetic microenvironment for ex vivo 
stem cell culture 
293
. The nanofibrous structure has a high surface area to volume 
ratio, providing more substrate for cell attachment (and therefore a higher cell 
density per unit of space) compared with other structures 
294
. Studies demonstrated 
that nanoﬁbrous scaffolds can mimic the natural ECM and give an in vivo-like in 
vitro environment for superior stem cell differentiation 
295-298
. 
However, up to now, the mechanism of MSCs adopting cardiac phenotype upon 
heart failure is elusive and the in vitro induction of MSCs into cardiomyogenic 
lineage still is a challenge. Therefore, this chapter aims to further confirm the 
cardiomyogenic differentiation potential of human MSCs (hMSCs) on the 
biomimetic PCL/gelatin nanofibrous substrate, and to identify the contributing 
factors that trigger MSCs to differentiate into cardiac lineage. PCL/gelatin 
nanofibers were used as a substrate for the cardiomyogenic differentiation of hMSCs 
by treatment of 5-aza in this study, as PCL/gelatin nanofibers has been demonstrated 
to promote the attachment of CMs together with the expression of cardiac specific 
proteins in Chapter 3. VEGF is an important signal protein that stimulates 
vasculogenesis and angiogenesis, but its short half-life cannot meet the long time 
requirements in TE application. Here we incorporated VEGF into the nanofibrous 
scaffolds to further induce the cardiac differentiation of MSCs seeded on the 
scaffolds. The control release of VEGF from the nanofibers could effectively retain 
its bioactivity and optimize the dosage effect. We hypothesize that the synergetic 
effect of the topographical cues of nanofibers and the biological cues of VEGF 
would promote the cardiomyogenic differentiation of hMSCs in vitro. 




4.2 Materials and methods 
4.2.1 Materials 
PCL (Mw = 80,000), gelatin type A, HFP, DMEM, 5-aza, monoclonal anti-α-
actinin, anti-troponin-T and anti-myosin heavy chain antibody produced in mouse, 
were all obtained from Sigma–Aldrich (St. Louis, MO). Hexamethyldisilazane and 
polyvinyl alcohol mounting medium were purchased from Fluka. FBS, PBS, 
trypsin–EDTA were purchased from Gibco, Singapore. CellTiter 96 AQueous One 
solution reagent was purchased from Promega (Singapore). Methanol was purchased 
from Sinopharm chemical reagent Co., Singapore. 
 
4.2.2 Fabrication of eletrospun nanofibers 
PCL/gelatin/VEGF (PGV) nanofibers were prepared by blend and core/shell 
electrospinning processes. To fabricate PGV blending nanofibers (PGV/B), PCL, 
gelatin and VEGF was dissolved in HFP to obtain the electrospinning solution with 
the concentration of 8 wt% at a weight ratio of 1g: 1g: 10μg. After stirred for 24 h, 
the solution was electrospun from a 5 ml syringe with a 27G blunted stainless steel 
needle at a flow rate of 1.0 ml/h. High voltage of 15 kV (Gamma High Voltage 
Research, USA) was applied when the polymer solution was drawn into fibers and 
collected on an aluminum foil wrapped collector kept at a distance of 10 cm from 
the needle tip. PG1:1 nanofibers (defined as PG in the following text) were also 
electrospun using the same parameters as control. A two-fluid coaxial spinneret was 
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used for electrospinning core/shell nanofibers, where the inner needle had a diameter 
of 0.4 mm and the outer needle had a diameter of 1.8 mm. 8 wt% PCL/gelatin (1:1) 
was dissolved in HFP to form the shell solution, while VEGF was dissolved in PBS 
in the concentration of 1 μg/ml to form the core solution. During the core/shell 
electrospinning, the flow rate was set as 0.4 ml/h for core and 1.0 ml/h for shell 
solution. DC power supply was used to provide a high voltage of 18 kV, and a 
collector plate was placed at a distance of 15 cm from the tip of the spinneret to 
collect the PCL/gelatin/VEGF core/shell nanofibers (PGV/CS). The fibers produced 
were subsequently vacuum-dried so as to remove any residual solvents. 
 
4.2.3 Characterization of electrospun nanofibers 
The morphology of electrospun nanofibrous scaffolds were studied by scanning 
electron microscopy (JSM5600, JEOL, Japan) at an accelerating voltage of 15 kV. 
Before observation, the scaffolds were coated with gold using a sputter coater (JEOL 
JFC-1200 fine coater, Japan). The diameter of the fiber was measured from the SEM 
micrographs using image analysis software (Image J, National Institutes of Health, 
USA). Verification of core-shell structure was carried out using transmission 
electronic microscopy (TEM, JEM-3010, JEOL Ltd, Tokyo, Japan) at 300kV, and 
the samples for TEM observations were prepared by collecting the nanofibers on 
carbon-coated Cu grids. In addition, FITC was added into the core solution during 
the coaxial electrospinning, and the FITC included core-shell nanofibers were 
viewed under confocal laser scanning microscopy (CLSM, Olympus Fluoview 
FV1000, Olympus Optical. Co., Ltd., Tokyo, Japan) at excitation wavelengths of 
488 nm to observe the fluorescent core of the electrospun coaxial nanofibers. 
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The wettability of the electrospun nanofibers was evaluated by drop water contact 
angle measurement using a VCA Optima Surface Analysis system (AST products, 
Billerica, MA). The droplet size was 0.5 μl. At least 5 samples were used for each 
test. 
Tensile properties of electrospun nanofibrous scaffolds were determined using a 
tabletop tensile tester (Instron 3345, Canton, MA, USA) at a load cell capacity of 10 
N. Test specimens of dimensions 10 mm breadth × 30 mm length were tested at a 
crosshead speed of 5 mm/min at a gauge length of 20 mm under ambient conditions. 
A minimum of 6 specimens of individual scaffolds were tested and the results 
obtained were plotted for the stress–strain curve of the scaffolds. 
 
4.2.4 In vitro VEGF release study 
In the VEGF release behavior study, 20 mg of each PGV nanofibrous mat was 
soaked in 10 ml PBS at 37ºC with gentle shaking. At each time point, 1 ml of 
supernatant was retrieved from the vial an equal volume of fresh PBS was replaced. 
The concentration of VEGF in the supernatant was determined by human VEGF 
ELISA kit (Immunocell, Singapore). 
 
4.2.5 Human MSCs culture and differentiation 
The electrospun scaffolds were sterilized under UV light for 2h, washed thrice 
with PBS for 20 min each, and incubated in DMEM for 2h before cell seeding. 
HMSCs (Lonza Walkersville, Inc., Walkersville, MD, USA) at early passage (<4) 
were cultured in DMEM supplemented with 10% FBS and 1% 
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penicillin/streptomycin. After reaching 70-80% confluency, the cells were detached 
by trypsin-EDTA and viable cells were counted by trypan blue assay. Cells were 
further seeded onto the scaffolds at a cell density of 1×10
4
 cells/well. Medium was 
changed every 2 days.  
To induce the cardiac differentiation of hMSCs, cells, 24 h after seeding, were 
exposed to α-MEM containing 10 µM 5-aza for 24 h and then washed 3 times with 
PBS. HMSCs continued to be cultured on the scaffolds for 2 weeks till the 
differentiation was evaluated by immunostaining and reverse transcription-
polymerase chain reaction (RT-PCR). 
 
4.2.6 Cell proliferation and morphology assay 
Cell proliferation with and without 5-aza treatment was analyzed after 5, 10, 15 
days using the colorimetric MTS assay. At each time point, cells were washed with 
PBS and incubated with 20% of MTS reagent containing serum free medium. After 
4 h of incubation at 37ºC in 5% CO2 incubator, aliquots were pipetted into a 96-well 
plate and the absorbance of the content of each well was measured at 492 nm using a 
spectrophotometric plate reader (Fluostar Optima, BMG Lab Technologies, 
Germany). 
Morphological study of hMSCs cultured on different scaffolds with and without 
5-aza treatment was carried out after 15 days of cell culture by SEM. The cell-
scaffold constructs were rinsed twice with PBS and fixed in 3% glutaraldehyde for 3 
h. The scaffolds were further rinsed in deionized water and dehydrated with 
increasing concentrations of ethanol (50%, 70% 90%, and 100%) for 20 min each. 
Finally, the cell-scaffold constructs were treated with hexamethyldisilazane and air 
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dried in a fume hood overnight. 
 
4.2.7 Immunocytochemistry 
Double immunofluorescent staining was performed to confirm the 
cardiomyogenic differentiation of hMSCs. After 15 days of culturing, cells were 
fixed using 2.5% paraformaldehyde and permeated using 0.1% Triton X-100. Cells 
were further blocked with 3% bovine serum albumin and incubated individually 
with mouse derived primary antibodies α-ACT, TP-T and MHC for 2 h at dilutions 
of 1:100 each. After washing with PBS, cells were incubated with secondary 
antibody Alexa fluor 488 (green) at a dilution of 1:400 for 1.5 h at room temperature. 
Then the samples were washed thrice with PBS and treated with hMSC specific 
marker CD44 for 2 h at room temperature. This was followed by the addition of the 
secondary antibody Alexa Fluor 546 (Red) and counterstained with DAPI (1:500) at 
room temperature. Samples were then mounted on glass slides using mounting 
medium and imaged using CLSM. The signal intensity of cardiac markers was 
measured by Image J. 
 
4.2.8 Gene analysis with RT-PCR 
After 15 days of culturing, cells on the scaffolds were used to do RT-PCR for 
gene analysis. RNA was extracted from these cells using an RNeasy Mini Kit 
(Qiagen, Valencia, CA). RNA concentration was determined using the S2100 Diode 
Array Spectrophotometer (Biochrom, Cambridge, CB) and cDNA synthesis was 
carried out using 80ng of total RNA and SuperScript II reverse transcriptase with 
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oligo(dT) primers. Real-Time PCR was performed on a iQ® 5 (Bio-RAD, California, 
USA) using 4μl of cDNA, 12.5μl of SYBR Green Master Mix (Qiagen, Valencia, 
CA) and the optimized concentration of primers, topped up to 25μl with nuclease 
free water. The program for all PCRs was the following: 95ºC for 3 min, followed 
by 40 cycles of amplification, consisting of a denaturation step at 94ºC for 60 s, an 
annealing step at 60ºC for 30 s and an extension step at 72ºC for 60 s. 
For the hMSCs induced by 5-aza and cultured on nanofibrous scaffolds, the gene 
expression levels of Tnnt3 (primer: forward, 5'-ACGTGGAAGCAAAAGTCACC-3'; 
reverse, 5'-CCTCCTTCTTCACCTGCTTG-3') was measured, and the reference 
household gene, GAPDH (primer: forward, 5'-CGGATTTGGTCGTATTGG-3'; 
reverse, 5'-TCAAAGGTGGAGGAGTGG-3') was used to normalize the amount of 














Fig. 4.1 SEM micrographs of electrospun (A) PG, (B) PGV/B and (C) PGV/CS nanofibers, 
and (D) a TEM micrograph and (E) CLSM image of PGV/CS. 
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4.2.10 Statistical analysis 
All the data presented are expressed as mean ± standard deviation of the mean. 
Single-factor analysis of variance was carried out to compare the means of different 
data sets, and a value of p ≤ 0.05 was considered statistically significant. 
 
4.3 Results 
4.3.1 Characterization of electrospun nanofibers 
Electrospinning parameters were optimized to obtain bead-less and uniform 
PG/VEGF nanofibers by two different methods: (i) blend spinning (ii) core/shell 
spinning. Fig. 4.1A, B and C shows the morphology of PG, PGV/B and PGV/CS 
nanofibers, with an average fiber diameter of 265 ± 72 nm, 199 ± 37 nm and 297 ± 
79 nm, respectively. To verify the core-shell structure of PGV/CS fibers, TEM and 
CLSM images were taken. As shown in Fig. 4.1D, the core-shell interface with core 
phase PCL encased by gelatin shells were exhibited by TEM analysis. Fig. 4.1E 
displays the CLSM image of PGV/CS modified by FITC, where the fibers look 






The surface hydrophilicity of electrospun scaffolds were determined by water 
contact angle test. Results (Table. 4.1) show that PG, PGV/B and PGV/CS scaffolds 
Table. 4.1 Fiber diameter, water contact angle and mechanical properties of 














PG 265 ± 72 35.2 ± 2.7 7.69 ± 0.80 4.07 ± 1.19 52.0 ± 6.5 
PGV/B 199 ± 37 21.7 ± 1.3 5.54 ± 0.64 1.91 ± 0.43 32.6 ± 7.2 
PGV/CS 297 ± 79 31.4 ± 2.5 8.48 ± 0.53 3.82 ± 0.91 35.8 ± 4.8 
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showed hydrophilic surfaces, with average water contact angle of 35.2 ± 2.7º, 21.7 ± 
1.3º and 31.4 ± 2.5º, respectively. The incorporation of VEGF into the nanofibers 
slightly increased the hydrophilicity of the VEGF blended nanofibers, but the 
surfaces of the core-shell fibers had no significant differences in contact angle 












The mechanical properties of electrospun nanofibers were evaluated from the 
stress-strain curves obtained from the Instron universal mechanical test machine, and 
the Young’s modulus, tensile strength and elongation at break of the scaffolds are 
shown in Fig. 4.2 and Table. 4.1. The average Young’s modulus of PG scaffold was 
7.69 ± 0.80 MPa, with a tensile strength of 4.07 ± 1.19 MPa and elongation at break 
of 52.0 ± 6.5 %. The addition of VEGF weakened the mechanical properties of the 
nanofibrous scaffolds. PGV/B showed the lowest mechanical properties, with 
Young’s modulus of 5.54 ± 0.64 MPa, tensile strength of 1.91 ± 0.43 MPa and 
elongation at break of 32.6 ± 7.2 %, while PGV/CS exhibited a similar stiffness 
 
Fig. 4.2 Stress-strain curve of electrospun PG, PGV/B and PGV/CS nanofibers. 
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(8.48 ± 0.53 MPa) and tensile strength (3.82 ± 0.91 MPa) but lower elongation at 













4.3.2 In vitro release study 
Release behaviors of VEGF from both kinds of nanofibers (PGV/B and PGV/CS) 
were investigated. As shown in Fig. 4.3, PGV/B released 42.8 ± 7.2% VEGF in the 
first 24h, while PGV/CS released 22.8 ± 1.3%, indicating that the initial burst 
release of the VEGF was controlled effectively from the core/shell structure. Further 
on the following 2 weeks, PGV/B showed significantly higher release of VEGF than 
those of PGV/CS at every time point of study. After 504h (21 days) of test, the total 
release amounts of PGV/B and PGV/CS were 81.6 ± 9.6% and 76.9 ± 5.8%, 
respectively. The results indicated that the core/shell structured PGV/CS nanofibers 
were more desirable for preventing the initial burst release as well as controlling the 
 
Fig. 4.3 Release profiles of VEGF from PGV/B and PGV/CS nanofibers. 
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4.3.3 Cell proliferation and morphology 
The proliferation of hMSCs on different electrospun nanofibrous scaffolds with or 
without 5-aza treatment was evaluated after 5, 10 and 15 days by MTS assay. As 
shown in Fig. 4.4, cell proliferations on both PGV/B and PGV/CS scaffolds was 
significantly higher than PG scaffolds (p ≤ 0.05). At the same time, there was no 
significant difference in cell proliferations between PGV/B and PGV/CS scaffolds. 
The results indicated that the VEGF containing scaffolds benefitted towards the 
proliferation of cells, due to the presence of the growth factor in it. In addition, 
compared to the results in normal culture media, 5-aza treatment caused a 
significantly lower numbers of cells on the scaffolds, indicating that the addition of 
 
Fig. 4.4 Proliferation of hMSCs with or without 5-aza treatment on PG, PGV/B and PGV/CS 
nanofibers, as determined by MTS assay. * Significantly different from cell proliferation on 
corresponding sample with 5-aza treatment at p ≤ 0.05; # Significantly different from cell 
proliferation on PG scaffolds with 5-aza treatment at p ≤ 0.05; $ Significantly different from 
cell proliferation on PG scaffolds without 5-aza treatment at p ≤ 0.05. 
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5-aza in culture medium have cytotoxicity to hMSCs and could reduce cell 










Fig. 4.5 shows the morphology of hMSCs on TCP and nanofibrous scaffolds with 
or without 5-aza treatment. hMSCs cultured on the scaffolds using normal media, 
elongated with extended filopodia were observed and there remained 
undifferentiated with fibroblastic phenotype. However, after 5-aza treatment, a few 
hMSCs on the nanofibers exhibited an entirely different morphology and were not 
elongated, instead they appeared round or star shaped, which was similar to the 
morphology of CMs (Fig. 4.5I). 
 
4.3.4 Expression of cardiac-specific proteins by immunostaining  
Dual immunofluorescence staining of cardiac proteins, α-ACT, TP-T and MHC, 
as well as the MSC-specific marker CD44 was carried out for cells grown on the 
scaffolds after 15 days of culture with 5-aza treatment. Fig. 4.6 shows that hMSCs 
on nanofibrous scaffolds expressed significantly higher levels of α-ACT than cells 
 
Fig. 4.5 Morphology of hMSCs on (A, E) TCP, (B, F) PG, (C, G) PGV/B and (D, H) PGV/CS 
without 5-aza treatment (A-D) and with 5-aza treatment (E-H). (I) CMs on nanofibers as 
positive control. Scale bar =100 µm. 
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on TCP. Higher expression of α-ACT was found for cells cultured on PGV/B and 
PGV/CS compared to those on TCP, indicating VEGF could promote the cardiac 
differentiation of hMSCs. Furthermore, cells on PGV/B was found to express higher 
α-ACT than those on PGV/CS, and the reason might be the faster release of VEGF 
from ‘blend’ nanofibers. Fig. 4.7 exhibits the expression of TP-T of hMSCs on TCP 
and nanofibers. hMSCs on nanofibers similarly showed significantly higher 
expression of TP-T than cells on TCP, but there was no significant difference found 
between PG and VEGF containing scaffolds (Fig. 4.7N). As shown in Fig. 4.8, cells 
on TCP expressed lower levels of MHC, and the cells on PGV/B showed the highest 
expression of MHC among all the different scaffolds of this study. In addition, 
although some of those hMSCs were positive to the cardiac proteins, the distribution 
of the protein was quite different from those expressed in the mature CMs, as none 













Fig. 4.6 Dual immunocytochemical analysis for the expression of (A-D) α-ACT and (E-H) CD44 
and (I-L) merged images showing the dual expression on (A, E, I) TCP, (B, F, J) PG, (C, G, K) 
PGV/B and (D, H, L) PGV/CS nanofibers. Scale bar =100 µm. (M) The expression of α-ACT in 
CMs on nanofibers as positive control. Scale bar =40 µm. (N) The signal intensity of α-ACT 
expressed in differentiated MSCs on TCP and PG, PGV/B and PGV/CS nanofibers. 
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4.3.5 RT-PCR analysis for the cardiac-specific gene expressions 
To assess the presence of various nanofibers on regulation of the cardiogenic 
differentiation of hMSCs, the expression of cardiac gene Tnni3 were examined by 
RT-PCR. As shown in Fig. 4.9, there was no significant difference in Tnni3 
expression on TCP and PG scaffolds, while cells on PGV/B and PGV/CS expressed 
significantly higher levels of Tnni3 than TCP. Moreover, PGV/CS nanofibers 














Stem cell therapy has been widely accepted as an effective approach for treating 
heart disease and MSCs with capacity for self-renewal and cardiomyogenic 
differentiation offer an extremely promising therapeutic strategy for myocardial 
 
Fig. 4.7 Dual immunocytochemical analysis for the expression of (A-D) TP-T and (E-H) CD44 
and (I-L) merged images showing the dual expression on (A, E, I) TCP, (B, F, J) PG, (C, G, K) 
PGV/B and (D, H, L) PGV/CS nanofibers. Scale bar =50 µm. (M) The expression of TP-T in CMs 
on nanofibers as positive control. Scale bar =40 µm. (N) The signal intensity of TP-T expressed in 
differentiated MSCs on TCP and PG, PGV/B and PGV/CS nanofibers. 
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regeneration. Instead of directly injecting stem cells to the heart, applying a patch of 
stem cell populated bio-graft might be more versatile in controlling the properties of 
the tissue graft. Furthermore, a well-designed engineered scaffold could be a “stem 
cell niche” which might also provide a suitable microenvironment for the cells to 
proliferate and differentiate into specialized mature cells such as CMs. In this study, 
we fabricated PCL/gelatin electrospun nanofibers containing VEGF as an artificial 














In vitro cardiomyogenic differentiation of MSCs by treatment of 5-aza was first 
reported by Makino et al. in early 1999 
85
. After treatment with 3 μM of 5-aza in 
culture medium, it was found that almost 30% of fibroblast-shaped mouse MSCs 
changed to ball-like phenotype or formed the characteristic rod-shaped CMs, and 




Fig. 4.8 Dual immunocytochemical analysis for the expression of (A-D) MHC and (E-H) CD44 
and (I-L) merged images showing the dual expression on (A, E, I) TCP, (B, F, J) PG, (C, G, K) 
PGV/B and (D, H, L) PGV/CS nanofibers. Scale bar =100 µm. (M) The expression of MHC in 
CMs on nanofibers as positive control. Scale bar =40 µm. (N) The signal intensity of MHC 
expressed in differentiated MSCs on TCP and PG, PGV/B and PGV/CS nanofibers. 
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Further, 5-aza treatment became a classic method for induction of MSCs to CMs. 
However, most of these differentiation studies were carried out on flat culture flasks 
or TCP. Studies of such kind on TCP cannot be regarded as suitable for any 
implantations and hence we carried out the differentiation of MSCs to 
cardiomyocytes on electrospun substrates. We chose a synthetic polymer PCL with 
good elasticity and bio-stability, along with a natural polymer, gelatin which has 
hydrophilic properties and excellent biocompatibility. Composite scaffold 
containing PCL and gelatin might enables to benefits of both types of polymers and 
cover singular defects. In our previous study, we have also demonstrated that PG 
nanofibers possessed suitable hydrophilic, mechanical and degradation properties 
and it favors the growth of CMs, holding great potential as a stem cell niche 
299
. 
Here we demonstrated the capability of differentiation of hMSCs to cardiac lineages 
on these nanofibrous scaffolds by 5-aza treatment. α-ACT is an important 
constituent of the contractile apparatus in the native CMs, TP-T is relative in the 
regulation of the force and velocity of myocardial contraction, and MHC is 
responsible for actin-based motility as well as contraction of cardiac muscle 
300-302
. 
Immunostaining results show that MSCs on PG nanofibers expressed significant 
higher levels of cardiac specific proteins than those on TCP. After quantification, the 
expression of α-ACT in the differentiated MSCs on PG was found 73.2% higher, 
while the TP-T was 3 times higher and MHC was 90.0% higher than that on TCP, 
indicating that the cardiac substrate with nanofibrous-topography could provide 
additional chemical and mechanical cues to promote the cardiac differentiation of 
MSCs. Similarly, Yang et al. found that the differentiated rat MSCs cultured on the 
silk fibroin/chitosan/hyaluronic acid cardiac patches expressed higher cardiac 
proteins (TP-T, cardiotin and CX43) and improved the expressions of cardiac genes 
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To improve cardiac differentiation, VEGF was incorporated in the nanofibers by 
two different approaches: blend spinning and core/shell spinning. VEGF, is as an 
important angiogenic growth factor, has been used in improving cardiac function 
after MI in animal models, and it was able to stimulate angiogenesis with formation 
of vascular structures in the infarcted area 
303, 304
. During our study, the VEGF 
blended nanofibers (PGV/B) had a reduced fiber diameter of approximately 199 ± 
37 nm, further resulting in a decreasing water contact angle as well as reduced 
mechanical properties (Table. 4.1). However, it is important to note that the lower 
Young’s modulus and tensile strength of PGV/B scaffolds might benefit for cardiac 
differentiation mainly because of the relatively non-rigid mechanical properties of 
native myocardium. On the other hand, encapsulating VEGF into PG nanofibers in a 
 
Fig. 4.9 Normalized gene expression of Tnni3 in differentiated hMSCs on TCP and PG, 
PGV/B and PGV/CS nanofibers with 5-aza treatment. 
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core/shell form did not significantly change the mechanical properties of nanofibers, 
except a slight decrease in its elongation at break (Table. 4.1). The possible 
influence on cellular behaviors from the structural and mechanical properties of 
PGV/CS fibers could therefore be eliminated, and the function of VEGF can be 
focused upon in this study.  
In TE, the speed of cell growth is important compared to the speed of regeneration 
of new tissue and rapid proliferation rate would result in an improved tissue 
development. Fig. 4.4 shows that the VEGF containing nanofibers significantly 
promoted the proliferation of hMSCs compared to pure PG nanofibers, even after 5-
aza treatment. Similarly, Huang et al. demonstrated that profiled addition of VEGF 
in the culture media increased the proliferation of mouse MSCs by 1.9-fold 
305
. Pons 
et al. found that co-injection of MSCs with VEGF into MI hearts increased grafted 
cell viability and improved cardiac function 
306
. VEGF could not only promote cell 
proliferation, but more importantly regulate cellular differentiation. As shown in Fig. 
4.6 and Fig. 4.8, cells on both PGV/B and PGV/CS expressed higher level of α-ACT, 
and cells on PGV/B showed higher expression of MHC than those on TCP and PG 
nanofibers. Furthermore, the results of cardiac gene expression by RT-PCR showed 
that the expression of Tnni3 was significantly improved for hMSCs cultured on 
PGV/B and PGV/CS compared to those on TCP and PG scaffolds. Tnni3 is a gene 
of Troponin I, a specific protein in cardiac myocytes, regulating muscle contraction 
in response to the change of calcium ion concentrations. The increased gene 
expression of cells on VEGF containing nanofibers further confirmed that critical 
function of VEGF in the developmental stages of cardiomyogenesis. Chen et al. 
previously reported that adding VEGF in culture medium significant enhanced 
alpha-MHC, Troponin-I, and Nkx2.5 expression in differentiated embryonic stem 





. Later, Song et al. proved that VEGF was a critical factor for the 
spontaneous differentiation of adipose tissue-derived stem cells (ADSCs), and the 
growth factor was responsible for the expression of cardiac markers via a paracrine 
mechanism 
103
. Here we demonstrated the positive function of VEGF in the 
cardiomyogenic differentiation of hMSCs on VEGF containing PG nanofibrous 
scaffolds and PCL/gelatin/VEGF substrates hold great potential application as a 
bioengineered cardiac patch for myocardial regeneration. 
 
4.5 Conclusion 
PG, PGV/B and PGV/CS nanofibrous scaffolds were fabricated to evaluate their 
effects on the growth and cardiomyogenic differentiation of hMSCs under 5-aza 
treatment in vitro. The incorporation of VEGF into the nanofibers improved the 
proliferation of MSCs, and more importantly improved the expression of cardiac 
specific markers. After 15 days, hMSCs cultured on PGV/B and PGV/CS scaffolds, 
showed higher expression of α-ACT, TP-T and MHC proteins and improved 
expression of Tnni3 genes compared to cells grown on pure PG nanofibers. Our 
study demonstrated the potential of PCL/gelatin nanofibers to be a “stem cell niche” 
for cardiac differentiation of hMSCs and MSCs as a suitable cell source for 
myocardial regeneration. 
 




Evaluation of nanofiber/stem cell 
composites as cardiac patch in rat 




Heart transplantation is currently considered as the best surgical option to restore 
the damaged myocardium, but is not the first choice for every patient due to 
limitations, such as the insufficiency of donor organs 
308
. Cell therapy, involving the 
use of live cells to repair failing myocardium, has gained great attention recently, 
opening a new horizon in the clinical field. However, poor cell retention and 
transplantation survival plague this technique 
77
. It is reported that greater than 90% 
of the injected cells are either lost during circulation or leaked out of the injection 
site 
78
. Even in the cases involving the success of injected cells, approximately 90% 
cells died in the first week of transplantation 
79, 309
, which limits the efficiency of cell 
therapy. These limitations of available therapies call for novel and more feasible 
alternative treatment strategies for regeneration of the heart. 
The placement of a cardiac patch by surgical ventricular restoration post-
infarction heart failure is a vital strategy for restoration of the geometry of the heart 
310
. Clinically applied patches of the current century are Dacron (polyethylene 
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terephthalate), Gore-Tex (polytetrafluoroethylene), glutaraldehyde-treated bovine 
pericardium, or glutaraldehyde-treated homografts 
311
. However, these patch 
materials are not viable, do not grow and do not provide pulsatile pulmonary flow, 
causing foreign body encapsulation by the host or it even necessitate reoperations to 
replace the patch 
312
. To serve as a replacement for regeneration biodegradable 
patches with a biodegradation rate comparable with the repair process, elastic and 
strong enough to resist damage from the contracting myocardium and which is 
bioactive to promote cell adhesion and growth is required.  
Tissue-engineered scaffolds as a cardiac patch offer a promising alternative to 
prevent heart failure by increasing the mechanical strength of the infarct for 
myocardial repair. Electrospun nanofibrous scaffolds hold a great potential and 
possess many desirable properties for constructing ideal cardiac patches, such as 
high porosity to permit diffusion of nutrients and metabolic waste necessary for cell 
growth, a high surface area to volume ratio to favour cell adhesion, migration, 
proliferation and differentiation, controllable fiber diameters to mimic the fibrous 
architecture of naturally ECM, and flexibility to blend multiple polymers and 
bioactive ingredients for tuneable mechanical properties and biodegradation rate 
313
.  
In this chapter, we investigated the in vitro and in vivo characteristics of 
biodegradable PCL/gelatin nanofibers as cardiac patches seeded with MSCs to 
repair a surgically created MI in the left ventricle of rat model. We hypothesized that 
the tissue-engineering strategy using electrospun PCL/gelatin nanofibrous patches 
would result in the formation of alternative cardiac tissue that could restore LV 
dilation, promote myocardial angiogenesis and improve cardiac function after 
extensive MI. 
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5.2 Materials and methods 
5.2.1 Nanofibrous scaffold preparation 
PCL was dissolved in chloroform/methanol (1:3) at a weight ratio of 10 wt % for 
overnight under stirring conditions. PCL/gelatin (1:1 at weight ratio) was dissolved 
in HFP to obtain a solution concentration of 7 wt % by stirring for 24 h. Each 
polymer solution was electrospun from 5 ml syringe with a 27G blunted stainless 
steel needle at a flow rate of 1 ml/h. A positive voltage of 12 kV was applied to the 
needle using a high voltage power supply (Gamma High Voltage Research, Ormond 
Beach, FL, USA). An aluminum sheet, used as the collector, was placed at a 
distance of 10 cm from the needle tip. Nanofibers collected on 15-mm cover slips 
and aluminum foil were dried overnight under vacuum and used for cell culture and 
animal experiments. 
 
5.2.2 In vitro cell assay 
MSCs were isolated from bone marrow of Sprague–Dawley (SD, 12–14 weeks) 
rats as previously described 
314
. The rats were obtained from the Medical Institute 
Animal Center of Fudan University (permit number SYXK (Shanghai) 2009-0019), 
China. The investigation was permitted by the Law of the People’s Republic of 
China on the Protection of Wildlife. After the rats were sacrificed by pulling neck, 
the femurs and tibias were removed from the rats, bone marrow was flushed out of 
the bones using PBS containing 100 U/mL heparin in a syringe. Suspension of the 
cells was centrifuged (1000 rpm, 8 min), then the cells were resuspended with 
DMEM (; Gibco Invitrogen, NY) supplemented with 10% FBS (Gibco Invitrogen) 
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and seeded in a 25 cm
2
 plastic flask. At day 3 after incubation, the non-adherent 
cells were discarded, the adhered cells continued to be incubated. The medium was 
changed every three days. The cells were passaged with digestion in 0.25% trypsin 
(Gibco Invitrogen) when 70% ~ 80% confluent reached. The experiments described 
below were performed using MSCs from the second to the fourth passage. 
The nanofibrous scaffolds and TCP were placed in 24-well plate while being 
pressed with stainless steel rings. The scaffolds were sterilized under UV radiation 
for 2h and then washed three times with PBS. Further the scaffolds were seeded with 
isolated rMSCs at a cell density of 1.0 × 10
4
 cells/well. These cells were allowed to 
adhere for overnight before adding medium, which was thereafter changed every 3 
days. 
The adhesion and proliferation of cultured rMSCs on scaffolds and TCP used as 
control were evaluated using the colorimetric MTS assay (CellTiter 96 Aqueous One 
solution, Promega, Madison, WI). After culturing the cells for a period of 3, 6 and 9 
days they were rinsed with PBS to remove unattached cells and incubated with 20% 
MTS reagent in serum-free medium for a period of 3 h at 37 C. Absorbance of the 
obtained dye was measured at 490 nm using a spectrophotometric plate reader 
(FLUOstar Optima, BMG Lab Technologies, Offenburg, Germany). 
Cell viability was also visualized after culturing the cells for 9 days on scaffolds 
and TCP, by using the LIVE/DEAD Assay (Molecular Probes, Invitrogen, 
Singapore), which contains calcein AM and ethidium homodimer. 20 µl of 2 mM 
ethidium homodimer solution and 5 µl of 4 mM calcein were added to 10 ml of PBS. 
Each sample was incubated with 1.5 ml this solution for 1h at room temperature. 
After the incubation, the samples were washed once with PBS and exam under 
CLSM (Olympus Fluoview FV1000, Olympus Optical. Co., Ltd., Tokyo, Japan), 
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where live cells produced green fluorescence while the dead cells showed red 
fluorescence. 
To check the cytoskeleton of cells, the cells after 9 days of culturing were fixed 
with 2.5% paraformaldehyde for 30 min at room temperature and permeated using 
0.1% Triton X-100. Cells were further incubated with phalloidin FITC labeled 
(Sigma) at a dilution of 1:500 in PBS for 90 min and counterstained with DAPI at 
room temperature. Samples were then mounted on glass slides using mounting 
medium and imaged with CLSM at excitation wavelengths of 405 and 488 nm. 
 
5.2.3 Transplantation of nanofibrous patches 
MI models were established according to proceedings previously described 
315
. 
Adult female SD rats (250±20g) were anesthetized with ketamine (60 mg/kg) and 
xylazine (5–10 mg/kg) by peritoneal injection. After endotracheal intubation and 
ventilation with a rodent ventilator (Taimeng, Chengdu), the heart was exposed 
through left lateral thoracotomy and cutting the pericardium open. The left anterior 
descending coronary artery (LADCA) was ligated between the left auricle and conus 
arteriosus. Successful establishment of MI models was determined by observing a 
pale discoloration of the myocardium and a high T-wave on the electrocardiogram. 
After LADCA ligation, the chest of the rats was sutured. 2 x 10
4
 U penicillin G 
benzathine was intramuscularly injected daily for 3 days.  
Cut into 0.8 x 1.0 cm pieces, nanofiber sheets were spread on the bottom of 
culture dish and irradiated in ultraviolet rays for 2 h. Following rinsing in PBS, the 
sheets were immersed in DMEM over night. Density of cells was adjusted to 1 x 10
7
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cells/ml. The cells were seeded on the sheets and incubated for 24 ~ 36 h, allowing 
the cells to adhere to the sheet and spread on the sheet. At one week after MI, the 
rats were randomly divided into control, PCL, PG and PG-cell sheet groups. The rats 
were anesthetized, their hearts were exposed. The infarcted area was covered with 
the PCL, PG or PG-cell sheet (cell side down in PG-cell sheet), then edges of the 
sheet was sutured to the border of the infarcted myocardium with absorbent silk 
string. In control group, PBS was injected using a micro-syringe at four spots (20 ml 
per spot). 2 x 10
4
 U penicillin G benzathine was intramuscularly injected daily for 3 
days.  
 
5.2.4 Echocardiography  
Echocardiograms were recorded with an ultrasonocardiograph (Visual Sonics, 
Toronto) under anesthetization for the rats before MI, at 1week after MI (baseline 
echocardiogram), and four weeks after patch transplantation. After adequate two-
dimensional images were obtained, the M-mode cursor was positioned to the 
parasternal long axis view at the level papillary muscles. Left venticular (LV) end-
diastolic diameter (LVEDD) and LV end-systolic diameter (LVESD) were measured 
from at least 3 consecutive cardiac cycles. For examining systolic function, LV end-
diastolic volume (LVEDV), LV end-systolic volume (LVESV), index of ejection 
fraction (EF, LVEDV - LVESV/LVEDV × 100%) and fractional shortening (FS, 
LVEDD - LVESD/LVEDD ×  100%) were measured 315, 316. Improvement of 
cardiac function was evaluated with changes of echocardiogram. 
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5.2.5 Examination of cardiac tissue 
All hearts were harvested after echocardiographic analysis at four weeks after 
transplantation of nanofiber cell sheets. The rats were anesthetized with 10% chloral 
hydrate (3 ml/kg) by peritoneal injection, the right atrium was cut to allow drainage. 
Following 0.9% saline solution was perfused into the hearts for removing blood, the 
hearts were fixed with 4% paraformaldehyde for 30 min by using a 21G Vacutainer 
needle (BD Diagnostics, MD) inserted into the cardiac apex of the left ventricle. 
Afterwards, whole heart was removed. With short axis section, the cardiac wall at 
the infarcted area was cut into upper, middle and lower parts and continued to be 
fixed with above solution for 4 h. After washing with PBS, the masses were 
dehydrated in 20% and 30% sucrose respectively, and then embedded in Tissue-Tek 
OCT Compound (Sakura Finetek, CA). The cryostat sections of 5 µm thickness 
were prepared by a Leica CM 1900 microtome (Leica Microsystems, Wetzlar, 
Germany). Discontinuous sections obtained from each model were stained with HE, 
Masson’s trichrome (Sigma) or immunofluorescent staining respectively. The blue 
regions in Masson’s stain sections indicate scar tissues. Scar area was defined as the 
percentage of blue region in whole myocardium of the cross-sectional area in LV 
wall by using computer-based planimetry with ImagePro Plus 6.0 analysis software 
(MediaCybernetics, Bethesda, MD).  
 
5.2.6 Immunofluorescent staining 
For determining angiogenesis and lymphangiogenesis in the peri-infarct and 
infarct regions, and the differentiation of transplanted cells toward endothelial cells 
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and CMs, immunostaing of CD31, LYVE 1, cardiac TP-T and CX43 were 
performed respectively or double. The cryostat sections were incubated with 10% 
goat serum and 1% bull serum albumin (BSA), and then incubated with mouse anti-
CD31 monoclonal antibody (1:200; Abcam, Cambridge, UK) or/and rabbit anti-
LYVE 1 polyclonal antibody (1:200; Abcam), or mouse TP-T monoclonal antibody 
(1:300; Santa Cruze, CA) or/and rabbit CX43 monoclonal antibody (1:200; Sigma, 
St Louis, MO) at 4oC overnight. After washing with PBS, the sections were 
incubated with DyLight 594 AffiniPure Goat Anti-Mouse IgG（1:300, EarthOx, 
San Francisco, CA） or/and FITC AffiniPure Goat Anti-Rabbit IgG（1:50, EarthOx） 
at room temperature for 1 h. The nucleus was counterstained with DAPI (1:1000, 
Sigma). For eliminating spontaneous fluorescence from the tissues, the sections 
were treated with 0.1% Sudan black (in 70% ethanol) at room temperature for 25 
min. For each staining, the primary antibodies were displaced with 0.1% BSA as 
negetive control. All images were obtained under a fluorescent microscopy 
(Olympus Corporation, Japan). Microvessel density within the peri-infarct and 
infarct regions was evaluated by counting positively stained tubular structures in 
sections at middle part of infarcted area, and area of tubular structures was measured 
with ImagePro Plus 6.0 analysis software (MediaCybernetics). Four high power 
fields (20x) were randomly selected and analyzed in each section from three 
independent sections (twelve images per animal). 
 
5.2.7 Fluorescence in situ hybridization 
For detecting the existence and differentiation of the transplanted cells, Y 
chromosome specific gene of the cells was detected by fluorescence in situ 
 Chapter 5 Evaluation of nanofibrous cardiac patch in rat MI model 
102 
 
hybridization according to modification of proceedings previously described 
316, 317
. 
The sections incubited with CD31, TP-T and CX43 antibody were immersed in 2x 
SSC for 30 min. Following dehydrated in gradient ethanol and dried in air, the 
sections were digested in 20 μg/μl protease K for 30 min. After rinsing with 2x SSC, 
the sections were dehydrated and dried again, and then immersed in denaturation 
buffer (70% formamide) at 85°C for 2 min to denature the fixed chromosome 
specimens. The sections were placed in cold 70% ethanol for 1.5 min, and then 
dehydrated and air dried. The biotin-labeled Y chromosome specific probe (Shan 
Jing, Shanghai) was denatured in 70% formamide (pH 7.0) at 72°C for 5 min and 
placed at 37°C for 3 h. Subsequently, the sections were incubated with the denatured 
probe at 42°C overnight. After washing with 2x SSC and 0.1x SSC respectively, the 
sections were incubated with streptavidin-FITC (BioLegend, San Diego, CA) and 
DyLight 594 AffiniPure goat anti-mouse IgG (1:300, EarthOx) or streptavidin-cy3 
(BioLegend) and FITC AffiniPure goat anti-rabbit IgG （1:50, EarthOx） at room 
temperature for 1 h. The nuclei were counterstained with DAPI. For eliminating 
spontaneous fluorescence from the tissues, the sections were treated with 0.1% 
Sudan black at room temperature for 25 min. Coexpression of Y chromosome and 
CD31, TP-T or CX43 in the transplanted cells was examined by a fluorescence 
microscope (Olympus Corporation). 
 
5.2.8 Statistical analysis 
All the data presented are expressed as mean ± standard deviation of the mean. 
Single-factor analysis of variance was carried out to compare the means of different 
data sets, and a value of p ≤ 0.05 was considered statistically significant. 




















5.3.1 Cell survival and proliferation on nanofibers 
MSCs were isolated from bone marrow of SD rats which might serve as a good 
cell model for MI therapy. In order to characterize the growth of MSCs on 
nanofibers in vitro, we tracked their metabolism over a span of 9 days. Proliferation 
of MSCs cultured on different nanofibers was analyzed by MTS assay after 
culturing for 3, 6 and 9 days. Fig. 5.1A shows that the cell growth on PG nanofibers 
 
Fig. 5.1 A. Proliferation of rat MSCs on TCP, PCL and PG, as determined by MTS assay. * 
p ≤ 0.05 indicates statistically significant difference. B. Live/dead cell assay showing MSCs 
on TCP, PCL and PG after 9 days of culture. Live cells produced green fluorescence and 
dead cells showed red fluorescence. 
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was statistically significant (p < 0.05) compared to that on PCL nanofibers devoid of 
gelatin after 9 days of culture, indicating that the ECM protein, gelatin facilitated 
numerous binding ligands to support cell attachment and proliferation on the 
PCL/gelatin scaffolds. In addition, the fluorescent cell viability assay was carried out 
after 9 days of cell culture on TCP, PCL and PG. Results demonstrated that very few 
apoptotic and necrotic cells were observed on PG nanofibers, while some cells 
underwent apoptosis and necrosis on TCP and PCL nanofibers (Fig. 5.1B), further 












5.3.2 Morphology and cytoskeleton feature of cells cultured on the nanofibers 
The morphology of MSCs grown on the nanofibers was analyzed using SEM and 
the images are shown in Fig. 5.2A-C. After 9 days of culture, cells on the scaffolds 
were found to spread along the orientation of nanofibers interacting well between 
each other with the extension of filopodia, compares to MSCs attached on TCP. 
 
Fig. 5.2 SEM micrographs showing the morphology of rat MSCs on (A) TCP, (B) PCL, (C) PG 
and cytoskeleton staining (F-actin) of the MSCs on (D) TCP, (E) PCL, (F) PG after 9 days of 
culture. 
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Moreover, MSCs on PG spread well to form a monolayer interconnected by 
intercellular junctions aligned in a parallel pattern, while cells on PCL remain 






















The cytoskeletal organization of MSCs was assessed through immunochemical 
 
Fig. 5.3 A. Cardiac function of rats with MI examined by echocardiography at 4 weeks after 
transplantation. B. and C. the change of EF and FS, D. and E. the change of LVEDD and 
LVESD, F. and G. the change of LVEDV and LVESV. *p < 0.01 compared with control groups; 
#p < 0.01 compared with PCL groups; &p < 0.01 compared with PG groups; $p < 0.01 compared 
with baseline. N = 6. 
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staining of F-actin as shown in Fig. 5.2D-F. With prominent actin filaments, cells 
were spread out into different cytoskeletal architecture on different substrates. Cells 
on TCP were well spread in a round or oval shape with very few pseudopodia. 
MSCs on PCL were poorly spread, showing narrow cell morphology with some 
extension of pseudopodia, while cells on PG nanofibers exhibited a well-spread 
morphology with a large number of prominent microfilament-rich pseudopodia 
attaching to individual fibers, indicating favorable interaction between MSCs and 
nanfibrous matrix. 
 
5.3.3 Improvement of cardiac function after nanofibrous patch transplantation 
A series of echocardiographic examinations were conducted to evaluate cardiac 
functions of LV for the study groups. Cardiac function in all rats was severely 
compromised by 1 week after LADCA occlusion, and decreasing cardiac function 
continued over the next 4 weeks in control group. When nanofibrous patches were 
implanted on the epicardium of the infarcted hearts, cardiac function of the hearts 
were improved significantly (Fig. 5.3). EF in PCL (27.87 ± 4.13%), PG (35.29 ± 
6.88%) and PG-cell (57.40 ± 4.25%) groups and FS in the groups (14.66 ± 2.37%, 
20.06 ± 4.51% and 32.03 ± 1.61%) increased significantly compared to the control 
(16.15 ± 3.65% and 8.96 ± 2.35%) group (p < 0.01). EF and FS in PG group were 
higher than that in PCL group (p < 0.01).  Notably, EF and FS in PG-cell group 
were not only higher than that in PCL group (p < 0.01), but also significantly higher 
than that in PG group (p < 0.01). In three transplantation groups, LVEDD, LVESD, 
LVEDV and LVESV were decreased obviously compared to the control group (p < 
0.01). LVEDD, LVESD, LVEDV and LVESV in PG-cell group were less than that 
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in PCL and PG groups (p < 0.01). LVESD in PG group was smaller than that in 
PCL group. All index of PG-cell group were significantly changed compared with 















5.3.4 Morphological changes of left ventricle after patch transplantation 
In control group, the free wall of the left ventricle demonstrated thinning, 
elongation and expansion of the infarcted region, and the ventricular cavity enlarged 
at five week after MI. In PCL, PG and PG-cell groups, expansion the free wall of the 
left ventricle was not observed. The ventricular wall of PG and PG-cell groups was 
thicker than that of control and PCL groups. Compared with PG group, the thickness 
of the ventricular wall in PG-cell group was greater (Fig. 5.4A). Four weeks after 
 
Fig. 5.4 Morphological changes of the left ventricular wall at four week after transplantation (HE 
staining). A. Microphotographs of the transverse sections of whole hearts at the widest parts of 
the infarcted regions (×20). B. The peri-infarcted region of the free wall of the left ventricule. C. 
The infarcted region of the free wall of the left ventricle. Asterisks indicate nanofibers. Bar = 200 
m. 
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transplantation, the degradation of PCL was not obvious, while PG was found partly 






















Masson’s staining shows the fibrous tissue in blue. In control group, the 
myocardium of the ventricular wall at the infarcted region was almost substituted by 
 
Fig. 5.5 A. Masson’s staining of scar size of the infracted hearts after transplantation for four 
weeks. Fibrous tissue (blue), myocardium (M, red), peri-infarcted (PIR) and infarcted regions 
(IR), vessel (V). Arrows indicate microvessels. Asterisks indicate nanofibers. Bar = 100 m. B. 
Statistical analysis of scar size of the infracted heart. * p  0.05, ** p  0.01, compared with 
control group respectively; # p  0.01 compared with PCL group; and & p  0.01 compared with 
PG group. N = 12. 
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fibrous tissue and a small myocardium portion was found beneath the endocardium. 
In PCL, PG and PG-cell groups, the myocardium was observed under the 
epicardium. Compared to PCL group, there was more myocardium at the infarcted 
region in PG and PG-cell groups and the thickness of the myocardium in PG-cell 
group was greater than that in PG group (Fig. 5.4B, 5.5A).  
Scar size was defined as the percentage of blue region in whole wall of the left 
ventricle in circumference of the cross-section. Scar size of the infracted region in 
PCL (41.06 ± 5.47, p < 0.05), PG (20.83 ± 5.48, p < 0.01) and PG-cell sheet (12.96 
± 1.45, p < 0.01) groups was smaller than that in the control group (46.69 ± 3.85). 
Compared with PCL group, the scar size in PG and PG-cell groups became 
significantly (p < 0.01) smaller. The effect of PG-cell sheet on cardiac repair was 
therefore greater than that of the PG group (p < 0.01) (Fig. 5.5B).  
 
5.3.5 Expression of cardiac markers TP-T and CX43  
Cardiomyogenesis in the infarcted region at four week after transplantation was 
determined by expression of TP-T and CX43. In control group, TP-T was expressed 
weakly by some cells beneath the endocardium, while CX43 expression was not 
observed. In PCL group, some cells under the epicardium expressed TP-T and CX43 
weakly. The cells expressing TP-T and CX43 under the epicardium in PG and PG-
cell groups were more than that of the PCL group, and the fluorescence density of 
TP-T- and CX43-positive cells were higher. CX43 was located mainly at 
conjunction of adjacent cells (Fig. 5.6A).  
Y chromosome was used for retracing the transplanted cells. Y chromosome 
fluorescence in situ hybridization in PG-cell sheets demonstrated that Y 
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chromosome-positive cells distributed on the medial surface of PG, in the 
epicardium and superficial layer of the myocardium. Some Y chromosome-positive 
cells expressed TP-T weakly. Morphological similarities were also found for the Y 























Fig. 5.6 A. Immunostaining of TP-T and CX43 of the myocardium at the infarcted region after 
transplantation for four weeks. B. Differentiation of transplanted cell retraced by Y 
chromosome fluorescence in situ hybridization towards CMs. Asterisks indicate nanofibers. Bar 
= 100 m. 





























Fig. 5.7 A. Immunostaining of CD31 at the peri-infarcted (PIR) and infarcted regions (IR) after 
transplantation for four weeks. Bar = 100 m. B. The distribution of the transplanted cells 
(arrows) traced with Y chromosome fluorescence in situ hybridization. Bar = 50 m. Asterisks 
indicate nanofibers. Epi: epicardium. C. Statistical analysis of microvessel density in the peri-
infarcted and infarcted regions. * p < 0.01, compared with control group; # p < 0.01, compared 
with PCL group; & p < 0.01, compared with PG group. N = 12. 

























5.3.6 Angiogenesis and lymphangiogenesis in the infarcted tissue 
Angiogenesis in the peri-infarcted and infarcted regions was determined by 
 
Fig. 5.8. immunostaining of LYVE-1 indicating the lymphatic capillaries at the peri-
infarcted regions after transplantation for four weeks. Asterisks indicate nanofibers. Bar = 
100 m. 
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evaluating the number of CD31-positive microvessels at four weeks after 
transplantation. CD31-positive microvessels could be observed in the peri-infarcted 
region and subepicardial tissue of infarcted region in all groups. There were more 
microvessels in both the peri-infarcted and infarcted regions in PG and PG-cell 
groups. However, the number of the microvessels in PG-cell group was greater than 
that in PG group (Fig. 5.7A). Y chromosome fluorescence in situ hybridization 
demonstrated that some Y chromosome-positive cells expressed CD31, and some of 
these cells were located on the wall of the microvessels in the nanofibers of the PG-
cell group (Fig. 5.7B). After calculation (Fig. 5.7C), the microvessels in PCL, PG 
and PG-cell groups are more than that in the control group significantly. Numbers of 
the microvessels in PG and PG-cell groups are greater than that in PCL group. 
Compared to PG group, the microvessel density of PG-cell group is high. 
Lymphangiogenesis was determined with LYVE-1 immunofluorescent staining. 
Compared to normal heart, the lymphatic capillaries in the infracted heart are more. 
There were less lymphatic capillaries in the peri-infarcted region in PG and PG-cell 
groups compared with the control and PCL groups (Fig. 5.8). 
 
5.4 Discussion 
5.4.1 Function of electrospun nanofibrous cardiac patches 
To attenuate LV dilatation after MI is important to prevent heart function 
deterioration and an advantage of cardiac patches is that they could restrain the 
infarcted LV by providing mechanical support to compensate the intraventricular 
pressure 
311
. In this study, we evaluated both the in vitro and in vivo properties of 
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PCL and PG nanofibers as cardiac patch. Our results showed that compared to the 
control group, both PCL and PG group showed restrained infarct expansion, retained 
cardiac function (EF and FS, Fig. 5.3), reduced the scar size (Fig. 5.5B) and induced 
formation of microvessels (Fig. 5.7C).  
As shown in Fig. 5.5 and Fig. 5.6, the scar size reduced and the expression of TP-
T and CX43 in the infarcted area promoted significantly in the PG group compared 
to PCL group, although there was only a small improvement in cardiac function for 
the PG group than the PCL group. One explanation might be the superior 
mechanical property of PG nanofibers compared to PCL nanofibers, as the stiffness 
of a cardiac patch is critical to its performance. Since the stiffness of myocardial is 
10-20 kPa at the beginning of diastole and 200-500 kPa at the end of diastole, 
cardiac patches with stiffness in this range might promote the proliferation of 
cardiac cells and improve the attenuation of LV dilatation better 
318
. Yeong et al. 
demonstrated that a porous PCL scaffold with the stiffness of 345 kPa could 
promote the proliferation and differentiation of C2C12 myoblast cells in vitro 
319
. 
Dang et al. investigated the mechanical influences of applying patches on dilated LV 
wall with a finite element model and found that the patches with stiffer properties 
would result in a negative effect on stroke volume 
320
. Our previous study (Chapter 2) 
has demonstrated that the Young’s modulus of PG nanofibers (1.45 ± 0.20 MPa) 
was much lower than that of PCL nanofibers (4.72 ± 0.53 MPa). The stiff PCL 
patches with an incompatible mechanical property to the native myocardium might 
be unable to provide a reduction in wall stress in tandem which allows myofiber 
stretch during diastole. Similarly, Fujimoto et al. investigated the feasibility of two 
elastic polymers with different stiffness as cardiac patches for MI treatment 
321
. 
Their results indicated that the polyester urethane urea (PEUU) patches with initial 
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modulus of 1.57 MPa could increase the percentage of fractional area change 
(%FAC) and maintain end-diastolic LV cavity area (EDA), whereas the 
polytetrafluoroethylene (ePTFE) patches with initial modulus of 51.5 MPa showed 
decreased %FAC and EDA. Furthermore, PEUU implantation induced muscle 
cellularization with cardiac specific markers (α-actinin and TP-T) in the infarcted 
area, whereas the ventricular wall in ePTFE group was composed of fibrous tissue.  
The lack of vascular density limiting mass and oxygen transport is one of the 
major obstacles in treating MI and heart failure. As shown in Fig. 5.7, it is 
interestingly found that significant micro blood vessels were formed in both PCL 
and PG groups compared to the control group. Commonly, cell or growth factor 
based therapies have been demonstrated as effective approaches to promote 
vascularization in the infarcted hearts, and biomaterial scaffolds traditionally play a 
role as a mechanical support instead of affecting cellular behaviors 
16, 322
. Our results 
demonstrated the ability of nanofibrous cardiac patches in triggering new vessel 
formation. Fujimoto et al. found that the implantation of PEUU cardiac patch 
increased capillary density significantly compared to the group without patches, as 
the mechanical support of the elastic polymer pronounced expression of bFGF and 
VEGF in the infarcted myocardium by paracrine mechanisms 
323
. In addition, 
significantly higher amount of blood vessels were founded in PG group than PCL 
group, indicating that addition of gelatin provided better biological 
microenvironment for tissue regeneration. Our in vitro results demonstrated that 
MSCs showed higher cell proliferation as well as favorable cell-cell and cell-matrix 
interaction on PG nanofibers compared to PCL. Li et al. reported bioengineered 
cardiac grafts made of 3D gelatin meshes seeded with fetal cardiac cells 
324
. After 
implantation on infarcted myocardial tissue for five weeks, new vessel formation 
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was found in the graft and the cells seeded in the graft still survived and formed 
junctions with the recipient heart tissue. Gelatin contains arginine-glycine-
asparagine (RGD) tripeptide motif which has been shown to promote cell anchorage 
and have angiogenesis properties 
325, 326
. Yu et al. demonstrated that the RGD 
modified alginate hydrogel showed greater angiogenic response and significantly 
higher arteriole density in the infarcted area compared to non-modified alginate and 
control group in the acute MI study 
327
. Therefore, PG cardiac patch with superior 
performance was utilized further to deliver cells to infarcted cardiac tissue due to its 
lower stiffness and bioactive surface with gelatin. 
 
5.4.2 Function of mesenchymal stem cells 
The other function of cardiac patches is cell delivery and the type of cells chosen 
for implantation in MI treatment is an important issue. To date, various types of cells 
have shown positive results in cardiac function for MI treatment in animal models 
280, 328
. Among all these cells, bone marrow derived MSCs have been chosen to 
utilize in our study because they can avoid the immunorejection problem, are easily 
obtained and have been demonstrated to induce regeneration of CMs and blood 
vessels in infarcted myocardium, which is critical for recovery of cardiac function 
20
. 
On the other hand, PG nanofibers provide the cells a temporary support and as 
shown in Fig. 5.3, the cardiac functions were found to improve significantly with a 
reduced scar size in PG-cell group. EF reached 59.56 ± 3.46% and FS increased to 
32.31 ± 2.36% in PG-cell group, indicating that the implantation of PG with MSCs 
not only prevented the attenuation of LV dilation, but also increased the LV function 
after transplantation. Similarly, Simpson et al. reported that the implantation of 
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collagen cardiac patches with human MSCs into rat infarcted hearts resulted in a 
reduction in LVESD and a 30% increase in FS, whereas the patches devoid of cells 
showed no improvement in LV function 
329
. Chi et al. investigated that the efficacy 
of silk fibroin/hyaluronic acid (SH) scaffolds with bone marrow MSCs as cardiac 
patches for the MI treatment in rat model, and they found that SH-cell group 
significantly improved the wall thickness of LV, reduced LVESD and increased FS 
values compared to SH group 
330
.  
The significant improvement of cardiac functions by MSC transplantation has 
been demonstrated in our study, but the mechanisms behind these beneficial effects 
are not entirely clear. Cardiomyogenesis might be a plausible hypothesis. The 
implantation of cardiac patches might reduce scar formation and retain functional 
myocardium, while MSC transplantation could generate new myocardium. 
Differentiation of transplanted stem cells toward CMs might be the one of the 
objectives of stem cell therapy in MI treatment. Some studies have reported that the 
transplanted MSCs in infarcted hearts expressed cardiac specific proteins, such as α-
ACT, MHC and CX43 
21
. Toma et al. demonstrated that after transplantation to adult 
murine myocardium for 60 days, human MSCs showed cardiomyogenic 
differentiation, by expression desmin, β-MHC, α-ACT and phospholamban 331. In 
our study, Y chromosome fluorescence analysis showed that some of the 
transplanted cells survived up to 4 weeks after implantation and, more importantly, 
expressed cardiac specific protein TP-T, indicating that those grafted cells could 
undergo cardiomyogenic differentiation and might hold great potential to form 
mature cardiac muscle fibers for regeneration of heart tissue. 
Another documented mechanism for myocardial recovery might be the increase 
in vasculature in the ischemic myocardium, and MSC transplantation has been 
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shown to significantly improve the vascularization in various animal models (canine, 
murine, porcine and rat) of MI 
332
. To date, accumulating studies support the 
hypothesis that the release of stem cell derived paracrine factors could be the 
predominant mechanisms to drive angiogenesis and arteriogenesis. MSCs, in 
particular, secrete high levels of proangiogenic and proarteriogenic factors, which 
have been demonstrated in the meditation of neovascularisation 
22
. After 
implantation of a bioengineered cardiac patch with multilayered MSCs for 
myocardial repair in a rat model, Wei et al. observed neo-muscle fibers and neo-
microvessels in the cardiac patch with the significantly increased expressions of 
angiogenic cytokines 
333
. In this study, we found that the vascular density was 
significantly increased in PG-cell group, and the Y chromosome fluorescence 
analysis demonstrated that some of the grafted MSCs expressed high level of CD31 
(Fig. 5.7), indicating that those cells directly incorporated into the formation of new 
vasculature. Our results showed that the implanted MSCs have differentiated into 
either cardiac muscle cells or endothelium. Similarly, Tang et al. found that a small 
number of transplanted MSCs in MI hearts were positive for TP-T and other MSCs 
were positive for CD31, indicating that implanted MSCs could improve cardiac 






Myocardial fluid homeostasis is regulated by the balance between fluid filtration 
from blood capillaries into the myocardial interstitium and its removal from the 
interstitium via myocardial lymphatics 
335
. Besides its function in fluid drainage, the 
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lymphatic system is also crucial for both circulating immune cells that function in 
immune surveillance and the dissemination of metastatic tumor cells in the body 
336
. 
MI could lead to impaired or insufficient lymphatic function, further resulting in 
interstitial fibrosis, pericardial effusion and subsequent myocardial dysfunction 
337
. 
Therefore, similar to angiogenesis, lymphangiogenesis also plays an important role 
in the regeneration of myocardium. The process of angiogenesis in the infarcted 
hearts has been investigated substantially by many researchers, but 
lymphangiogenesis has rarely been studied. In this study, we investigated the effects 
of different cardiac patches on the lymphangiogenesis in the infarcted area using 
LYVE-1 antibody. Our results showed that the lymphatic vessel density increased 
remarkably in the infarcted heart. Dashkevich et al. found that that ratio of open 
LYVE-1 positive lymph vessels in failing heart was significantly higher and the 
myocardial initial lymphatics in the terminal failure hearts underwent significant 
morphological changes compared to the normal hearts 
335
. Ishikawa et al. 
demonstrated that a subsequent increase of lymphatic vessel density was found in 
the end stages (granulation, fibrosis and scar formation) of myocardial remodeling 
after infarction, which lagged behind blood vessel angiogenesis 
338
. In our studies 
less lymphatic capillaries were found in PG and PG-cell groups compared to the 
control and PCL groups (Fig. 5.8), indicating that implantation of PG cardiac 
patches and MSCs effectively reduced the interstitial edema, decreased the 
formation of lymphatic vessels and finally enhanced the healing process after MI. 
Park et al. demonstrated that transplantation of endothelial progenitor cells into 
infarcted mouse hearts improved LV function, decreased the expression of potent 









Our study demonstrated that MSC-seeded PG nanofibrous scaffolds as cardiac 
patches attenuated the LV remodeling, improved cardiac function and promoted 
angiogenesis in rat infarction model. PG nanofibrous cardiac patches served as a 
mechanical barrier against progressive LV dilation, while the grafted MSCs 
differentiated into cardiac muscle cells and endothelium, effectively induced 
neovascularization and attenuated lymphangiogenesis in infarcted areas. The MSC 
seeded PG nanofibers hold great potential to provide an attractive alternative to 
cellular cardiomyoplasty or ventricular restraint devices for MI treatment. 
 




Electrically conductive nanofibrous 
scaffolds for cardiac regeneration 
 
6.1 Introduction  
An perfect tissue engineered heart muscle should not only have the structure and 
function that favors heart contraction and generation of pressure to eject the blood, 
but also to rhythmically transmit the electrical signals over the entire myocardium 
280
. Many efforts in myocardial TE have been dedicated to optimize the structural 
and mechanical properties of scaffolds by micro/nano-fabrication processes in order 
to control the stiffness and anisotropy of the materials 
165, 340
. Other researchers have 
focused on the improvement of biocompatibility and bioactivity of scaffolds by 
surface modification to regulate cell behavior on biomaterial substrates 
158, 159
. 
Various types of native and synthetic polymeric materials has been applied as 
biomaterial scaffolds in cardiac TE and some of them have showed capability of 
providing biocompatible homing for cardiac cell attachment and proliferation 
14
. Our 
previous studies (Chapter 3-5) have proved that PCL/gelatin nanofibrous scaffolds 
promoted MSC differentiation and cardiac tissue integration, potentially to be a 
suitable cardiac patch for MI treatment. However, as traditional biomaterials, PCL 
and gelatin, are not able to conduct electrical signals and action potentials to the 
regenerating heart muscle, and also lack the ability to effectively reduce the chaotic 
and irregular beating rhythms and improved the decreased pumping efficiency 
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caused by MI. 
To date, conducting polymers gained huge interest to bioengineers and clinical 
researchers as a gifted candidate for applications in TE. Conducting polymers such 
as PPy, PANi and PEDOT, exhibit positive attributes with respect to its 
biocompatibility, conductivity, redox stability, and suitable hydrophobicity, which 
make them suitable for cell interaction studies and other tissue regeneration 
applications 
147
. Among the various conducting polymers, PPy is the most 
extensively studied for its utilization in biomedical and regenerative medicine (such 
as neural probes and bioengineered graft) due to their better biocompatibility and 
conductive properties. Few researchers demonstrated that the cells such as the 
neurons, fibroblasts and endothelial cells, are able to adhere and grow on substrates 
containing PPy by in vitro studies 
185, 341, 342
. These promising results indicate the 
potential application of PPy as suitable material for cardiac regeneration with 
possibility of electrical signal transmission. Such conductive polymeric scaffolds 
might have the benefit to guide the regular beating of heart, which is rarely possible 
using any conventional non-conductive polymeric biomaterials. 
Despite the promising properties to regulate cellular function, it is difficult to 
fabricate substrates with an appropriate three-dimensional structure from PPy 
because of its brittleness and rigidity, and hence surface coating of conductive 
polymeric scaffolds is the only processing method used before TE applications. To 
overcome this limitation, we blended PPy with PCL and gelatin to electrospin novel 
conductive nanofibers, and studied the attachment and proliferation of CMs on the 
nanofibers, and evaluated the cell behavior and cell-scaffold interactions, 
demonstrating them as potential substrates for myocardial regeneration.  
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6.2 Materials and methods 
6.2.1 Fabrication of conductive nanofibers 
Doped PPy (Sigma–Aldrich, St. Louis, MO) was added into HFP and stirred for 3 
hours. A mixture of PCL and gelatin (50:50) was added to the doped PPy solution, 
making the total concentration of 7 wt%, and further stirring for 24h, and the 
solution was finally filtered through a regular 0.22 µm filter unit. Two different 
weight ratios of PPy/PG were prepared: PPy/PG: 15:85 (PPG15) and PPy/PG: 30:70 
(PPG30). The solution was filled into a 5 ml syringe with a 27G blunted stainless 
steel needle for electrospinning. The flow rate was 1 ml/h and high voltage of 12 kV 
(Gamma High Voltage Research, USA) was applied one the tip of the needle. The 
polymer solution was drawn into fibers by electrical force and collected on an 
aluminum foil covered collector. The distance between collector and needle tip was 
10 cm. PG nanofibers were also electrospun using the same paramenters. 
 
6.2.2 Characterization of conductive nanofibers 
SEM was utilized to observe the morphology of electrospun nanofibrous 
scaffolds. Before observation, the scaffolds were coated with gold using a sputter 
coater (JEOL JFC-1200 fine coater, Japan). The diameter of the fiber was detected 
from the SEM images using image analysis software (Image J, National Institutes of 
Health, USA).  
The surface hydrophilicity of the nanofibous membranes was evaluated by drop 
water contact angle measurement using a VCA Optima Surface Analysis system 
(AST products, Billerica, MA). The droplet size was 0.5 µl. At least five samples 
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were used for each test. ATR-FTIR spectroscopic analysis of electrospun 
nanofibrous scaffolds was performed on Avatar 380 (Thermo Nicolet, Waltham, 
MA, USA) over a range of 700–4000 cm-1 at a resolution of 4 cm-1.  
Mechanical properties of electrospun nanofibers were measured using a universal 
mechanical test machine (Instron 3345, Canton, MA, USA). All samples were cut 
into a rectangular shape with dimensions of 30 × 10 mm. The load cell capacity was 
10 N and the crosshead speed was 5 mm/min. A minimum of six specimens of 
individual scaffolds were tested. Conductivity of electrospun nanofibers were 
evaluated by using 4-probe method (Autolab PG STAT 30, Eco Chemie, 
Netherland), in which two pairs of contacts are used to measure the conductivity.  
To test the degradation of nanofibers, the scaffolds were placed in excess PBS 
(pH 7.4) and shaken at 37ºC. At each time point, samples were removed from PBS, 
washed with DI water and dried in vacuum. The dry sample weight was measured 
and compared with the initial dry weight to determine the fractional mass remaining. 
In addition, electrospun nanofibrous scaffolds were soaked in PBS in vitro at 37ºC 
for 1 week. After the degradation period, samples were washed with DI water and 
dried in vacuum oven at room temperature for 48 h. Later, SEM was applied to 
evaluate the morphology of the scaffolds. 
 
6.2.3 Cardiomyocytes isolation and seeding 
Primary CMs were isolated from New Zealand white rabbits (2.0-2.5 kg) by 
collagenase digestion as previously reported by Takasaki et al. 
279
. Then, after 
successful isolation, the harvested CMs continued to culture in DMEM 
supplemented with 10% FBS, and 1% penicillin/streptomycin.  
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The electrospun nanofibers with 15 mm diameter were placed in 24-well tissue 
culture plate and stainless steel rings were used to press the nanofibers to prevent 
them from floating up and ensure fully contact between nanofibers and wells. After 
sterilized under UV light for 2 h, the specimens were washed three times with PBS 




6.2.4 Cell proliferation assay 
The colorimetric MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was utilized to evaluate 
cell proliferation on electrospun PG, PPG15 and PPG30 scaffolds and TCP. After 
culturing for 2, 4, 6 and 8 days in 24-well tissue culture plate, medium was removed 
and CMs were washed with PBS for three times. After PBS was siphoned off, 20% 
of MTS reagent containing serum free medium was added into the well to incubate. 
After incubation with the reagent for 4 h at 37ºC in 5% CO2 incubator, aliquots were 
added into a 96-well plate. The absorbance of each well was detected by a 
spectrophotometric plate reader (Fluostar Optima, BMG Lab Technologies, 
Germany). 
 
6.2.5 Cell morphology 
SEM was utilized to analysis the morphology of rabbit CMs cultured on electrospun 
PG nanofibers after 4 and 8 days of cell culture. After washed three times with PBS, 
the samples was fixed with 3% glutaraldehyde solution for 4 h. The cell-nanofiber 
constructs were further washed in DI water, and further dehydrated with different 
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concentrations of ethanol (50%, 70% 90%, 95% 100%) for 15 min each. Finally 
HMDS was added onto the wells and the samlpls was dried in fume hood at room 
temperature for 24 h. 
 
6.2.6 Immunocytochemistry 
After 8 days of cell culture, medium was removed and 300 μl of ice cold 
methanol was added to fix the CMs and further 0.1% Triton X-100 was used for 
pretreatment. CMs were then blocked with 3% bovine serum albumin and incubated 
individually with primary antibodies α-ACT, TP-T and CX43, respectively for 2 
hour period at dilutions of 1:100 each. After washing with PBS, cells were incubated 
with secondary antibody, either Alexa fluor 488 (green) or Alexa Fluor 594 (red) at 
a dilution of 1:400 at room temperature. DAPI was also added for counterstaining. 
Samples were then mounted on glass slides using mounting medium and imaged 
with a CLSM at excitation wavelengths of 405 and 488 nm or 594 nm. 
 
6.2.7 In vitro electrical stimulation 
The method for electrical stimulation (ES) of CMs on PPG nanofibrous scaffolds 
was similar to that utilized by Ghasemi-Mobarakeh et al. 
149
. Cells were seeded on 
PPG15 scaffolds at a density of 1.0 × 10
4
 cells/well and further incubated for 24 h to 
permit attachment and spreading. In the ES group, two sliver electrodes were 
inserted to opposite ends of the scaffolds kept in culture medium and trains of 
electrical pulses (rectangular, 150 ms, 1V/cm, 1Hz) were applied at 1 h/day for 3 
days. After ES, the cells continued to be incubated with fresh medium till the 
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assessments were carried out. Cell proliferation using MTS was tested at day 3, 6 
and 9 after first cell seeding and immunostaining of CX43 were carried out at day 15. 
 
6.2.8 Statistical analysis 
All the data presented are expressed as mean ± standard deviation (SD) of the 
mean. Single-factor analysis of variance was carried out to compare the means of 












6.3.1 Morphology, chemical, conductive and mechanical properties of electrospun 
nanofibers 
The morphology of electrospun PG, PPG15, and PPG30 nanofibers is shown as 
Fig.1. It is observed that the addition of PPy slightly reduced the average fiber 
 
Fig. 6.1 SEM micrographs of electrospun (A) PG, (B) PPG15, (C) PPG30. 












PG 239 ± 37 24.3 ± 1.8 7.9 ± 1.6 61.1 ± 17.3 0 
PPG15 216 ± 36 46.9 ± 2.0 16.8 ± 1.9 13.6 ± 3.2 0.013 ± 0.007 
PPG30 191 ± 45 63.5 ± 2.8 50.3 ± 3.3 3.7 ± 1.4 0.37 ± 0.11 
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diameters in PPG, and the PG, PPG15 and PPG30 nanofibers (Table. 6.1) had a fiber 
diameter of 239 ± 37 nm, 216 ± 36 nm and 191 ± 45 nm, respectively. 
The wettability of electrospun scaffolds was determined by water contact angle 
test. As shown in Table. 6.1, the addtion of PPy lead to the higher hydrophobicity of 
the scaffolds, and the reason probably is that pure PPy is highly hydrophobic, and 
the contact angle of nanofibers increased from 24.3 ± 1.8° for PG, 46.9 ± 2.0 for 











Fig. 6.2 shows the FTIR spectra of electrospun PG, PPG15 and PPG30 
nanofibers. All the three nanofibers exhibited the carbonyl peak at 1720 cm
-1
, CH2 
stretching at 2950 cm
-1
 and 2865 cm
-1
, C–O stretching at 1050 cm-1, C–O–C 
stretching at 1240 cm
-1
, respective of PCL and gelatin  related stretching peaks at 
1650 cm
-1
 and 1550 cm
-1
(amide I and amide II). Besides the above stretching modes, 
the PPy related peaks, such as the N–H stretching band at 3400 cm-1 and the C–H 
stretch at 3100 cm
-1
; the symmetric C=C ring stretches at 1480 cm
-1
; the C–N stretch 
at 1445 and 1175 cm
-1
; the ring stretching at 1410 cm
-1
; and the C–H deformation in 
 
Fig. 6.2 FTIR spectra of PG, PPG15 and PPG30 nanofibers. The characteristic PPy peaks are 
marked with ↑, gelatin peaks are marked with ★, and PCL peaks are marked with ●. 
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pyrrole ring at 1315 and 1050 cm
-1
, were also showed on PPG15 and PPG30 fibers. 
The mechanical properties of PG and PPG nanofibers was evaluated by the 
tensile stress-strain test, and the Young’s modulus and maximum elongation were 
measured and shown in Table.1. The Young’s moduli of the scaffolds improved 
significantly with PPy content, from 7.9 ± 1.6 MPa for PG fibers to 50.3 ± 3.3 MPa 
for PPG30 fibers. On the other hand, the maximum elongation of the nanofibers 













Fig. 6.3 shows the typical current verse voltage (I-V) curve for electrospun 
PPG15 and PPG30 scaffolds. Excellent linear variation of current with voltage was 
achieved for the PPG nanofibers, which means that the blending of PPy with PG is 
an effectual approach to produce electrically conductive nanofibers. Compared to 
PPG15, the PPG30 nanofibers showed higher slope of the curve, which 
demonstrates that a high content of PPy in the system results in superior electrical 
 
Fig. 6.3 The typical Current verses Voltage (I-V) curve for PPG15 and PPG30 scaffolds. 
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conductivity. After calculation, the PPG nanofibers had the conductivities of 0.013 ± 
















6.3.2 In vitro degradation of conductive nanofibers 
The degradation behavior of electrospun PG and PPG nanofibers were evaluated 
by calculating the mass loss of the samples with regard to the incubation time. As 
shown in Fig. 6.4A, the addition of PPy into PG nanofibers increased the 
degradation rate of the nanofibers, and PPG15 and PPG30 had the similar mass loss 
profiles. In the first week, which PPG15 lost 35.9% of its original mass and PPG30 
lost 36.3% of its mass. After 10 weeks of degradation, PPG15 remained 49.8% of its 
 
Fig. 6.4 (A) Degradation profile of PG, PPG15 and PPG30 nanofibers with incubation time, and 
(B) the morphology of PG, PPG15 and PPG30 after 7 days of degradation. 
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original mass while PPG30 remained 48.5% of its mass. Although PPG15 and 
PPG30 shared the similar weight loss profiles, their morphological change were 
different. As shown in Fig. 6.4B, PG and PPG15 scaffolds were found to show a 
certain degree of swelling and degradation, whereas PPG30 exhibited major 
morphological changes with substantial fragmentation of the fibers. The rapid 
degradation of PPG30 nanofibers would lead to immediate loss of its electrical and 















6.3.3 Cell proliferation 
The CM proliferation on different electrospun nanofibrous scaffolds was 
evaluated after 2, 4, 6 and 8 days by MTS assay (Fig. 6.5). PPG15 scaffolds showed 
 
Fig.6.5 Proliferation of CMs on TCP, PG, PPG15 and PPG30 nanofibers, as determined by 
MTS assay. *Significant against cell proliferation on PG scaffolds at p ≤ 0.05. 
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significantly higher cell proliferation rate than the cell growth on PG scaffolds after 
4 days of culture, which means that the 15% PPy in nanofibers is able to encourage 
CM proliferation. On the other hand, the PPG30 scaffolds favored the cell growth 
during early days of culture period (before Day 4), and further inhibited the 
proliferation of CMs and had significant lower cell numbers compared to the other 
two scaffolds after 8 days. We conclude that the fast biodegradation rate of PPG30 
in medium might be a main reason why they limited cell proliferations after 8 days, 















6.3.4 Cell Morphology 
Fig. 6.6 shows the SEM micrographs of CMs grown on PG and PPG15 
 
Fig. 6.6 Morphology of CMs on electrospun nanofibers. (A) CMs on PG after 4 days of culture, 
(B) CMs on PPG15 after 4 days of culture, (C) CMs on PG after 8 days of culture, (D) CMs on 
PPG15 after 8 days of culture 
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nanofibers after 4 days and 8 days of cell culture. At 4 days, CMs were observed to 
attach and spread on the nanofibrous scaffolds (Fig. 6.6A, B), and the morphology 
of CMs on both the scaffolds were found to be similar, spreading along the 
orientation of nanofibers interacting well with the fibers and between each other. 
After culturing for 8 days, CMs spread, migrated, and proliferated to confluence on 














6.3.5 Cardiac protein expressions 
As shown in Fig. 6.7, the rabbit CM expressed three major cardiac specific 
proteins on PG and PPG nanofibrous scaffolds after 8 days of culture. CMs on both 
PG and PPG15 expressed high levels of α-ACT and TP-T and interacted well with 
the nanofibers and elongated along the nanofibers, orientating with the sarcomeric 
 
Fig. 6.7 Immunofluorescent staining of CMs on (A-C) PG and (D-F) PPG15 nanofibers for (A, D) 
α-actinin, (B, E) troponin-T and (C, F) connexin-43. Scale bars = 50 µm. 
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structures of mature cardiac myocytes. Moreover, cells on PPG15 exhibited 
remarkably higher density of CX43 than that on PG, indicating that PPG15 
nanofibers could potentially promote the electrical and chemical signal propagation 


















6.3.6 In vitro electrical stimulation on conductive nanofibers 
The proliferation of CMs on PPG15 under ES was evaluated after 3, 6 and 9 days 
by MTS assay. As shown in Fig. 6.8A, after 9 days of culture, the cell proliferation 
 
Fig. 6.8 (A) Proliferation of CMs on PPG15 with or without ES after 3, 6 and 9 days of 
culture, and immunofluorescent staining of CM for CX43 on PPG15 (B) without ES and 
(C) with ES. * p ≤ 0.05 indicates statistically significant difference.  
 Chapter 6 Electrically conductive nanofibers for cardiac regeneration 
135 
 
on PPG15 significantly increased under 3 days of ES compared to those without ES 
(p ≤ 0.05). In addition, immnuostaining analysis after 15 days showed that the CMs 
under ES (1V) expressed much higher level of CX43 (Fig. 6.8B) than those without 
ES (Fig. 6.8C).  
 
6.4 Discussion 
6.4.1 Design and fabrication of PPy nanofibers 
Native myocardium has good-conductivity pathways for electrical signal 
propagation because of the high cell density and the presence of gap junction. 
However, after MI the upregulated matrix metalloproteases lead to degradation of 
the myocardial ECM, which further results in weakening of the infarct wall and 
slippage of myocytes as well as lost of conductivity 
39
. Therefore, a strategy to 
improve the microenvironment with electrophysiological function at the infarct area 
is critical for improving the efficacy of MI therapy. To fabricate suitable conductive 
scaffolds for cardiac TE, two different ratios of PPy (15% and 30%) were added to 
PG to fabricate composite nanofibers. As shown in Fig. 6.1, uniform and randomly 
oriented nanofibers were obtained by electrospinning and PPy dispersed uniformly 
throughout the whole nanofibers. With increasing the concentration of PPy in the 
blend solutions, the average diameter of the electrospun nanofibers decreased from 
239 ± 37 nm to 191 ± 45 nm. These results demonstrated that the concentration of 
the conductive polymer had a direct co-relation towards the fiber morphology. 
Studies by Li et al. also showed that the incorporation of PANi into gelatin solution 
reduced the fiber diameter from 803 ± 121 nm for pure gelatin fibers to 61 ± 13 nm 
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for 60:40 PANi/gelatin fibers 
266
. One explanation to this phenomenon is that the 
addition of conductive polymers increased the conductance and charge density of the 
blended solutions, which lead to the imposition of stronger elongation forces on the 
solutions resulting in substantially smaller diameters of the electrospun fibers 
343
. 
Mechanical performance of scaffold is a crucial factor for tissue regeneration, as 
it is related to the integrity and stability of implanted graft in vivo. A suitable 
scaffold material must be able to withstand the load exerted by the tissue and 
provide mechanical strength. In our study, PPy being a brittle polymer, the ductile 
PCL was introduced into the system to enhance the elasticity and flexibility of the 
scaffolds. With the addition of PCL and gelatin to PPy, the Young’s modulus of the 
composite scaffolds was reduced while the elasticity of nanofibers was improved. 
Zhou et al. found that blending of PCL with PPy decreased the Young’s modulus of 
the membranes from 48.4 ± 7.6 MPa for PPy/PCL nanofibers (20% PPy) to 25.7 ± 
0.8 MPa for PCL, while the elongation at break declined from 86.2 ± 9.1% to 129 ± 
27% 
186
. Though the incorporation of PPy weakened the elasticity of the nanofibers, 
it endows the scaffolds with certain electrical conductivity, which is essential for 
functional myocardial regeneration. Native myocardium possesses a unique 
mechanical property for transmitting pressure and forcing to pump blood and, more 
importantly, the electrical conductivity for the delivery of action potential. PPy is a 
polymer with excellent conductivity, and the conductivity of pure PPy might reach 
40~200 S/cm depending on the type of doping agent used for its preparation 
147
. In 
our system, PPG nanofibers exhibited electrical conductivities ranging from 0.013 
mS/cm to 0.37 mS/cm, and these scaffolds could be more suitable for investigating 
the effects of ES on cell growth and differentiation in vitro 
248
. Therefore, our PPG 
blend nanofibers not only possess good conductivity for transmission of electrical 
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signals, but also contain gelatin on the scaffold surfaces, thus delivering biological 
signals for cell growth, required for cardiac regeneration. 
 
6.4.2 Function of PPy to cardiac regeneration 
Cardiac TE based on the regenerative properties of cardiac cells and their 
potential to proliferate and to differentiate to form organized and functional 
structures. The incorporation of the conductive polymers in the scaffolds may 
facilitate cardiac growth and assist in restoring certain conduction of action 
potentials. In this study, rabbit CMs was utilized to evaluate the biocompatibility of 
newly produced PPG conductive scaffolds and their effect in CM proliferation, 
spreading and protein expressions. MTS assay showed that the PPG15 nanofibers 
significantly improved CM proliferation, indicating that the presence of conductive 
polymers could potentially accelerate cardiac cell attachment and proliferation. By 
blending gelatin nanofibers with conductive polymer PANi, Li et al. suggested 
enhanced proliferation and migration of H9c2 rat cardiac myoblasts 
266
. The 
mechanism by which the inclusion of PPy can enhance CM adhesion and 
proliferation is unclear, but there are two possible explanations: 1) the slight positive 
charge of PPy may act as electrical binding sites to electrostatically attach the 
negatively charged cell membrane, which bring the cells close to the scaffold surface 
and establish stronger attachment sites 
154
; 2) the presence of conductive polymer 
alters the local electrostatic charge of the scaffold, further changing the protein 
adsorption and enhancing cell attachment and proliferation 
344
.  
Although the biocompatibility of PPy has been widely evaluated, our results 
showed that the proliferation of CMS were limited on scaffolds with a PPy 
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concentration of 30%. Castano et al. applied a similar approach, where these 
researchers  deposited PPy in varying concentrations of pyrrole monomer on the 
surface of TCP, and found that the proliferation of rat MSCs were enhanced using 
20 mM PPy film, while the same reduced on surfaces containing higher 
concentrations of PPy 
345
. The chemical and thermal stability of PPy in human body 
is a matter of great concern while considering the scope of this material in 
biomedical applications. Results of the degradation test (Fig. 6.4B) showed that 
PPG30 was unstable in phosphate buffer solutions, and it highlight the fact that in 
vivo conditions might result in quick loss of its electrical and mechanical properties, 
and thus the degraded PPG30 scaffolds were not capable of  providing a chemically 
and structurally stable microenvironment for cell attachment and metabolism. 
SEM micrographs of CMs grown on PPG15 scaffolds showed that the 
nanofibrous topology of the scaffold provided cues to the CMs favoring an isotropic 
or anisotropic growth of the cells on these scaffolds. Furthermore, upon completing 
8 days of cell culture, cells were able to craft more cell-cell connections and it even 
formed anisotropic cell sheets, with its organized structure comparable to the 
phenomena observed in native heart tissue. Therefore these scaffolds might benefit 
in coordinating the contractile behavior of CMs 
238
. Bio polymeric scaffolds not only 
can influence the cell morphology but also can direct the cellular activities, such as 
the expression of specific proteins. The expression of cardiac-specific proteins by 
the CMs seeded on the scaffolds was measured by immunostaining analysis. As 
shown in Fig. 6.7, CMs on both PG and PPG15 nanofibers expressed high levels of 
α-ACT and TP-T, suggesting the ability of these scaffolds to retain the contractile 
ability of CMs. Another important cardiac specific protein, called as the gap junction 
protein or  CX43, creates membrane channels to link with adjacent CMs, and it 
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plays an central role in propagating the electrical signals to regulate coordinated 
muscle contraction for blood pumping 
87
. Various growth factors such as the 
fibroblast growth factor-2 and transforming growth factor-β have also been proved 
to be able to promote the establishment of CX43 
33
. In addition to growth factors, 
scaffolds with aligned surface topography have potential to recapitulate the 
expression of CX43 by guiding the orientation of CMs and its alignment. Rat 
neonatal CMs cultured on 10×5×5 microgrooved surfaces were found oriented and 
they also expressed CX43 equivalent to the amounts present in neonatal heart 
346
. 
During our study, we found that the CMs grown on PPG15 (Fig.7F) expressed 
higher CX43 than the cells grown on PG nanofibers (Fig.7C) with higher amounts 
were specifically oriented around the cell periphery. These promising results 
demonstrate the significance of PPy scaffolds with regard to its electrical 
conductivity behavior and thus able to regulate the CX43 expression and established 
gap junctions. It was therefore ascertained that the conductive PPy nanofibers might 
have the function of ensuring rapid and apt capability to cause conduction of action 
potential across the scaffolds, upon its implantation on the infarct myocardium, such 
that it can cause direct chemical and electrical communication between the CMs, 
and accelerate the myocardial regeneration process. 
In our polymeric system, PCL provided the elasticity pertaining to the 
mechanical properties of a scaffold with bio-stability; gelatin moieties assisted the 
cell adhesion behavior with proliferation, and PPy acted as a material for 
conductivity phenomena such that it cause signal transmission and communication 
between CMs, and their synergistic effects produced PPG15 nanofibrous scaffolds 
with attractive physicochemical, biocompatible and conductivity properties, 
highlighting its potential application as a bioengineered graft for cardiac 





6.4.3 In vitro electrical stimulation of CMs on PPy nanofibers 
Myocardium is an electroactive tissue to enable the propagation of electrical 
signals and to allow the heart beating. ES has been demonstrated as a useful role in 
cardiac TE to help for cell alignment and functional enhance in vitro. Our study 
found that the ES on conductive PPG15 scaffolds enhanced the proliferation of CMs 
as shown in Fig. 6.8A. Ghasemi-Mobarakeh et al. reported that the proliferation of 
nerve stem cells on conductive PANi/PCL/gelatin nanofibers increased under 1.5 V 
ES 
149
. On the molecular level, Fig. 6.8C showed that the CMs on PPG15 exhibited 
much higher expression of CX43 under ES, indicating that suitable ES through 
conductive scaffolds enable to improve the interaction between the cells. Similarly, 
Radisic et al. found that electrical field stimulation (rectangular, 2ms, 5 V/cm, 1Hz) 
induced the alignment and coupling of neonatal rat CMs with the upgraded 
expression of CX43 after 8 days of culture 
259
. They suggested that ES is capable of 
establishing and maintaining functional gap junctions, which would further enhance 
the cell alignment and elongation. Mooney et al. investigated the cardiomyogenic 
differentiation of MSCs on conductive carbon nanotube based polylactic acid 
nanofibrous scaffolds. The results indicated that the increased level of CX43 
expression was observed in the cells after ES (2 ms, 0.15 V/cm, 1 Hz) 
262
. Our study 
opens up the opportunity to apply the PPy conductive nanofibers for ES in cardiac 
regeneration 
 




In this study, we fabricated electrospun conductive nanofibrous scaffolds by 
blending different concentrations of PPy into PG and investigated their potential 
application in cardiac regeneration. PPG15 nanofibers, which contained 15% PPy, 
were found to provide more balanced mechanical, electrical conductivity and 
degradation properties compatible for cardiac regenerations than PG and PPG30 
scaffolds. CMs seeded on PPG15 nanofibrous scaffolds showed significantly higher 
cell adhesion, proliferation, and enhanced expression of cardiac specific proteins. 
The ES of CMs on PPG15 enhanced the cell proliferation and the expression of 
CX43. Hence PPG15 holds great potential as a suitable cardiac substrate, promising 
its convenient application for reconstruction of infarct myocardium. 
 
(Note: Some of the text and results in this chapter have been published and 
reprinted from Kai D, Prabhakaran MP, Jin GR, Ramakrishna S. Polypyrrole-
contained electrospun conductive nanofibrous membranes for cardiac tissue 
engineering. Journal of Biomedical Materials Research, Part A.99A:376-85. 2011 
Copyright with permission from John Wiley and Sons) 
 




Conclusions and Recommendations 
 
7.1 Conclusions 
The scope of this research encompasses the fabrication and optimization of 
electrospun PCL/gelatin blended nanofibers for cardiac TE scaffolds, and the 
cardiomyogenic differentiation of BM-MSCs on the artificial ECM-mimicking 
environment. The PG/MSCs composite as cardiac patch has showed superior effects 
on the improvement of cardiac function and myocardial regeneration in rat MI 
model. In addition, PPy/PCL/gelatin nanofibers have been developed a novel 
nanofibrous scaffolds were developed as a novel electrically conductive substrates 
for the enhancement of cell-cell interaction. 
 
Main conclusions: 
 PCL/gelatin composite nanofibrous scaffolds were successfully 
electrospun by incorporating different concentrations of gelatin to PCL. 
PG1:1 nanofibers exhibited the most favorable characteristics, such as  
small fiber diameter (239 ± 37 nm), required tensile strength (0.17 ± 0.05 
MPa) and Young’s modulus (1.45 ± 0.20 MPa) in wet condition, with 
suitable biodegradation properties to match the requirements of a cardiac 
tissue. Cell assay showed that PG1:1 scaffold promoted CM attachment, 
proliferation, interaction and expression of cardiac-specific proteins.  
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 The potential of hMSCs to cardiomyogenic differentiation using 5-aza 
was confirmed on PG nanofibers. Immunoﬂuorescence staining analysis 
showed that after 15 days of in vitro culture the hMSCs differentiated on 
PG nanofibers and expressed significantly higher level of cardiac specific 
proteins, such as α-ACT, TP-T and MHC, compared to the MSC on TCP.  
 To further induce the cardiac differentiation, VEGF was incorporated into 
the nanofibers by blending or coaxial electrospinning, and in vitro release 
study showed that the growth factor could cause sustained release of 
VEGF from the nanofibers up to a period of 21 days. Cell culture results 
indicated that the incorporation of VEGF into nanofibers improved the 
proliferation of MSCs, and more importantly promote the expression of 
cardiac proteins compared to TCP and PG nanofibers. 
 PCL, PG and PG/MSCs cardiac patches were implanted into a rat MI 
model. After four weeks implantation, nanofibrou patches served as a 
mechanical barrier against progressive LV dilation, while the grafted 
MSCs differentiated into cardiac cells and endothelium, effectively 
induced neovascularization in infarcted areas. Moreover, PG/MSCs 
patches showed the best results in attenuating the LV remodeling, 
improving cardiac function and promoting angiogenesis. 
 Electrically conductive nanofibrous scaffolds composed of PPy, PCL and 
gelatin were fabricated to provide electrophysiological cues to cardiac 
myocytes. By increasing the concentration of PPy (0 to 30%) in the 
composite, the average fiber diameters reduced from 239 ± 37 nm to 191 
± 45 nm, and the tensile modulus increased from 7.9 ± 1.6 MPa to 50.3 ± 
3.3 MPa.  
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 PPG15 exhibited the most balanced properties of conductivity, 
mechanical properties, and biodegradability, matching the requirements 
for regeneration of cardiac tissue. The cell analysis showed that the 
PPG15 scaffold promote cell attachment, proliferation and interaction 
with expression of cardiac-specific proteins compared to other scaffolds, 
signifying the potential of using PPy containing nanofibers for the 
regeneration of infarct myocardium. 
 
7.2 Recommendations for future work 
The PG nanofibers described in this project has shown promising results as a 
cardiac TE scaffold for cardiac growth and the cardiac differentiation of MSCs in 
vitro. It is also demonstrated that PG nanofibers as cardiac patch attenuated the LV 
remodeling and improved cardiac function in rat MI model. Large animals (dogs or 
pigs), which are closer to clinical relevance, should be employed to evaluate the 
performance of the nanofibrous cardiac patch. Meanwhile, further investigations are 
required to demonstrate the mechanisms of cardiac repair by monitoring and 
identified significant secreted factors stimulated by paracrine/autocrine effects.  
In Chapter 7, PPy/PCL/gelatin conductive nanofibers have shown to be effective 
in promoting cell-cell interaction with higher expression of cardiac-specific proteins 
and have been demonstrated to potentially be a suitable platform for ES. However, it 
is found that the mechanical properties of the nanofibers changed dramatically after 
adding PPy and PPy-containing nanofibers became rigid and brittle. As cardiac TE 
needs soft and elastic scaffolds to tolerant circular cardiac contraction, it is therefore 
to develop conductive nanofibrous with suitable mechanical properties. Some elastic 
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polymers, such as PLCL, PGS, Poly(1,8-octanediol-cocitrate) could be used to 
electrospin nanofibers. In addition, further studies should be conducted to 
investigate the cardiomyogenic differentiation of human MSCs on conductive 
nanofibers, and in order to maximize the differentiation efficiency, optimization of 
ES parameters (including voltage, frequency, pulse duration, ES period) remains an 
area of future work. A protocol for tissue engineering of synchronously contractile 
cardiac constructs by differentiating stem cells towards CMs under ES needs to be 
estabilished. The gene expression and cellular electrophysiology of MSCs under ES 
render further investigation to understand the mechanisms of the cardiac 
differentiation of MSCs. The biocompatibility and biostability of PPy-contained 
nanofibers needs to be tested in vivo. Electromechanical integration between the 
conductive nanofibers and host myocardium should be evaluated by with a NOGA-
Star mapping system. To limit the risk of arrhythmias, electrophysiological 
assessments (such as electrocardiogram) need to be carried out after long-term 
implantation. 
In the native heart, myocardial ECM mainly consists of a complex array of 
aligned cardiac collagen fibers, which cover the aligned CMs 
5
. The alignment of 
CMs and ECM fibers play an important role in the transmission of electrical signals 
and direction of mechanical forces in a distinct manner in heart 
347
. It is reported that 
that scaffolds with oriented patterns are capable of CM alignment, thus improving 
the cardiac regeneration process 
260
. Therefore, an aligned nanofibrous scaffold 
should be developed. To date, advanced technologies in electrospinning are able to 
obtain aligned nanofibers by rotating the grounded collector and higher velocity of 
the grounded surface leads to better fiber alignment 
180, 181
. In the further, aligned 
electrospun nanofibers with appropriate anisotropic mechanical properties will be 
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fabricated to guide cardiac cell orientation for cardiac reconstruction. In addition, 
aligned conductive nanofibrous scaffolds could be developed as an ideal scaffold for 
cardiac tissue engineering, as the aligned nanofibrous structure that mimicks the 
hierarchy of the native myocardial ECM could control cellular alignment, while the 
conductive polymers in the fibers would form anisotropic channels to guide 
electromechanical coupling and signal propagation between CMs.  
One drawback of nanofibrous cardiac patch is that the implantation procedure 
requires an open-heart surgery. For clinical application, injectable scaffolds would 
be a better option than implantable cardiac patch to minimize the negative effects of 
open-heart surgery to patients, such as discomfort, scar formation, risk of infection 
and cost of the operation. For this perspective, hydrogels with the potential of 
injectability offer distinct advantages for minimally invasive surgery. Therefore, an 
injectable fiber/hydrogel nanocomposite should be considered for cardiac TE. 
Moreover, in the past study, we have successfully incorporated PCL/gelatin 
nanofibers into gelatin hydrogels to fabricate nanofiber/hydrogel nanocomposites. 
The structure of fiber/hydrogel nanocomposite is similar to the structure of native 
ECM, which is a collagen fiber network embedded in proteoglycan hydrogel, and 
the results showed that the incorporation of nanofibers enhanced the mechanical 
properties of hydrogel and favored the growth of MSCs 
348
. In the future work, 
conductive nanofibers could be added into a biodegradable, thermoresponsive 
hydrogel to develop injectable fiber/hydrogel scaffolds to delivery stem cells or 
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